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Epithelial branching morphogenesis is a critical step in the development of many 
epithelial organs including the lungs and the salivary glands. Many of the signalling 
pathways that orchestrate this process show a resurgence in the diseased state. 
We sought to determine the role of a common disease pathway, the 
phosphoinositide 3-kinase (PI3K) pathway, in the branching program of the lung. 
We utilised ex-vivo cultures of embryonic murine lungs that best recapitulates the 
developmental process. Inhibition of PI3Kα, or its downstream signalling 
components Akt and mammalian target of rapamycin, was able to greatly enhance 
the branching potential of embryonic lungs, implying a negative role for PI3K in the 
lung branching morphogenesis. Moreover inhibition of PI3K was sufficient to alter 
the morphogenic properties of fibroblast growth factor 7 on isolated murine lung 
epithelium from a cystic to a branching response.  
 
We also investigated protein mediated drug delivery tools to provide a means of 
enhancing the delivery of PI3K based therapeutics. Cell-penetrating peptides 
(CPPs) are small proteins that are able to transport a drug cargo across the 
membrane of a cell. However, given that many CPPs are derived from viral 
proteins and venoms we sought to determine if common CPPs could induce an 
immune response. CPPs we capable of delivering a protein cargo into the interior 
of epithelial cells without inducing an immune response as measured by a lack of 
NFκB activation and no observable increase in interleukin-6 or -8 secretion.  
 
We finally explored the potential of repurposing bacterial toxins for therapeutic 
applications. The toxins Pseudomonas aeruginosa exotoxin A (PEx) and Cholix 
(Chx) are natively capable of entering cells and subsequently being transported to 
either the cytoplasm of non-polarised cells, or undergoing transcytosis across 
polarised cells. We were able to identify that the C16:1 ceramide chain variant of 
the ganglioside GM1 is capable of enhancing the intracellular transport of PEx to 
the Golgi network. Moreover, we demonstrated that PEx is able to transport an 
siRNA cargo across polarised monolayers of Caco-2 cells and deliver said cargo 
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1.1 The mammalian lung 
 
The mammalian lung is a remarkable organ, elegantly adapted for the process of 
gas exchange between the body and outside world. In order to effectively feed a 
respiring body with sustaining oxygen the lung requires two key design features: a 
very large surface area, approximately the size of a tennis court; and a very thin 
tissue barrier, separating the outside world with the circulatory system (Weibel, 
2009). The first of these is achieved through the generation of an elaborate 
network of branching airway tubes that supply the 480 million gas exchanging 
alveoli with oxygen and blood (Ochs et al., 2004). The second of these 
requirements is accomplished by the alveoli, the primary gas-exchanging structure 
of the lung. Two specialised alveolar epithelial cell (AEC) types comprise an 
alveolus and function to maximise gas exchange. Type I cells make up 
approximately 96% of the alveolus surface and are extremely thin, minimising the 
space between the blood and atmosphere. Type II cells make up the other 4% and 
serve to replenish damaged type I cells and secrete surfactant proteins that 
reduce surface tension across the alveolus (Castranova et al., 1988).  
 
Changes in the ability of this organ to effectively exchange gas, either through 
developmental complications or acquired disease, are therefore detrimental to the 
health of an individual and to society. In 2011 three of the ten leading causes of 
death in the world were a result of lung related diseases ().  
 
As our understanding of the cellular processes involved in disease has increased 
similarities between the diseased environment and the developmental state of the 
organ are becoming apparent. Increased insight into the development of the lung 
will further increase our understanding of disease process and will lead to novel 
regenerative therapies. Alongside insights into the disease process, novel delivery 
methods need to be developed for emerging therapeutics that either cannot be 
administered by conventional means, require help in reaching their cellular target 
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1.2 Lung development and disease 
 
Asthma 
Asthma is an airway inflammatory disease characterised by intermittent airway 
obstruction and is one of the most prevalent chronic diseases in the developed 
world (Barnes, 2004). Symptoms of asthma are mediated by increased mucus 
production and hyper responsive airway smooth muscle. Studies have identified 
that the airway-remodelling characteristic of asthma (goblet cell metaplasia, airway 
smooth muscle hyperplasia) are already established in infants before the onset of 
symptoms (Warner et al., 1998). Considering that airway smooth muscle is formed 
and is active during the development of the lung (Schittny et al., 2000), any 
abnormalities in this process may persist in the infant thus predisposing them to 
childhood asthma. 
 
Chronic obstructive pulmonary disease 
Chronic obstructive pulmonary disease (COPD) is an obstructive lung disease 
characterised by chronically reduced airflow. A major component of COPD is 
emphysema, the progressive loss of the respiratory surface area. Although there is 
a strong association with smoking and the development of emphysema, genetic 
factors can also be influential. For instance, α-1 antitrypsin deficiency predisposes 
individuals to emphysema. α-1 antitrypsin is produced from epithelial cells of the 
airways and acts as an inhibitor of neutrophil elastase. Deficiency of this gene 
therefore allows unimpeded neutrophil elastase function. This leads to the break 
down of elastin present in the alveoli, impairing their function and causing 
emphysema-like symptoms (Stockley and Turner, 2013). Mice deficient in Smad3, 
a major signalling component of the transforming growth factor (TGF) β pathway, 
exhibit impaired lung alveolarisation. This deficiency leads to the mice displaying 
an emphysema-like phenotype later in adulthood (Chen et al., 2005). Impairment 
in the development of the alveoli, or how they are maintained, may therefore 
reduce an individual’s resilience to airway irritants later in life.  
 
Pulmonary fibrosis 
Pulmonary fibrosis is characterised by the progressive build up of connective 
tissue in the lung leading to loss of function and eventual death due to heart 
Chapter 1: Introduction 	  
 4 
failure; the primary driving force behind this disease is the generation of 
myofibroblasts within the lung (Scotton and Chambers, 2007). These cells 
proliferate and produce extracellular matrix that remodel the lung, destroying the 
gas exchange surface. The source of these cells is currently not well understood 
but TGFβ is considered to be an essential factor. TGFβ overexpression in the 
lungs of adult rats leads to an aggressive fibrosis (Sime et al., 1997). Similarly, 
mice deficient in Smad3 (and thus reduced TGFβ signalling) exhibited a resistance 
to bleomycin-induced fibrosis (Zhao et al., 2002). As loss of TGFβ signalling also 
leads to emphysema (Chen et al., 2005), appropriate levels of this factor are 
critical for the function of the lung. This is also true for the development of this 
organ as reduced TGFβ signalling impairs lung alveolarisation (Chen et al., 2005). 
Equally, overexpression of TGFβ in the epithelium of embryonic lung either 
through adenoviral overexpression or application of exogenous TGFβ inhibits the 
growth of the airway network (Xing et al., 2008; Zhao et al., 1999).  
 
Cancer 
Many epithelial cancers involve the aggressive proliferation and migration of 
cancerous cells into the surrounding environment. Studies from prostate (Pritchard 
et al., 2009; Schaeffer et al., 2008), breast (Zvelebil et al., 2013) and lung cancers 
(De Leij et al., 1987; Rudin et al., 2012) have identified that many pathways 
activated in the epithelial cells during the development of these organs become 
reactivated in the cancerous setting. As an example, two genes commonly found 
to be dysregulated in breast cancer, Tbx3 and Gata-3, are essential in the 
development of the mammary gland. Deletion of either severely impairs the 
formation of the ductal tree and reduces epithelial cell differentiation (Asselin-
Labat et al., 2007; Davenport et al., 2003). SOX2 is commonly upregulated in 
small cell lung cancer (Rudin et al., 2012). This transcription factor is also found 
during the development of the lung, overexpression of which results in an 
increased number of epithelial cell progenitor cells and impairs the development of 
the airway network (Gontan et al., 2008). Together, these studies would imply that 
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Epithelial-mesenchymal transition 
Epithelial-mesenchymal transition (EMT) is a process whereby epithelial cells lose 
their epithelial characteristics and adopt those of a mesenchymal cell (Figure 1.1). 
EMT is found during a number of developmental processes including gastrulation 
(Nieto et al., 1994), and neural crest formation (Duband et al., 1995; Theveneau et 
al., 2013). Incomplete EMT in the development of the neural crest is a cause of 
cleft palate in infants (Nawshad and Hay, 2003; Yu et al., 2009). Epithelial cancers 
are thought to undergo an EMT like event in the acquisition of a migratory 
phenotype, invading the surrounding tissue and giving rise to secondary tumours 
(Birchmeier et al., 1996). Moreover, EMT has been identified as a potential source 
of disease promoting myofibroblasts in lung fibrosis. This comes from the 
observations that a portion of cells taken from the lungs of mice with experimental 
fibrosis, and epithelial cells isolated from patients with idiopathic pulmonary 
fibrosis, express markers of both epithelial and mesenchymal cells, indicative of a 
cell undergoing EMT (Kim et al., 2006; Marmai et al., 2011).  
 
One of the most well studied promoters of EMT is the pro-fibrotic cytokine TGFβ 
(Miettinen et al., 1994; Willis et al., 2005). TGFβ can induce characteristic features 
of EMT in cultured epithelial cells such as the loss of the adherens junction protein 
E-Cadherin and the gain of the mesenchymal proteins vimentin and fibronectin. 
The transcription factors slug and snail are crucial for this process and act 
downstream of TGFβ to directly inhibit E-Cadherin transcription and promote 
fibroblast protein transcription (Cano et al., 2000; Naber et al., 2013). Prolonged 
exposure to TGFβ also induces the expression of smooth muscle actin (αSMA) 
and the production of extracellular matrix proteins (Shirakihara et al., 2011), 
hallmarks of the fibrotic process. TGFβ is therefore an attractive target for fibrosis. 
Indeed, p38 kinase inhibitor pirfenidone, and the only currently licenced drug for 
pulmonary fibrosis, exerts its anti-fibrotic actions partly through the suppression of 
TGFβ activity (Iyer et al., 1999). Moreover, pirfenidone can reduce TGFβ-induced 
EMT in cultured epithelial cells (Hisatomi et al., 2012). However the use of 
pirfenidone for pulmonary fibrosis in the clinic is controversial based on a 
somewhat limited efficacy and a large number of adverse side effects (Anon., 
2013; Takeda et al., 2014). New, more potent therapies for pulmonary fibrosis may 
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emerge from an enhanced understanding of the mechanisms that govern the EMT 
process in both development and disease.  
 
 
Figure 1.1. Characteristic features of epithelial–mesenchymal transition. Diagram 
illustrating the main cellular changes in morphology and protein expression during 
epithelial-mesenchymal transition in response to TGFβ.   
 
1.3 Lung development 
 
The embryonic development of the lung can be split into five separate stages 
based on morphological appearance and function: i) embryonic, ii) 
pseudoglandular, iii) canalicular, iv) saccular and v) alveolar (Figure 1.2) (Joshi 
and Kotecha, 2007; Warburton et al., 2010): 
 
Embryonic (embryonic day (E) 9 – 12 in murine embryos, 3 – 7 weeks in human 
pregnancy): The lung initially develops as an outgrowth of the ventral foregut, the 
laryngotracheal groove. The trachea forms from invading cells of the foregut 
endoderm. This tracheal line subsequently develops into two primary bronchi by 
the end of this stage. 
  
Pseudoglandular (E12 – 16 in murine embryos, 5 – 17 weeks in human 
pregnancy): During this stage the primitive epithelial tubes of the lung undergo 
successive rounds of highly coordinated branching. Cells of the branching 
epithelium invade the surrounding mesenchyme in a stereotypical fashion 
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organ (Figure 1.3A) (Metzger et al., 2008). 23 generations of airways are formed in 
humans and 12 in mice (Weibel and Gomez, 1962). Interactions between the 
branching epithelium and the surrounding mesenchymal tissue tightly control at 
what point branches form and separate from one another.  
 
Canalicular (E15 – 17 in murine embryos, 16 – 26 weeks in human pregnancy): 
Once the branched network of airway epithelial tubes has formed there is a 
substantial vascularisation of the airways. Terminal bronchioles and alveolar ducts 
comprising the acini of the lung also begin to form and epithelial cells begin to 
differentiate from the immature type II AECs cells of the pseudoglandular stage to 
mature type I and type II AECs.  
 
Saccular (E17 – Birth in murine embryos, 26 – 36 weeks in human pregnancy): 
Thinning of the acinar structures occurs accompanied by the formation of saccular 
structures. Epithelial cells further differentiate into mature type I and type II AECs 
 
Alveolar (Birth to postnatal day 20 in mouse, 36 weeks of pregnancy to 8 years of 
age in humans): The majority of the gas-exchanging surface is formed at this 
stage and continues following the birth of a mammal. A human infant is born with 
approximately 20-50 million alveoli that will develop into 480 million by adulthood 
(Kotecha, 2000; Ochs et al., 2004).   
Figure 1.2. Stages of mammalian lung development. Illustrations of the main 
morphological changes that define the different stages of lung development. Approximate 
time for each stage in human and murine development is given. Lung epithelial tissue is 
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1.4 Lung branching morphogenesis  
 
Epithelial branching morphogenesis is a process critical for the development of 
many epithelial organs such as the lung, pancreas, mammary and salivary glands. 
Remarkably, lungs are sufficiently identical between mice so as to suggest a pre-
determined pattern of lung growth. Indeed, the apparent complexity of the 
branched network can be adequately modelled through the repetition of simple 
patterns (fractal mathematics) (Mandelbrot, 1983).  
 
Analysis of the branched structure of the lung revealed that with each successive 
generation of the airway tree, the diameter of each airway reduces by a constant 
factor (Weibel and Gomez, 1962). Surprisingly, this factor is optimum for airflow in 
a branched system, minimising the work required to overcome flow resistance and 
dead space volume (Murray, 1926; Weibel, 2009).  
 
The branching of the lung can be further simplified by the discovery in mice that 
there are only three modes of branching repeated throughout the pseudoglandular 
stage: domain branching, planar bifurcation and orthogonal bifurcation (Figure 
1.3). In domain branching, daughter branches form along the proximal part of a 
parent branch. This process occurs from the start of the lung branching program 
and is found throughout the pseudoglandular stage. From E12 onwards, planar 
bifurcation is found, during this process the tip of an expanding branch splits into 
two daughter branches, which continue to develop along the same plane as the 
parent. The final branching process, orthogonal bifurcation, occurs from E13 
onwards and is similar to planar bifurcation in that two daughter branches are 
formed from the tip of a parent. However, following bifurcation the two daughter 
branches rotate and continue to develop along a different plane from the parent 
(Metzger et al., 2008). This provides answers as to how the lung can create such a 
vast network of branches in such a small area. 
 
This branching program therefore requires substantial regulation to coordinate 
where branches should form and regulate their size to maximise on the space 
available for growth. Equally, the branching program needs to achieve the optimal 
number of terminal buds. Too few a number and there would not be enough 
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terminal branches to give rise to an effective number of alveoli. Too many and 
there would be insufficient space for the alveoli to dilate into at the latter part of 
their development, thus compromising their effectiveness. To achieve this delicate 
balance there is considerable cross talk between the branching epithelium and the 
surrounding mesenchyme using a plethora of communication factors. 
 
Peristaltic waves in branching morphogenesis  
As the branched network of the lung is formed the developing lumen is filled with 
fluid that is constantly been forced though the branched network by peristaltic 
waves of contraction (Schittny et al., 2000). These constant waves of contraction 
are propagated by airway smooth muscle lining the proximal branches and appear 
to regulate branching morphogenesis. Increasing the peristalsis of cultured lung 
explants through the addition of nicotine conferred an increased branching 
response. Similarly, reducing peristalsis through addition of the calcium channel 
blocker nifedipine reduced branching (Jesudason et al., 2006; Jesudason et al., 
2005). Calcium waves underpin this airway peristalsis as evidenced by studies 
observing waves of calcium propagating along the airways moments prior to a 
contractile wave (Featherstone et al., 2006). Alterations to the levels of calcium 
present in lung explant cultures affect the branching response (Finney et al., 
2008), potentially through affecting these peristaltic waves.  
 
Airway smooth muscle cells are derived from fibroblast growth factor (FGF) 10 
producing cells of the mesenchyme. During the branching process, bone 
morphogenic protein (BMP) 4 and sonic hedgehog (Shh) are produced in the 
epithelium in response to FGF10 stimulation. These factors signal back to the 
FGF10 producing cells promoting their migration and differentiation to airway 
smooth muscle cells, which line the proximal airways (Mailleux et al., 2005; 
Weaver et al., 2003). Approximately 6% of the FGF10 producing cells end up as 
these airway smooth muscle cells with the rest forming either vascular smooth 
muscle cells (4%), lipofibroblast cells (30%) or other fibroblast cells (60%) (Agha et 
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Figure 1.3. Murine lung branching morphogenesis. A. Expression of the epithelial 
marker E-Cadherin in lungs taken from murine embryos during the pseudoglandular stage 
of lung development. Scale bar = 500 µm. B. Schematic demonstrating the three types of 
branching found during lung development: domain branching, planar bifurcation and 
orthogonal bifurcation. Parent branches are coloured in blue and daughter branches in 
yellow. The resulting plane of the daughter branches with respect to the parent is 
represented in the right part of the panel. RCr –right cranial, RMd – right middle, RAc – 




1.5 Fibroblast growth factors 
 
FGFs comprise a family of 23 factors that bind four types of tyrosine kinase 
receptors (FGFR1-4) (Zhang et al., 2006). The FGFR contains three extracellular 
immunoglobulin-like domains and a binding sequence for heparan sulphate 
molecules. Alternative splicing of the first of these immunoglobulin-like domains 
confers multiple receptors with different ligand specificity, summarised in table 1.1 
(Miki et al., 1992). Moreover, this splicing event allows for tissue specific 
expression of alternate FGFRs. As an example, two of the splice variants of 
FGFR2, FGFR2b and FGFR2c are preferentially expressed in the epithelium and 
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interact with heparan sulphate molecules is also important for their function as 
heparan sulphate can limit FGF diffusion, thus restricting the action of an FGF to a 
specific site on a tissue (Flaumenhaft et al., 1990; Makarenkova et al., 2009).  
 
FGF Family FGF FGFR selectivity 
FGF1 subfamily FGF1 
FGF2 
All FGFRs 
FGFR 1c, 3c > 1b, 4 > 2c > 2b 




FGFR 1c > 3c, 4 > 2c > 1b, 2b 




FGFR 2b > 1b > 4 




FGFR 3c > 4 > 2c > 1c > 3b  




FGFR 3c > 2c > 1c, 3b > 4  




FGFR 1c > 2c, 3c, 4 




No known activity 
Table 1.1. Selectivity of FGF family members to FGFR isoforms. Adapted from (Ornitz 




Formation of the FGF: FGFR complex stabilises receptor dimerization and induces 
receptor trans-phosphorylation. This in turn recruits a number of signalling 
effectors including phospholipase-C γ (PLCγ) (Mohammadi et al., 1991), and 
fibroblast growth factor receptor substrate 2 (FRS2) (Kouhara et al., 1997; Ong et 
al., 2000). PLCγ produces diacylglycerol (DAG) and inositol 1,4,5-trisphosphate 
[Ins(1,4,5)P3] from phosphatidylinositol 4,5-bisphosphate [PI(4,5)P2] present in the 
plasma membrane (Carpenter and Ji, 1999). Ins(1,4,5)P3 induces the release of 
calcium from intracellular stores, thus activating calcium dependent kinases such 
as Ca2+/calmodulin-dependent protein kinase, whereas DAG activates protein 
kinase C (PKC). Once recruited to the receptor FRS2 is phosphorylated, which is 
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dependent on the further recruitment of the adaptor protein Shb (Cross et al., 
2002). Following phosphorylation, FRS2 recruits the adaptor protein Grb2 
(Kouhara et al., 1997), which in turn recruits the guanine nucleotide exchange 
factor (GEF) SOS, and the scaffolding molecule Gab1 (Kanai et al., 1997). SOS 
activates the GTPase Ras thus initiating the mitogen activated protein kinase 
(MAPK) cascade through Raf, MEK and ERK (Kouhara et al., 1997). Gab1 recruits 
the lipid kinase phosphoinositide 3-kinase (PI3K) (Ong et al., 2001). Together 
these signalling events govern a range of cellular processes, notably cell 
proliferation, differentiation and migration. This signalling cascade is summarised 
in figure 1.4. 
 
FGFR signalling is mediated by a number of factors that negatively feedback to 
several elements of the FGFR cascade. Grb2 recruits the ubiquitin ligase Cbl, 
which targets FGFR for internalisation (Wong et al., 2002). Further feedback 
inhibition comes from the induction of the negative regulators sprouty, dual 
specificity phosphatase (DUSP) and Sef. Sprouty is produced in response to ERK 
signalling (Ding et al., 2003), and is phosphorylated by FRS2-recruited SRC 
kinase (Li et al., 2004; Rubin et al., 2005). Sprouty exerts its inhibitory action on 
FGFR signalling by competing with SOS for Grb2 binding (Lao et al., 2006), and 
directly inhibiting Raf (Yusoff et al., 2002). DUSPs dephosphorylate, and thus 
inactivate, ERK. As with sprouty, DUSP transcription can be initiated by MAPK 
signalling downstream of FGFR (Mandl et al., 2005; Smith et al., 2006b). 
Moreover, phosphorylation of DUSP by ERK can increase the stability of the 
protein, thus increasing its activity (Brondello et al., 1999). Sef is a transmembrane 
protein that is transcribed in response to FGFR signalling. Sef directly interacts 
with FGFR resulting in impaired receptor phosphorylation (Kovalenko et al., 2003).  
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Figure 1.4. FGF receptor structure and signalling. Schematic of FGFR showing FGF 
molecules bound to the three extracellular immunoglobulin-like domains, which results in 
receptor dimerisation. Following activation, and receptor trans-phosphorylation PLCγ is 
recruited. PLCγ converts PI(4,5)P2 to Ins(1,4,5)P3 and DAG. Ins(1,4,5)P3 releases calcium 
from intracellular stores, which in turn activates calcium dependent calmodulin. DAG 
activates PKC. FRS2 is also recruited to active FGFR. FRS2 further recruits Grb2 and 
Gab1. Grb2 recruits SOS, which initiates Ras/Raf/MEK/ERK signalling. Gab1 promotes 
PI3K recruitment and activation. Sprouty and DUSP are transcribed in response to ERK 
signalling and regulate FGFR signalling at the indicated sites.  
 
 
FGFs in disease 
FGFRs have key roles in cell proliferation, survival, differentiation, migration and 
angiogenesis making them an important signalling event in many cancers (Turner 
and Grose, 2010). This is highlighted by their potential use as biomarkers for 
cancer prognosis. As an example, a high level of FGF2 in the serum of patients 
with small cell lung caner is an indicator of poor prognosis (Ruotsalainen et al., 
2002). FGFRs can become overactive in cancer through a number of 
mechanisms. Non-small cell lung cancer cells have been demonstrated to acquire 
autocrine FGF signalling which promotes the growth and survival of the cancer 
cells (Marek et al., 2009). Cancer cells can also adopt mutations that give rise to 
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active signalling components (Liao et al., 2013). Isoform switching of FGFRs have 
also been reported in cancer cells, and during fibrosis, thus sensitising cells to 
FGFs that they would otherwise not interact with (Shirakihara et al., 2011; Yan et 
al., 1993). Finally, cancer cells can supress negative regulators of FGFR 
signalling, such as sprouty, to increase FGFR signalling and drive pathogenesis 
(Sutterlüty et al., 2007).  
 
FGFRs are therefore an attractive target for a number of diseases, particularly 
cancer. The FGFR shares high sequence homology with the vascular endothelial 
growth factor receptor (VEGFR) (Manning et al., 2002; Turner and Grose, 2010). 
As a result, many FGFR tyrosine kinase inhibitors are also VEGFR inhibitors. For 
instance, the tyrosine kinase inhibitor PD173074 binds to the ATP binding pocket 
of both VEGFR and FGFR (Mohammadi et al., 1998). This may actually be 
advantageous, as a dual VEGFR and FGFR inhibitor would effectively block both 
angiogenesis and cancer cell proliferation. However, the use of FGFR inhibitors in 
the clinic may be hampered by the acquisition of resistance following prolonged 
treatment, which has been reported in a number of tumour cell lines (Chell et al., 
2013). Moreover, the lack of inhibitor specificity between isoforms of FGFR may 
further limit the use of these compounds in the clinic.  
 
FGFs and branching morphogenesis 
FGFs have been identified as crucial signalling factors in the branching program of 
animals with conserved roles from Drosophila to mammals. Integral to the 
branching process is FGF10 and its receptor FGFR2b, present on the branching 
epithelium (Figure 1.5A). Knockouts of the Drosophila homologs of these proteins, 
branchless and breathless, fail to produce a tracheal network as a result of 
impaired cellular migration from tracheal pits (Klämbt et al., 1992; Sutherland et 
al., 1996). Similarly, lungs from mice deficient in either FGF10 or FGFR2b develop 
an initial trachea and primary lung buds but lack any distal lung branching (De 
Moerlooze et al., 2000; Min et al., 1998). Functionally, FGF10 is produced from 
sites in the mesenchyme ahead of an epithelial branch. FGF10 then acts as an 
attractant for the epithelial cells of a branch by signalling through epithelial 
FGFR2b. The expression of these FGF10 producing cells changes dynamically 
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around the branching epithelium conferring where branches will form and in which 
direction they will develop (Bellusci et al., 1997; Park et al., 1998).  
 
A level of regulation for FGF10 signalling comes from the induction of the negative 
regulator sprouty, specifically the sprouty2 isoform, in the branching epithelium. 
The Drosophila homologue of sprouty2, sprouty, is induced by branchless and 
blocks signalling in the proximal regions of the branch. Deletion of sprouty results 
in overactive branchless signalling and increased tracheal branching (Hacohen et 
al., 1998). In the mouse, sprouty2 is found in the distal tips of developing branches 
and is induced by FGF10 signalling. Antisense knockdown of sprouty2 in murine 
lung explants stimulates epithelial branching (Tefft et al., 1999), whereas 
overexpression reduces (Mailleux et al., 2001). 
 
FGF9, produced from the mesothelium and acting through mesenchymal FGFR2c 
is also implicated in the regulation of branching. FGF9 null mice exhibit reduced 
mesenchymal growth and impaired branching (Colvin et al., 2001). Addition of 
FGF9 to lung explants and isolated lung mesenchyme increases the expression of 
FGF10 suggesting that FGF9 directly influences FGF10 expression in the 
branching lung.  
 
FGF7 is found in the lung mesenchyme later in the pseudoglandular stage, from 
E14.5 onwards (Finch et al., 1995; Mason et al., 1994), nevertheless it appears to 
contribute to lung branching. Addition of FGF7 to isolated lung epithelium 
promotes the growth of large cystic structures from the initial epithelium (Cardoso 
et al., 1997). Antisense knockdown of FGF7 in cultures of rat lung explants impairs 
branching (Post et al., 1996). However, mice lacking FGF7 do not exhibit any lung 
abnormalities suggesting a redundancy for FGF7 in the branching program (Guo 
et al., 1996).  
 
FGF7 is structurally similar to FGF10 and both act through the epithelial FGFR2b 
(Igarashi et al., 1998). Despite this, both factors produce strikingly different 
morphological effects when applied to cultures of isolated lung epithelium. FGF10 
produces a directed branching response, whereas FGF7 promotes a large uniform 
growth of the epithelium (Bellusci et al., 1997; Cardoso et al., 1997). FGF10 and 
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FGF7 are also required for epithelial branching in the developing salivary gland. 
However, the actions of these factors differ from the lung. FGF7 induces an initial 
budding response from the salivary gland epithelium whereas FGF10 promotes 
elongation of epithelial buds (Makarenkova et al., 2009). The reason for this 
apparent disparity between the two factors may lie in how FGF10 signalling is 
regulated during branching morphogenesis. 
 
Restriction of FGF10 signalling to branch sites 
The FGF10 receptor FGFR2b is ubiquitously expressed across the lung epithelium 
(Cardoso et al., 1997), the signalling of FGF10 therefore has to be restricted to 
sites of branching. This is achieved by two means. Firstly, FGF10 producing cells 
only appear ahead of a developing branch (Bellusci et al., 1997), FGF10 would 
therefore be concentrated at the closest part of the epithelium and be reduced 
elsewhere through diffusion. However, this tendency for FGF10 producing cells to 
only appear ahead of sites of branching may be dispensable for the branching 
process as ubiquitous expression of FGF10 across the lung mesenchyme fails to 
perturb branching morphogenesis (Volckaert et al., 2013). Equally, the addition of 
recombinant FGF10 to cultures of isolated epithelium is able to induce branching 
despite its concentration being equal across the culture (Xing et al., 2008).  
Secondly, FGF10 signalling is restricted to sites of branching through binding to 
locally expressed heparan sulphate (Izvolsky et al., 2003) (Figure 1.5B). This 
explains how FGF10 and FGF7 can promote different effects in isolated lung 
epithelium as FGF7 natively lacks a heparan-binding domain. Addition of 
exogenous heparan sulphate to cultures of isolated lung or salivary gland 
epithelium perturbs the endogenous heparan gradient, allowing FGF10 to act 
uniformly across the epithelium. This results in FGF10 producing a uniform growth 
of the lung epithelium, or a budding response in salivary gland epithelium, 
comparable to the related factor FGF7 (Izvolsky et al., 2003; Patel et al., 2008). 
Similarly, deletion of the heparan-binding component of FGF10 creates a factor 
whose morphogenic response is equal to that of FGF7 (Makarenkova et al., 2009).  
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Figure 1.5. FGF signalling in branching morphogenesis. A. Schematic illustration of 
FGF signalling in the branching lung. Epithelium is represented in blue, mesenchyme in 
orange and mesothelium in purple. FGF10 producing cells/ airway smooth muscle cells 
are labelled in red. Mesothelium derived FGF9 regulates the expression of FGF10-
producing cells that in turn promote epithelial branching. BMP4/Shh produced from the 
epithelium in response to FGF10 induces the migration and differentiation of FGF10 
producing cells into airway smooth muscle. These smooth muscle cells line the proximal 
part of a branch and undergo periodic waves of contraction, forcing fluid back and forth 
along the lumen. FGF7 is produced elsewhere in the mesenchyme and induces the 
growth of the epithelium. B. Illustration showing restriction of FGF10 signalling to a site of 
branching through production of FGF10 ahead of a developing branch and local 
expression of heparan sulphate from the epithelium. 
 
1.6 Phosphoinositide 3-kinase 
 
Phosphoinositide (PI) lipids constitute a major component of the plasma 
membrane. The phosphorylation state of the six carbon atoms that comprise the 
intracellular inositol ring, particularly at positions 3, 4 and 5, are tightly regulated by 
a number of lipid kinases and phosphatases to generate seven types of PI 
derivatives (Figure 1.6).  Of these lipid kinases, the PI3K family is the most widely 
studied due to its crucial role in a number of cellular events and the recognition 
that PI3K dysfunction is apparent in a number of diseases. Three distinct 
subfamilies of PI3K exist; classes I, II and III, based on their substrate specificities 
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Figure 1.6. Phosphorylated derivatives of phosphoinositide and their regulation by 
lipid kinases and phosphatases. Figure adapted from (Okkenhaug, 2013). 
 
Class I PI3K 
Each member of the class I PI3K family is composed of a regulatory and a 
catalytic subunit. The class IA family contains five regulatory subunits encoded by 
three genes: PIK3r1, which encodes for p85α and its alternative transcripts p55γ 
and p50α; PIK3r2, which encodes for p85β; and PIK3r3, which encodes p55γ. 
These regulatory subunits pair with one of three catalytic subunits (p110α, β, δ) 
encoded by three separate genes (PIK3CA, PIK3CB, PIK3CD). The class IB 
catalytic subunit p110γ (encoded by PIK3CG) couples with either the p84/p87 or 
p101 regulatory subunits (encoded by PIK3R5 and PIK3R6 respectively) (Foster et 
al., 2012). Four distinct isoforms of the class I PI3K family therefore exist, PI3Kα, 
PI3Kβ, PI3Kδ and PI3Kγ. All PI3K p110 catalytic subunits can interact with, and be 
activated by, the GTPase Ras (Rodriguez-Viciana et al., 1994). PI3Kα/β/δ signals 
downstream of receptor tyrosine kinases (RTKs), such as FGFR (Ong et al., 
2001), whereas PI3Kγ signals downstream of G-protein coupled receptors 
(GPCRs) (Bohnacker et al., 2009). There does appear to exist some redundancy 
between the isoforms as PI3Kβ can also signal through GPCRs (Guillermet-
Guibert et al., 2008). PI3Kα and PI3Kβ are ubiquitously expressed in mammals 
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al., 2000; Vanhaesebroeck et al., 1997). PI3Kδ and PI3Kγ can also be found in 
fibroblasts (Conte et al., 2011), and PI3Kγ can be found in cells of the heart and 
endothelium (Crackower et al., 2002; Patrucco et al., 2004). 
 
Class I PI3K family phosphorylates the D3 position on the inositol ring of PI(4,5)P2 
to generate PI(3,4,5)P3. PI(3,4,5)P3 acts as a docking site for a number of 
pleckstrin homology (PH) domain containing proteins including Akt and a range of 
scaffolding proteins and GEFs (Figure 1.7) (Park et al., 2008). The generation of 
PI(3,4,5)P3 is tightly regulated by the lipid phosphatases phosphatase and tensin 
homolog (PTEN) and SH2-domain containing inositol-5-phosphotase (SHIP). 
PTEN is a 3’ phosphatase, producing PI(4,5)P2 from PI(3,4,5)P3 whereas SHIP is 




Figure 1.7. The PI3K signalling cascade. The class II and III PI3K family members 
produce PI(3)P from PI, which recruits a number of proteins that contain either an FYVE 
or PX binding domain. The class I PI3K family members produce PI(3,4,5)P3 from 
PI(4,5)P2. The phosphatase PTEN reverses this reaction whereas the phosphatase SHIP 
produces PI(3,4)P2 from PI(3,4,5)P3. Both PI(3,4,5)P3 and PI(3,4,)P2 recruit a number of 
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Class II and III PI3K 
Mammalian cells contain three isoforms of the class II PI3K, C2α, C2β and C2γ. 
Class II PI3K phosphorylate either PI or PI(4)P to create PI(3)P or PI(3,4)P2 
respectively (Misawa et al., 1998), although their preferred substrate is PI. The 
sole class III PI3K member, Vps34, uses PI as its substrate to produce PI(3)P 
(Schu et al., 1993) (Figure 1.5). PI(3)P is regulated by the 3’ phosphatase 
myotubularin which converts PI(3)P back into PI (Taylor et al., 2000). Moreover 
PI(3)P can be sequestered into intracellular vacuoles, leading to its degradation 
(Wurmser and Emr, 1998). PI(3,4)P2  is regulated by the 4’ phosphatase inpp4b, 
which generates further PI(3)P (Norris et al., 1997). 
 
PI(3)P recruits a number of proteins that contain either a PX or FYVE binding 
domain (Figure 1.7). Many of these proteins, including early endosome antigen-1 
(Patki et al., 1997), Fab1 (Rusten et al., 2006), and SNX3 (Xu et al., 2001), have 
been identified to have critical roles in vesicular transport within cells. Others, such 
as the PX containing kinase SGK3, are involved in amino acid transport and 
nutrient uptake (Palmada et al., 2005; Tessier and Woodgett, 2006). Amino acids 
are also capable of activating Vps34, which in turn can activate mammalian target 
of rapamycin (mTOR) (Nobukuni et al., 2005). PI(3)P can also be phosphorylated 
at the D5 position by PIKfyve to generate PI(3,5)P2, which also has important roles 
in endosomal transport (Ikonomov et al., 2006).  
 
PI3K/Akt/mTOR signalling 
Of the signalling effectors recruited by PI(3,4,5)P3  the PI3K/Akt/mTOR cascade is 
the best understood (Figure 1.8). Following generation by PI3K, PI(3,4,5)P3 
recruits 3-phosphoinositide-dependent protein kinase 1 (PDK1) and Akt. PDK1 
phosphorylates, and thereby activates, Akt at the threonine 308 position (Alessi et 
al., 1997; Franke et al., 1995). The product of SHIP, and of the class II PI3Ks, 
PI(3,4)P2 is also involved in the recruitment and activation of Akt (Franke et al., 
1997).  
 
Following activation, Akt affects a number of signalling proteins, including tuberous 
sclerosis complex (TSC), FOXO, Bad and glycogen synthase kinase (GSK) 3β 
(Manning and Cantley, 2007). TSC is phosphorylated by Akt (Inoki et al., 2002; 
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Potter et al., 2002), which releases the small GTPase Rheb from the inhibitory 
actions of TSC. Rheb then activates mTOR (Gao et al., 2002; Garami et al., 2003). 
mTOR exist as a complex of proteins that function as serine/threonine kinases. 
Two complexes exist, the rapamycin sensitive mTOR complex (mTORC) 1, and 
the rapamycin insensitive mTORC2. mTORC2 can phosphorylate Akt at the serine 
473 position (Facchinetti et al., 2008; Sarbassov et al., 2005). This leads to the 
complete activation of Akt, which exhibits fivefold more activity than 
phosphorylation at threonine 308 alone (Sarbassov et al., 2005). mTORC1 
activates ribosomal S6 kinase (S6K) and inactivates the transcriptional repressor 
4E-BP1 thus promoting protein translation.  
 
As well as activating protein translation, S6K can regulate the activity of the 
PI3K/Akt/mTOR signalling cascade by inactivating mTORC2, thus reducing Akt 
phosphorylation at serine 473 (Julien et al., 2010). Moreover, S6K induces the 
downregulation of insulin receptor substrate 1 present at RTKs, which in turn 
reduces PI3K recruitment and signalling (Haruta et al., 2000; O'Reilly et al., 2006). 
S6K has also been identified to directly phosphorylate mTOR, thus providing an 
element of positive feedback (Holz and Blenis, 2005).   
 
FOXO is a transcription factor that is phosphorylated in response to Akt activation. 
This phosphorylation retains FOXO in the cytoplasm of the cell and prevents 
FOXO from activating its target genes. FOXO controls the expression of several 
negative regulators of the cell cycle and several pro-apoptotic genes such as p27 
and Bim (Lam et al., 2006). Thus, inhibition of FOXO by Akt can promote cell 
survival and growth. Akt also promotes cell cycle progression through the 
inactivation of the pro-apoptotic protein BAD (Datta et al., 1997), and inactivation 
of GSK3β, which normally targets the cell cycle factor cyclin D for proteolysis 
(Diehl et al., 1998). Recently, FOXO has been shown to increase the transcription 
of the mTORC2 protein rictor, which serves to promote Akt activation (Lin et al., 
2014).  
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Figure 1.8. PI3K/Akt/mTOR signalling pathway. Once activated by either GPCRs or 
RTKs PI3K phosphorylates the D3 position of PI(4,5)P2 creating PI(3,4,5)P3. PDK1 and 
Akt are then recruited to the cell membrane. PDK1 phosphorylates threonine 308 on Akt 
thus activating this kinase. Akt then inactivates TSC removing the inhibitory effect on the 
small GTPase Rheb. Once released from TSC, Rheb activates mTOR. mTORC2 can feed 
back and fully activate Akt at the serine 473 position. mTORC1 activates S6K which 
negatively regulates mTORC2, and PI3K signalling from RTKs. 
 
PI3K signalling in disease 
Hyperactive PI3K signalling, particularly via PI3Kα, is a hallmark of many cancers. 
Generally there are two methods of PI3K activation in cancer; over-activation of 
RTKs and mutations in elements of the PI3K pathway (Engelman, 2009). Many 
anticancer agents that act through inhibition of RTKs rely on their ultimate 
inhibition of PI3K for therapeutic effect (Engelman et al., 2005; Yakes et al., 2002). 
For example, non-small cell lung cancer cell lines sensitive to the epidermal 
growth factor receptor inhibitor gefitinib exhibit enhanced PI3K signalling whereas 
those insensitive to gefitinib do not (Engelman et al., 2005). Mutations in the 
PIK3CA gene are found in many cancers (Samuels et al., 2004), this leads to 
PI3Kα over-activation through at least two mechanisms. Firstly, in the wild type 
PI3Kα the p85 regulatory subunit can inhibit the catalytic activity of the p110α 
subunit. This inhibitory effect is lost in a number of PIK3CA mutations leading to 
enhanced PI3K activity (Huang et al., 2007). Secondly, mutations can occur that 
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2008). Inhibition of PI3Kα is therefore an attractive target for the treatment of 
cancer. Indeed, knockdown or inhibition of PI3Kα, but not PI3Kβ, severely impairs 
the function of small cell lung cancer cells isolated from patients (Wojtalla et al., 
2013). Expression of PI3Kδ and PI3Kγ has also been noted in cell types outside of 
their normal expression pattern that may contribute to the cancer progression 
(Edling et al., 2010; Sawyer et al., 2003). Aside from Class I PI3K signalling, the 
class II PI3K C2β has been implicated in the migration of epithelial cells (Domin et 
al., 2005; Maffucci et al., 2005), thus suggesting a role for this isoform in cancer 
progression.  
 
Due to their preferential expression and multiple roles in cells of the immune 
system, PI3Kδ and PI3Kγ are commonly found to be influential in the progression 
of inflammatory diseases of the lung (Foster et al., 2012). Emphysema requires 
neutrophil recruitment to the lung for the production of neutrophil elastase. 
Neutrophil recruitment can be abrogated through inhibition of PI3Kγ suggesting 
that inhibition of PI3Kγ would be capable of reducing the progression of 
emphysema (Thomas et al., 2005). During an allergic asthma attack mast cells 
undergo degranulation, releasing numerous factors that act to promote airway 
contraction, a process that heavily relies on PI3Kδ (Ali et al., 2008). Similarly, 
inactivation of PI3Kδ, by genetic means or pharmacologically, reduces the 
hyperactive response to the airway allergen ovalbumin and reduces airway 
inflammation and remodelling (Lee et al., 2006; Nashed et al., 2007).  
 
PI3K activity has also been implicated in the pathology of lung fibrosis (Hinz and 
Gabbiani, 2010). Inhibition of either PI3Kα or PI3Kγ reduces the proliferation of 
myofibroblasts and airway smooth muscle cells and inhibits the production of 
collagen in response to TGFβ (Conte et al., 2011; Moir et al., 2011). Treatment of 
rats with the PI3Kγ inhibitor AS605240 conferred a protection from bleomycin-
induced fibrosis (Wei et al., 2010), although this response may be largely due to 
the immunosuppressant actions of PI3Kγ inhibition rather than anti-fibrotic.  
 
The importance of PI3K in disease is highlighted by the fact that there are 
currently eighteen compounds targeting PI3K signalling in clinical trials, the 
majority targeting cancer (Foster et al., 2012). Future insights into how PI3K acts 
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during the disease process will surely lead to more of these compounds entering 
trials and the clinic for a wider range of conditions.  
 
PI3K signalling in branching morphogenesis 
PI3K has been implicated in the branching program of many organs but the 
precise role for this kinase has yet to be fully established. Inhibition of PI3K with 
the pan class I inhibitor LY294002 inhibits branching in cultures of murine 
embryonic salivary gland. This inhibition could be partially rescued with the 
application of the main product of PI3K, PI(3,4,5)P3 (Larsen et al., 2003). Inhibition 
of PI3K was also able to reduce epithelial budding in response to FGF7, but had 
no effect on the elongation response elicited by FGF10, in cultures of isolated 
salivary gland epithelium (Steinberg et al., 2005). Together, these data would 
suggest that PI3K regulates branching at the epithelial level. Similar findings have 
been reported from the branched urogenital sinus tissue. Inhibition of PI3K 
signalling, with LY294002, reduced branching of cultured murine urogenital sinus 
tissue. Conversely, mice deficient in the negative regulator PTEN, and thus 
exhibiting enhanced PI3K signalling, also showed a decrease in branching (Ghosh 
et al., 2011).   
 
Two downstream signalling effectors of PI3K, Akt and Rac1, localised to the sites 
of, and were required for, branch initiation and elongation during the formation of 
mammary epithelial branches in response to hepatocyte growth factor (Zhu and 
Nelson, 2013). Consistent with the pharmacological data in cultured cells, mice 
expressing homozygous knockdown of PI3Kα under the control of a mammary 
gland specific promoter exhibited impaired mammary branching. Conversely, 
knockdown of PI3Kβ enhanced mammary branching (Utermark et al., 2012). Data 
from mammary glands may therefore point towards divergent roles for PI3K 
isoforms in the branching process.  
 
Conflicting results exist for PI3K in the branching program of the lung as well. 
Murine lung explants cultured with LY294002 show reduced branching implying a 
requirement for PI3K-dependent signalling in branching as observed with salivary 
glands and urogenital sinus tissue (Wang et al., 2005). However, in isolated lung 
epithelium derived from mice deficient in PTEN, branching in response to FGF10 
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was significantly impaired compared to wild type epithelium (Xing et al., 2008). 
Information from mice with conditional deletions of PTEN also presents a 
conflicting role for PTEN, and by extension PI3K, in lung branching 
morphogenesis. Mice with a lung specific deletion of PTEN under control of the 
Nkx2.1 promoter exhibited no branching abnormalities. These mice did show 
enhanced epithelial cell proliferation conferring protection from naphthalene-
induced lung injury in the adult (Tiozzo et al., 2009). Conversely, mice with a lung 
specific deletion of PTEN under the control of the surfactant protein C (SPC) 
promoter, exhibited reduced epithelial branching. As with the PTEN knockouts 
under the control of Nkx2.1, these mice showed an enhanced capacity for 
epithelial proliferation, which led to spontaneous adenocarcinoma (Yanagi et al., 
2007).  
 
PTEN has also been identified as having an important role in the formation of 
epithelial tube lumen. PTEN is recruited to the apical surface of polarising 
epithelial cells, which enriches PI(4,5)P2 at the apical membrane and PI(3,4,5)P3 
at the basolateral (Martin-Belmonte et al., 2007). The exogenous application of 
PI(4,5)P2 to the basolateral surface of epithelial cells induces the recruitment of 
apical proteins thus perturbing the polarisation, and morphogenesis of the 
epithelium. This is also true for the exogenous application of PI(3,4,5)P3, which 
converts the apical surface to basolateral  (Gassama-Diagne et al., 2006). 
 
Little is currently known about the class II and III PI3K family members in 
branching morphogenesis. This is due to a lack of pharmacological tools with 
which to study these kinases and the embryonic lethality of the class III Vsp34 
knockout mice (Zhou et al., 2011). Knockout mice for the class II PI3K isoforms 
C2α and C2β exist and are viable beyond early embryonic development. C2α 
knockout mice show poor postnatal development and exhibit sever renal failure. 
However whether there was a branching defect in the development of the kidneys 
that may have contributed to the renal failure was not examined (Harris et al., 
2011). C2β knockout mice appear viable, are fertile, and do not exhibit any gross 
abnormalities (Harada et al., 2005). A requirement for both C2α and C2β in the 
formation of endothelial tubular formation has been demonstrated with siRNA 
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approaches (Biswas et al., 2013; Tibolla et al., 2013), which may imply a role for 
these isoforms in epithelial branching as well.  
 
Pharmacological intervention of PI3K/mTOR signalling 
Aberrant signalling of PI3K in many diseases, particularly cancer, makes PI3K an 
attractive target for therapeutic intervention. This has spurred the development of 
many pharmacological tools with which to dissect the role of PI3K signalling in 
cellular processes. The first compounds identified to target PI3K signalling were 
the pan class I inhibitors wortmannin and LY294002 (Arcaro and Wymann, 1993; 
Vlahos et al., 1994). Although extremely useful in exploring the PI3K pathway their 
numerous off-target effects, particularly their inhibitory actions on mTOR signalling 
(Brunn et al., 1996; Davies et al., 2000), limits the use of these compounds. X-ray 
crystallography data of LY294002 bound to the ATP binding pocket of p110γ has 
helped in the design of new inhibitors with increased selectivity against each 
isoform of PI3K and many of its downstream effectors (Walker et al., 2000) (Table 
1.2). 
 
Debate exists as to the optimal site of intervention in the PI3K/Akt/mTOR 
signalling cascade to achieve optimum therapeutic output. Direct inhibition of PI3K 
prevents Akt activation through PI(3,4,5)P3. However, Akt can also be 
phosphorylated at threonine 308 and serine 473 by IKBKE independently of PI3K 
(Guo et al., 2011). Direct Akt inhibition is also a possibility. Although, Akt inhibition 
may actually increase PI3K signalling by removing the negative regulation of PI3K 
induced through mTORC1 activation (Haruta et al., 2000; O'Reilly et al., 2006). 
Moreover, Akt inhibition may potentiate mTORC2 activity by removing the 
inhibitory effect on FOXO, which in turn can increase the transcription of the 
mTORC2 protein rictor (Lin et al., 2014). mTOR is another potential site of 
inhibition but again this has the caveat of potentially enhancing PI3K activity by 
removing the negative feedback loop induced through S6K. Furthermore, 
mTORC1 inhibition would increase Akt activation by removing the inhibitory effect 
on mTORC2 (Julien et al., 2010) (Figure 1.8). Inhibition of PI3K and mTORC1/2 
would potentially produce the best therapeutic effect, as this approach would shut 
down the PI3K/Akt/mTOR signalling cascade and these positive feedback loops. 
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Pharmacological intervention of PI3K signalling may be tempered in the clinic by 
off-target and systemic effects of the compounds. A particular concern is the 
action of PI3K directed therapies on the cardiovascular system (McLean et al., 
2013). As an example, LY294002 exhibits inotropic effects on the heart through off 
target effects on potassium channels (Sun et al., 2004). Another concern is 
whether an effective therapeutic window can be achieved with PI3K targeted 
compounds, especially as PI3K compounds are being combined with other 
inhibitors to increase their therapeutic effect (Shimizu et al., 2012). The 
introduction of compounds with enhanced selectivity may overcome some toxicity 
through a reduction in off-target effects. However, as mentioned, the inhibition of 
multiple sites in the PI3K signalling cascade may have better therapeutic output. 
Compounds that target both PI3K and mTOR come with the caveat of potentially 
increased toxicity due to the non-selective nature of the compounds (Fruman and 
Rommel, 2014). One compound that may overcome this caveat is the Semaphore 
compound SF1126. SF1126 is a derivative of LY290042 and therefore inhibits 
both PI3K and mTOR signalling. SF1126 benefits from the addition of an RGD 
peptide, which improves compound solubility and targets the compound to the pro-
angiogenic integrins αvβ3/α5β1 present within the tumour environment (Garlich et 
al., 2008). SF1126 is currently in phase I clinical trials for solid tumours and 
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Compound 
IC50 value (nM) 
Reference PI3K isoform mTOR p110α p110β p110δ p110γ 
LY294002 183 98 227 1967 5000 (Brunn et al., 1996) 
ZSTK474 16 44 4.6 49 >100,000 (Kong and Yamori, 
2007) 
PIK75 5.8 1300 76 510 1000 (Knight et al., 2006) 
BYL719 5 1200 290 250 >9100 (Furet et al., 2013) 
A66 32 >12500 >1250 3480 >5000 (Jackson et al., 2005) 
GSK2636771 2000 13 79 1000 3200 (Sanchez et al., 2012) 
TGX-221 5000 5 100 >10,000 N/A (Jackson et al., 2005) 
IC-87114 >100,000 1820 70 1240 N/A (Bilancio et al., 2006) 
AS-605240 3400 >20,000 >20,000 190 N/A (Bilancio et al., 2006) 
AZD8055 >1000 >1000 >1000 >1000 0.8 (Chresta et al., 2010) 
 Akt1 Akt2 Akt3  
Akt inhibitor 
VIII 58 210 2120 (Lindsley et al., 2005) 
Table 1.2 IC50 values of some commonly used PI3K/Akt/mTOR inhibitors. Individual 
IC50 values derived from in-vitro assays with either purified or recombinant protein. 
 
 
1.7 Targeted drug delivery 
 
Many challenges exist in the effective delivery of a therapeutic to an intended site 
of action. The target may be intracellular and therefore only accessible to cell-
permeant small molecules. The target tissue may also be largely inaccessible, as 
is the case for pancreatic cancer where the poorly perfused tumour acts as an 
effective obstacle for drug delivery (Olive et al., 2009). Further, balancing a 
therapeutic concentration of an agent in the target tissue while minimising toxic 
systemic effects is a constant challenge. These obstacles have lead to the 
development of drug carriers that can facilitate the delivery of a therapeutic agent 
and protect its journey through the body to a site of action.   
 
Drug delivery carriers, such as liposomes, encapsulate a drug molecule and can 
be modified in a variety of ways to tailor their function. For instance, carriers can 
exhibit photo-thermal properties allowing for direct targeting of tumours regardless 
of the overall distribution of the carrier (O'Neal et al., 2004). The versatility of 
carriers can also be used to protect the carrier itself from the body. For example, a 
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common modification of a carrier is the coating with polyethylene glycol, which 
reduces the clearance of the carrier by phagocytic cells (Owens and Peppas, 
2006). This modification also extends the circulation time of the carrier thus 
increasing the likelihood of delivery to the site of action. Once a drug carrier has 
reached its intended target and penetrated into a cell the drug carrier can become 
trapped within lysosomes. These acidic organelles are filled with proteases that 
may destroy the drug carrier and the drug itself, greatly reducing the effectiveness 
of the therapeutic. Again, carriers can be modified to aid in their release from 
lysosomes into the cytoplasm of a cell. Polyethylenimine has an inherent buffering 
capacity that acts as a ‘proton sponge’ inside lysosomes ultimately causing the 
rupture of a lysosome that releases the carrier into the cytosol (Akinc et al., 2005).  
 
The following sections will discuss two emerging strategies for targeted drug 
delivery, cell penetrating peptides (CPPs) and bacterial toxins. These tools will 
help overcome many of the delivery challenges faced by both small molecule 
compounds, oligonucleotides and macromolecule therapeutics.   
 
1.8 Cell-penetrating peptides 
 
CPPs are small peptides comprising an amino acid sequence with either a large 
proportion of cationic amino acids, such as lysine or arginine, or have sequences 
that contain an alternating pattern of polar and nonpolar amino acids. CPPs are 
noted for having the remarkable ability to facilitate the transport of macromolecules 
across the membrane barrier of a cell to reach the cell cytoplasm. By being 
covalently attached, or by forming electrostatic complexes to a cargo, these 
peptides offer the exciting potential for use as an efficient delivery system for small 
therapeutics that are otherwise cell membrane impermeable, such as proteins or 
oligonucleotides (Milletti, 2012). CPPs also provide an added bonus of protecting a 
labile cargo from enzymatic degradation, such as endonucleases in the case of 
siRNA delivery (Crombez et al., 2009), on its journey from administration to the 
intended site of action.  
 
Broadly speaking, CPPs can be classified into three groups based on their 
chemical properties: cationic, amphipathic and hydrophobic (Milletti, 2012). 
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Cationic CPPs, such as HIV-TAT (Frankel and Pabo, 1988), are composed of at 
least eight positively charged amino acid residues, which are required for their 
uptake into a cell (Futaki et al., 2001). Amphipathic CPPs, such as Antennapedia 
(Berlose et al., 1996), are CPPs that contain both polar and non-polar regions. 
Finally, hydrophobic CPPs are CPPs that contain only apolar amino acid residues, 
such as the PFVYLI peptide (Watkins et al., 2009).  
 
There are currently several CPP based drugs in clinical trials that show promising 
results. These include RT001, a botulinum toxin A topical gel, for the removal of 
wrinkles (Glogau et al., 2012); AZX100, a cell-permeant HSP20 mimic, for the 
treatment of keloid and surgical scarring (ClinicalTrials.gov identifiers 
NCT00811577, NCT00825916 and NCT00892723); and p28, an Azurin-derived 
peptide, for metastatic refractory solid tumours (ClinicalTrials.gov identifier 
NCT00914914).  
 
Mechanisms of CPP cell entry  
Although there has been many examples of CPP mediated drug delivery in the 
literature and in the clinic, the precise mechanisms by which CPPs can enter a cell 
are still not fully understood. This has arisen from conflicting results in the 
literature, describing different cell entry routes for the same CPP. CPP entry may 
therefore be largely dependent on the experimental conditions; cell type, cargo, 
incubation period, analytical tools etc. (Richard et al., 2003; Tünnemann et al., 
2006). Alternatively, CPPs may utilise multiple mechanisms at once to enter the 
interior of a cell (Guterstam et al., 2009). Despite these complications there 
appears to be two primary mechanisms for CPP entry into cells: direct 
translocation and endocytosis.  
 
Direct translocation: The first studies to investigate the mechanisms by which 
CPPs enter cells identified that they enter passively through temperature and 
receptor independent processes that are insensitive to inhibitors of endocytosis 
(Derossi et al., 1994; Vivès et al., 1997). However, these studies were reliant on 
the imaging of fixed cells, a technique which was later demonstrated to produce 
artefacts concerning CPP entry and localisation (Richard et al., 2003). 
Nevertheless, direct translocation across the membrane has been demonstrated 
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using live imaging techniques and biophysical approaches (Guterstam et al., 2009; 
Jiao et al., 2009). 
 
Direct translocation is proposed to occur when positively charged residues of 
CPPs interact with negatively charged phospholipids of the cell membrane. This 
interaction results in the invagination of the cell membrane. Disruption of the cell 
membrane then releases the CPP into the cytoplasm (Alves et al., 2008; Derossi 
et al., 1994; Joanne et al., 2009) (Figure 1.9A). Alternatively, CPPs have been 
proposed to translocate directly across the lipid bilayer (Rothbard et al., 2005). 
Positively charged CPPs again interact with negatively charged phospholipids 
forming a transient ion pair complex that is able to diffuse across the cell 
membrane. This diffusion is driven by the membrane potential which favours the 
movement of positively charged substances into cells. In support of this, 
depolarising a cell membrane significantly reduces, whereas hyperpolarising 
increases, CPP entry into a cell (Rothbard et al., 2005) (Figure 1.9A).  
 
Endocytosis: Endocytosis of CPPs has been demonstrated to occur through three 
pathways: caveolae- and clathrin- mediated endocytosis and macropinocytosis 
(Figure 1.9B). Caveolae mediated endocytosis involves the interaction of a CPP 
with a lipid raft; cholesterol-interacting calveolin proteins then oligomerise forming 
an endocytotic vesicle around the CPP (Rothberg et al., 1992). Clathrin-mediated 
endocytosis is mediated by the adaptor protein AP2 which recruits clathrin to the 
membrane resulting in the formation of an endocytotic vesicle (Keen et al., 1979; 
Pearse, 1976). 
 
Live cell imaging of fluorescently labelled CPPs has demonstrated that CPPs co-
localise with cholera toxin, an indicator of caveolae-mediated endocytosis, at the 
cell membrane. Further, these tagged CPPs did not co-localise with transferrin, a 
marker of clathrin-mediated endocytosis, suggesting that calveolin mediated 
endocytosis is the predominant entry mechanism for CPPs (Fittipaldi et al., 2003; 
Jones et al., 2005). However, others have presented contradicting results, 
suggesting dependence on clathrin, and not caveolae, for CPP entry. CPP entry 
into cells was shown to be unaffected by inhibitors of caveolae-mediated 
endocytosis (nystatin and filipin III) but reduced by inhibitors of clathrin-mediated 
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endocytosis (chlorpromazine and potassium depletion) (Richard et al., 2005). 
Moreover, CPP entry has also been shown to localise with transferrin (Richard et 
al., 2003).  
 
Macropinocytosis is neither caveolae nor clathrin-dependent and involves the 
encapsulation of a CPP by actin-containing membrane protrusions, forming a 
macropinosome. This is supported by the CPP-induced formation of lamellipodia 
(Gerbal-Chaloin et al., 2007). Additionally, CPP entry is reduced when cells are 
pre-treated with 5-(N-ethyl-N-isopropyl) amiloride, an inhibitor of the Na+/H+ 
antiporter required for macropinocytosis (Nakase et al., 2004; Nakase et al., 
2007).  
 
Following endocytosis of a CPP into a cell CPPs can become trapped in 
endosomal compartments, preventing cargo release into the cytoplasm. This is 
supported by studies utilising endosomolytic compounds such as chloroquine to 
release a trapped CPP, which greatly increased the effectiveness of a CPP 
(Rudolph et al., 2003). As a result, many of the CPPs in development today 
contain modifications to increase their endosomal escape. These modifications 
include the addition of histidine motifs to a CPP, which acts a proton sponge (Lo 
and Wang, 2008; Lundberg et al., 2007). Alternatively, CPPs have been attached 
to the intracellular transport domain of a bacterial toxin. The transport domain of a 
bacterial toxin allows the CPP to be transported through multiple compartments of 
a cell ultimately leading to the release of the CPP into the cytosol (Mohammed et 



































Figure 1.9. Mechanisms of CPP cell entry. A. Direct translocation. CPPs interact with 
negatively charged phospholipids on the cell membrane. Interactions of the positively 
charged CPPs with negatively charged phospholipids either causes invagination of the 
membrane i) or results in the CPP being transported across the membrane relative to 
membrane potential ii). The CPP is then released into the cytoplasm of the cell. B. 
Endocytosis. CPPs either interact with i) caveolin containing lipid rafts or ii) instigate the 
recruitment of clathrin to the membrane. iii) Alternatively, the actin is reorganised, forming 
lamellipodia, enveloping the CPP by the process of macropinocytosis. The CPP is then 
endocytosed into the cell and is retained in endosomes.  
 
Immunogenicity of CPPs 
Like other drug carriers, CPPs have been modified over the years to increase their 
effectiveness. The CPPs in development today are usually based on sequences 
from the originally identified natural CPPs. The HIV-TAT peptide is derived from 
the human immunodeficiency viral protein trans-activator of transcription. This 
protein natively serves to increase the transcription of all HIV derived genes in a 
host cell but was identified as having the ability to form a complex with a cargo and 
transport it across a cell membrane (Frankel and Pabo, 1988). Although yet to be 
proved, it has been suggested that the CPP function of the full length TAT peptide 
may serve to allow secreted TAT peptide to enter non-infected cells and prime 
them for transcription of viral proteins following subsequent infection. Another 
CPP, Antennapedia, was derived from a transcription factor isolated from 
B
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Drosophila (Berlose et al., 1996). Similar to the HIV-TAT peptide, it is currently 
unknown if the biological action of the Antennapedia protein is influenced by its 
CPP properties. However it is believed that any biological role would reflect the 
capability of homeodomain proteins such as Antennapedia to be released from 
one cells and influence another in a paracrine fashion (Berlose et al., 1996).  
 
CPPs have also been derived from various scorpion, snake and wasp venoms 
(Gurrola et al., 2010; Rádis-Baptista and Kerkis, 2011). In this context the CPP 
action of the protein appears to be required for the function of the venom. The 
scorpion toxin imperatoxin A contains a CPP motif that allows translocation of the 
toxin across cardiomyocyte membranes. Following penetration into 
cardiomyocytes the toxin can promote the release of calcium through the 
activation of ryanodine receptors present on intracellular calcium stores thereby 
exhibiting inotropic effects on the heart (Gurrola et al., 2010).   
 
Given their foreign nature there is potential for CPPs to be toxic to cells. Indeed 
studies have identified that, at high concentrations, CPPs can greatly affect the 
viability of cells (Hansen et al., 2012; Kilk et al., 2009; Watkins et al., 2009). This 
effect occurs at concentrations of CPPs above those required for efficient entry of 
a CPP into a cell. Nevertheless there still remains the possibility that CPPs may be 
recognised by the body as foreign, which could result in the initiation of an immune 
response. If CPPs were capable of initiating an immune response this would be 
detrimental to their use in the clinic. It is therefore quite surprising that this has not 
been investigated given the current interest in CPP based therapies and that a 
number are entering clinical trials. In fact, to date only a few studies have 
examined if CPPs can initiate an immune response. 
 
In one study involving the THP-1 cell line, the CPP PepFect, which is based on the 
more commonly used CPP Transportan, was shown to efficiently deliver and 
induce the expression of a DNA plasmid containing a green fluorescent protein 
(GFP) expression vector (Suhorutsenko et al., 2011). This delivery with PepFect 
did not elicit the production of pro-inflammatory cytokines from the THP-1 cells. 
Similarly, intravenous injection of PepFect into mice did not cause an elevation in 
serum levels of pro-inflammatory cytokines (Suhorutsenko et al., 2011). In another 
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study, the nasal delivery of complexes of insulin and the CPP Penetratin to rats 
was assessed for an immunogenic response. Following the delivery of these 
complexes to rats there was no increase in pro-inflammatory cytokines in either 
nasal lavage fluid or blood plasma (Khafagy et al., 2013). This study would 
suggest that CPPs produce no inflammatory reaction either at the site of 
administration or systemically immediately following CPP delivery or for many 
days after.  
 
One study has presented evidence for an immune response from CPPs. In this 
study the successfully delivery of a p38 siRNA duplex conjugated to either the 
CPP HIV-TAT or Penetratin to murine lungs was evaluated. Intratracheal 
administration of Penetratin covalently coupled to an siRNA was found to increase 
the levels of the pro-inflammatory cytokines tumour necrosis factor α (TNFα), 
interleukin (IL)-1β and interferon γ in murine lungs six hours post administration 
(Moschos et al., 2007). Interestingly, neither HIV-TAT conjugated to an siRNA nor 
HIV-TAT or Penetratin alone induced a similar immune response in the mice. This 
may suggest that some CPPs induce an immune response whereas others do not. 
Alternatively, this may reflect potential differences between CPPs in their modes of 
uptake and transport within cells, which can also be dependent on the type of 
cargo and method of association (covalent or non-covalent) (Lundin et al., 2008; 
Madani et al., 2011; Milletti, 2012). It is therefore possible that the Penetratin–
siRNA complex transported to a region within cells where either the Penetratin 
sequence, or the siRNA itself (Sioud, 2006), was recognised by pattern recognition 
receptors.  
 
1.9 Bacterial toxins as therapeutic tools 
 
Microorganisms secrete toxins as virulence factors to aid in their evasion of the 
bodies’ defences. These toxins are generally harmful and sometimes fatal but also 
have the potential to be repurposed for therapeutic applications. A common 
approach is the creation of ‘immunotoxins’. Immunotoxins are hybrids composed 
of an antibody linked to a toxin that has had their cell-binding domain removed. 
This creates a therapeutic that has high target specificity and high toxicity.  
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The most commonly used bacterial toxins for therapeutic applications are 
diphtheria toxin (DTx) produced from Corynebacterium diphtheria (Marsh, 1988), 
Pseudomonas aeruginosa exotoxin A (PEx) (FitzGerald et al., 1986), and more 
recently Cholix toxin (Chx) produced from Vibrio cholerae (Sarnovsky et al., 2010). 
These three toxins share a similar intoxication pathway and protein structures 
composed of three distinct domains. Domain one is responsible for receptor 
binding and toxin entry into cells. The receptor for DTx is a heparin-binding EGF-
like growth factor precursor (Naglich et al., 1992) and PEx binds to low density 
lipoprotein receptor-1 (CD91) (Kounnas et al., 1992). The receptor for Chx is 
currently unknown, although given its sequence homology with PEx it may also 
bind CD91 (Jørgensen et al., 2008). Domain two is required for the transport of the 
toxin from endosomal compartments to the cytosol in non-polarised cells. Domain 
three is the enzymatic portion of the toxin, which inhibits protein translation within 
cells leading to the induction of apoptosis. These domains can be manipulated for 
therapeutic use; domain I can be replaced with an antibody or another protein to 
produce a cell selective ‘immunotoxin’. Alternatively, the third domain can be 
removed and replaced with a therapeutic cargo, aiding the delivery of such a cargo 
into the cell cytosol (Figure 1.10). This has been demonstrated by combining the 
translocation domain of PEx with a CPP and a GFP cargo. The addition of the 
translocation domain greatly enhanced the endosomal escape of GFP compared 
to the CPP-GFP complex alone (Mohammed et al., 2012).    
 
In 2008 the first immunotoxin was approved for clinical use. Denileukin diftitox is 
an immunotoxin composed of DTx coupled to IL-2, thus specifically targeting DTx 
to cells expressing the IL-2 receptor, and is used for the treatment of cutaneous T 
cell lymphoma. Denileukin diftitox produced a 30% clinical response in patients, 
with 10% showing complete remission (Olsen et al., 2001). The success of this 
immunotoxin has lead to the generation of many more that are currently in clinical 
trials (Dosio et al., 2014). These include a phase III trial of Moxetumomab 
pasudotox, an anti-CD22 antibody coupled to PEx, for the treatment of hairy cell 
leukaemia (ClinicalTrials.gov identifier NCT01829711) and a phase I/II trial of 
cintredekin besudotox, an immunotoxin composed of IL-13 coupled to PEx, for the 
treatment of adrenocortical carcinoma (ClinicalTrials.gov identifier NCT01832974). 
As well as being used as single agents, immunotoxins may also be used in 
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combination with other therapeutics to have a greater net effect. For example, the 
combined application of the PI3K inhibitor ZSTK474 and a PEx based 
immunotoxin targeting prostate cancer cells had a greater therapeutic effect on 
prostate cancer in mice than either treatment alone (Baiz et al., 2013).  
 
These immunotoxins appear to be initially well tolerated by the body. However, 
following prolonged exposure (around three weeks) the body produces 
neutralising antibodies against the immunotoxin (Posey et al., 2002). Strategies to 
overcome this obstacle include co-administering an immunosuppressant with the 
immunotoxin (Hassan et al., 2004), or altering the protein sequence of the 
immunotoxin to remove antigenic epitopes (Onda et al., 2011; Onda et al., 2008). 
Immunosuppressive approaches have had limited success (Hassan et al., 2004), 
whereas altered immunotoxins have managed to prolong the use of an 
immunotoxin before the development of neutralising antibodies (Onda et al., 2008; 
Onda et al., 2011). An alternative strategy is to use a second immunotoxin based 
on another bacterial toxin once a neutralising response has developed for the first. 
This has been proven in principle by a study indicating that neutralising antibodies 
directed at a PEx based immunotoxin do not affect the function of a similar 








































Figure 1.10. Bacterial toxins as therapeutic agents. i) The bacterial toxins DTx, PEx 
and Chx are polypeptides composed of three domains; a receptor binding domain (I), a 
translocation domain (II) and an enzymatic domain (toxic; III). These domains can be 
altered a to create a variety of therapeutic agents. Domain I can be replaced with an 
antibody, producing a cell specific immunotoxin (ii). Alternatively, the toxic domain can be 
replaced with a drug cargo creating a cell permeable drug delivery vehicle (iii). Finally, ii 
and iii can be combined to create a cell-specific drug delivery vehicle (iv). 
 
 
DTx and PEx intoxication pathway 
The intoxication pathways for DTx and PEx are well defined in non-polarised cells 
and are similar in that they both require receptor-mediated endocytosis and 
subsequent release into the cytosol for their action. This section will focus on the 
intoxication pathways for DTx and PEx, as the current pathway for Chx is currently 
unknown. Following entry into cells by receptor mediated endocytosis DTx and 
PEx are cleaved by the protease furin into two fragments, the active form of the 
toxin (fragment A, containing domains II and III) and the receptor binding element 
(fragment B) (Gordon et al., 1995). This step appears to be essential for the toxic 
activity of DTx and PEx as transfection of furin into furin-deficient cells is sufficient 
to overcome their innate resistance to DTx and PEx (Gordon et al., 1995). PEx 
and DTx also requires a second reduction step before the two fragments can be 
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in acidic endosomes DTx undergoes a conformational change, the B fragment 
inserts itself into the membrane of the endosome creating a pore. The A fragment 
can then be released directly into the cytosol (Lemichez et al., 1997; Papini et al., 
1993; Zalman and Wisnieski, 1984) (Figure 1.11). PEx requires subsequent 
translocation to the trans Golgi network and endoplasmic reticulum (ER) before 
being release into the cytosol. 
 
Once in endosomes, PEx is transported to the Golgi network either through an 
Arf1/Rab9 or Syn16/Rab6 dependent mechanism, which appears to be cell-type 
dependent (Smith et al., 2006a). Once in the Golgi the REDL sequence present on 
PEx interacts with the KDEL receptor to direct the transport PEx to the ER. The 
REDL sequence of PEx is similar to that of the KDEL sequence, an ER retention 
and retrieval signal in mammalian cells (Giannotta et al., 2012; Lewis and Pelham, 
1990). Consistent with a requirement for this REDL sequence, the toxicity of PEx 
is enhanced if the number of KDEL receptors are increased, or visa versa 
(Jackson et al., 1999). However, the REDL sequence is not crucial for the 
transport of PEx as a toxin construct with the REDL sequence removed is still 
capable of accessing the cytoplasm (Mohammed et al., 2012). Once in the ER 
PEx undergoes its reduction step, releasing fragments A and B. Fragment A then 
associates with the ER pore Sec61, affecting its gating properties and allowing 
fragment A to exit into the cytosol (Wirth et al., 2003).  
 
Upon entry into the cytosol the enzymatic A fragment of DTx and PEx inactivates 
elongation factor 2 (EF2) through the ADP-ribosylation of a modified histidine 
residue, termed diphthamide, present on EF2 (Collier, 1975; Foley et al., 1995; 
Iglewski et al., 1977) (Figure 1.11). EF2 catalyses the movement of a polypeptide 
chain along a ribosome, inactivation of EF2 therefore halts protein synthesis. This 
results in the depletion of the anti-apoptotic protein Mcl-1 that is rapidly turned 
over, thus, initiating cell apoptosis (Du et al., 2010).  
 
 



















Figure 1.11. DTx and PEx intoxication pathway in non-polarised cells. DTx 
intoxication. i) DTx binds to heparin-binding EGF-like growth factor precursor and is 
internalised into cells. ii) Once in endosomes the protease furin cleaves DTx into 
fragments A and B. iii) The acidic nature of the endosome causes a conformational 
change in fragment B, which inserts itself into the endosomal membrane, allowing 
fragment A to exit into the cytosol. PEx intoxication. 1) PEx binds to CD91 and is 
internalised. 2) Once in endosomes PEx is cleaved by furin. However, a disulphide bond 
still covalently links the two fragments. 3) PEx is transported to the Golgi network where 
the REDL sequence of fragment A is recognised by the KDEL-receptor. 4) The two 
fragments are then transported to the endoplasmic reticulum. 5) Inside the endoplasmic 
reticulum the disulphide bond connecting fragments A and B is reduced, separating the 
two fragments. 6) Fragment A interacts with Sec61, releasing fragment A into the cytosol. 
iv) & 7) Fragment A of DTx and PEx catalyse the ADP ribosylation of elongation factor 2 
(EF2) resulting in arrest of protein synthesis.  
 
 
Directing toxin transport within a cell 
Studies have suggested that as little as one molecule of toxin is sufficient to 
induce apoptosis in a cell (Yamaizumi et al., 1978). However, significantly more 
than this is required for the intoxication of cells (Kreitman and Pastan, 1998). This 
would suggest that <1% of the internalised toxin is not transported to the 
cytoplasm but instead ends up in other intracellular compartments, potentially 
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as drug delivery vehicles as substantial amounts of a drug may be lost to 
degradative pathways, thereby rendering the therapeutic ineffective.  
 
PEx has been shown to take two possible routes to the Golgi network, an Arf1 
dependent route that can transport PEx to either the Golgi or to lysosomes from 
late endosomes, and a Syn16 dependent route that transports PEx straight from 
early endosomes to the Golgi network (Smith et al., 2006a). It could be conceived 
that altering PEx to only take the Syn16 route would increase the amount 
delivered to the cytosol by avoiding lysosomal degradation. However, inhibition of 
the Arf1-dependent route, and thus presumably increasing the amount of PEx in 
the Syn16 route, did not increase the sensitivity of the cells to PEx (Smith et al., 
2006a). Nevertheless, identifying the interactions that govern the route a toxin 
takes within a cell may lead to improved toxins that have greater delivery to the 
cytosol.  
 
A potential candidate is the ganglioside GM1, the native receptor for cholera toxin 
(Holmgren et al., 1975). GM1 is composed of an extracellular oligosaccharide that 
binds cholera toxin, and a ceramide domain that anchors the lipid in the 
membrane. Both of these domains exist in multiple forms that can influence the 
transport of GM1 within the cell (Chinnapen et al., 2012; Hakomori, 2003). For 
example, cholera toxin is transported to the Golgi network in cells loaded with the 
C16:0 ceramide chain variant of GM1 but transports to lysosomes in cells loaded 
with the C18:0 variant (Chinnapen et al., 2012). As PEx also binds to GM1 (R. 
Mrsny. Unpublished observations) there is the potential for this bacterial toxin to 
also utilise GM1 as a sorting mechanism within cells.  
 
Drug administration using bacterial toxins 
A major obstacle for the delivery of macromolecules (for example insulin) is the 
initial administration of the agent to the body. Macromolecules are too large to 
cross the epithelial barriers present at the skin, intestine, or airways. The intestinal 
route also has the added obstacle of passing through the stomach, which due to 
its acidic nature would likely render a therapeutic useless. Many macromolecules 
therefore need to be administered directly to the blood stream by intravenous 
administration. This is not ideal as it requires experienced hands and comes with a 
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social stigma that reduces patient compliance (Hanas and Ludvigsson, 1997). 
Oral, or other, formulations of macromolecule-based drugs would therefore be well 
received by the medical community.  
 
As well as a potential use as a drug carrier to specific target cells and intracellular 
compartments, bacterial toxins such as PEx and Chx also have the potential to aid 
in the administration of therapeutics to the body. Pseudomonas aeruginosa is an 
opportunistic pathogen of the airways that releases PEx as a method of immune 
evasion. PEx passively crosses the polarised epithelial layer that comprises the 
mucosal lining of the airways and subsequently enters and induces apoptosis in 
non-polarised cell types, particularly antigen presenting cells, present in the 
submucosal space (Daugherty et al., 2000; Mrsny et al., 2002). It is hoped that by 
exploiting this mechanism of transcytosis by PEx, therapeutics could be developed 
that allow delivery via mucosal routes such as the airway and intestine (i.e. 
inhalation or oral delivery). This would ultimately involve the replacement of the 
third domain of PEx with a therapeutic (Figure 1.10 iii). PEx would then be able to 
transport its therapeutic cargo across a polarised epithelial surface and deliver it to 
the other side. The toxin could be further modified to either allow the delivery of 
the therapeutic to non-polarised cells or for the therapeutic to be cleaved from the 
toxin to allow it to act systemically.  
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1.10 Project aims and objectives 
 
The experimental work in this thesis is divided into three sections. The first part will 
dissect the role of the disease relevant pathway PI3K in the embryonic 
development of the lung airways. The second part will investigate the use of CPPs 
as delivery mechanisms to epithelial cells with a focus on their potential 
immunogenic properties. The final part will examine the transport of bacterial 
toxins within cells to explore their prospective use as drug carriers. These 
elements come together with the intent to provide an improved understanding of 
potential therapeutic targets for pulmonary diseases, potential delivery of novel 
medicines into the cytoplasm of epithelial cells using CPP strategies, and the 
possibility of delivering biopharmaceuticals to the submucosal space using 
bacterial-derived delivery mechanisms. 
 
i) Developmental pathways are regularly reactivated in the disease state where 
they can contribute to the remodelling of an organ, as is the case in fibrosis (Shi et 
al., 2009), or can increase the aggressive properties of epithelial cancers (De Leij 
et al., 1987). PI3K has been identified as a critical mediator in many of these 
disease processes. However comparatively little is known about PI3K in the 
development of the lung with current research producing conflicting results (Wang 
et al., 2005; Xing et al., 2008). This part of the thesis will utilise a pharmacological 
toolkit of specific inhibitors for PI3K and its downstream signalling components to 
dissect the role of this kinase in branching morphogenesis. This work aims to: 
 
- Examine the role of PI3K in the process of EMT, which is relevant to 
both developmental and pathogenic mechanisms.  
- Establish models of embryonic lung branching and explore approaches 
to manipulate the signalling pathways involved, e.g. pharmacological 
and lentiviral gene delivery. 
- Using these approaches the role of PI3K will be examined in a 
physiologically relevant model of airway branching. 
- Explore possible mechanisms of PI3K involvement in branching 
morphogenesis. 
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ii) CPPs are a useful tool to deliver otherwise cell impermeable therapeutics into 
cells (Milletti, 2012). However, as many of the CPPs currently in development are 
based on naturally derived CPPs there is the potential for these CPPs to elicit an 
immune response in the body that would be detrimental to their use in the clinic. 
Surprisingly there is currently little evidence related to the potential of CPPs to 
elicit an immune response. This part of the thesis seeks to explore this possibility 
by:  
 
- Demonstrate the delivery of a cargo to epithelial cell lines by three 
commonly used CPPs; HIV-TAT, Antennapedia and Transportan, in-
vitro. 
- Establish if these CPPs can induce an immune response from the cells 
by measuring the activation of immune-related pathways in-vitro. 
 
iii) Bacterial toxins are commonly used as immunotoxins, targeting specific cell 
types for effective destruction (Dosio et al., 2014). There is also the potential to 
use elements of these toxins as drug carriers either into cells (Mohammed et al., 
2012), or across epithelial monolayers for oral or inhalation administration (Mrsny 
et al., 2002). However, question still remain concerning the amount of drug that 
can be delivered into a cell and whether bacterial toxins can effectively transport a 
therapeutic across epithelial barriers. This part of the thesis will investigate the 
utility of using bacterial toxins for this purpose by:  
 
- Identify if the ganglioside GM1 can affect the trafficking of bacterial 
toxins within non-polarised cells. 
- Assess the transport of bacterial toxins across polarised epithelial cells 
and examine the subsequent delivery of a therapeutic to a non-polarised 
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The pan class I PI3K inhibitors ZSTK474 and LY294002, the PI3Kα inhibitors A66 
and PIK-75, the PI3Kβ inhibitor TGX-221, the mTORC1/2 inhibitor AZD8055 (, the 
mTORC1 inhibitor rapamycin, the c-Jun N-terminal kinase (JNK) inhibitor 
SP600125 and the FGFR inhibitor PD173074 were purchased from Selleckchem 
(Suffolk, UK). Akt inhibitor VIII was acquired from Merck chemicals (Dramstadt, 
Germany). The PI3Kβ inhibitor GSK2636771 was obtained from Axon Medchem 
(Groningen, The Netherlands). The PI3Kα inhibitor BYL719 was provided by 
Novartis (Basel, Switzerland). The GSK3β inhibitor 1M was a gift from Professor 
Melanie Welham (University of Bath) (Bone et al., 2009). 
 
2.2 Cell Culture 
 
Human A549 (alveolar), A431 (epidermal), Caco-2 (intestinal) and HEK293T 
(kidney) epithelial cells were maintained in DMEM: F12 cell culture medium 
(Gibco, Paisley, UK) supplemented with 10% foetal bovine serum (FBS) (Source 
Bioscience, Nottingham, UK), 2 mM L-glutamine (Gibco), 100 U/ml penicillin and 
100 µg/ml streptomycin (Gibco). Murine 3T3 fibroblasts and J774.2 macrophages 
were also maintained in DMEM: F12 medium.  Wild type Chinese hamster ovary 
(CHO) cells and CHO cells deficient in CD91 (CHOCD91-/-), a gift from David 
Fitzgerald (National Cancer Institute, Bethesda, USA), were maintained in MEM 
medium (Gibco) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin. All cells were grown in a 37°C 95% air/ 5% 
CO2 incubator.  
 
Murine embryonic fibroblasts (MEF) deficient in the ganglioside GM1 (MEFGM1-/-) 
and A431 cells expressing GFP tagged Rab5, Rab7, Rab 11, Sec61 or Golgin 97 
were maintained at Professor Wayne Lencer’s laboratory (Boston Children’s 
Hospital, Boston, USA) in DMEM cell culture medium (Gibco) supplemented with 
10 % FBS.  
 
For EMT experiments A549 cells were cultured to ~70% confluence then serum 
starved overnight prior to the application of 5 ng/ml TGFβ (Peprotech, London, 
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UK). A549 cells were cultured for a further 48 hours in serum free conditions prior 
to analysis.   
 
Polarised monolayers of Caco-2 cells were grown by initially seeding 70,000 cells 
onto Transwell polycarbonate filters (0.4 µm pore size; Corning, Amsterdam, The 
Netherlands). Cells were then cultured for a period of 14-21 days until complete 
polarisation was achieved as indicated by consistent trans-epithelial electrical 
resistance values that were substantially above background.  
 
2.3 Embryonic lung isolation 
 
All animal experiments were performed within UK Home Office regulations and 
with the approval of the University of Bath ethics committee. E12.5 embryos were 
removed from timed pregnant CD1 mice and placed into ice cold plain DMEM: F12 
medium. Using a Leica MZ75 stereomicroscope the organ tree containing the 
heart, lungs, stomach, liver and pancreas was initially separated from the 
surrounding embryonic tissue (Figure 2.2). Whole embryonic lungs were then 
carefully removed from the organ tree and placed into ice cold DMEM: F12 cell 
culture medium.  
 
Whole lung explant culture 
Isolated whole lung explants were placed on top of a nuclepore track etched 
membrane (8 µm pore size; Fisher scientific, Paisley, UK) suspended on top of 
DMEM: F12 culture medium supplemented with 0.5% FBS (Del Moral and 
Warburton, 2010). Whole lung cultures were then placed in a 37°C incubator 
gassed with 95% air/ 5% CO2 for 48 hours. Images of lung growth were collected 
every 24 hours by a Canon EOS 1100D digital SLR camera attached to an 
Olympus CKX41 inverted light microscope. Airway branching was quantified by 
calculating the percentage increase in the number of terminal branches over 24 
and 48 hours relative to the number at isolation using the equation:  
 
% Increase in branching = (Terminal branches24/48 hours- Terminal branches0 hours) ÷ 
Terminal branches0 hours × 100. 
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Figure 2.1. Embryonic murine lung isolation. Images representing the separate stages 
of murine embryonic lung isolation are shown. Initially, E12.5 murine embryos are 
removed from their respective uteri. The organ tree is then dissected from the embryo 
from which the whole embryonic lung is removed. H – Heart, L – Liver, I – Intestine, Lb – 
Lung bud, S – Stomach.  
 
 
Whole lung explant time-lapse imaging 
E12.5 murine lung explants were prepared as above and placed on top of 
Transwell polycarbonate filters (3 µm pore size; Corning) inserted into DMEM: F12 
culture medium supplemented with 0.5% FBS. Transwell plates were then placed 
onto a Zeiss Axio Observer.Z1 microscope attached to a Hamamatsu CCD digital 
camera with incubator system XLmulti S1. Lung explants were maintained at 37°C 
in a 95% air/ 5% CO2 atmosphere over 48 hours. Images were collected every 15 
minutes and compiled into a time-lapse movie using Zeiss blue 2012 image 
software.  
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Embryonic lung epithelium isolation and culture 
Isolated lung epithelial cultures were prepared by taking freshly isolated E12.5 
whole lung explants and placing them into complete FBS in a glass petri dish. Fine 
insulin needles were then used to carefully remove the mesenchymal tissue from 
the epithelial branch tips. These epithelial tips were then separated from the 
remaining lung explant and placed into a growth factor reduced Matrigel (BD 
Bioscience, Oxford, UK) dome mixed 1:1 with DMEM: F12 cell culture medium 
supplemented with 0.5% FBS (Figure 2.2). Matrigel domes containing isolated 
epithelium were then allowed to polymerise at 37°C for 30 minutes before being 
covered with DMEM: F12 cell culture medium supplemented with 0.5% FBS and 
either 100 ng/ml FGF7 (Miltenyi Biotech, Surrey, UK), 100 ng/ml FGF1 (Miltenyi 
Biotech), 250 ng/ml FGF10 (Miltenyi Biotech) or 10-100 ng/ml FGF2 (Peprotech). 
Epithelial isolates were cultured for 96 hours with the culture medium being 
changed every 48 hours. Images of isolate growth were acquired at the start and 
end of culture. 
 
Figure 2.2. Schematic of murine embryonic lung epithelium isolation and culture. 
(1) E12.5 murine lung explants are dissected from timed pregnant females. (2) Epithelial 
tips are stripped of mesenchymal tissue using fine needles. (3) The mesenchyme is 
subsequently discarded and (4) the isolated epithelium is positioned inside a Matrigel 
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siRNA transfection of epithelial isolates 
SMART pool siRNA targeting either the catalytic p110α (PIK3CA) or p110β 
(PIK3CB) subunits of PI3K or the regulatory p85α (PIK3R1) or p85β (PIK3R2) 
subunits were purchased from Dharmacon (Leicestershire, UK). Sequences are 
provided in table 2.1.  
 
To aid siRNA delivery into isolated lung epithelium three different transfection 
reagents were examined: lipofectamine 2000 (Invitrogen, Paisley, UK), jetPRIME 
(Source Bioscience) and 3D-Fect (OZ Biosciences, Marseille, France). Complexes 
of transfection reagent with 10-50 nM siRNA were prepared following 
manufactures instructions prior to incubation with fresh mesenchyme-stripped 
murine lung epithelium. 
 
When using siRNA complexed with lipofectamine/jetPRIME, lung epithelial isolates 
were placed in solutions of transfection complexes on glass slides and incubated 
at 37°C in a humidified atmosphere for 2 hours. The isolates were then removed 
from transfection complex, placed into Matrigel domes and cultured as outlined in 
section 2.3.3. When using siRNA complexed with 3D-Fect the transfection 
complexes were combined with the Matrigel dome prior to the addition of a lung 
epithelial isolate.  
 
The resulting cultures were grown for 96 hours then the isolates were released 
from their Matrigel dome using BD Matrigel recovery solution (BD Bisocience). 
Subsequently, RNA was extracted from the isolates using Trizol reagent 
(Invitrogen). Chloroform was used to separate the RNA, which was then 
precipitated using propan-2-ol. Following centrifugation the resulting RNA pellet 
was washed with 75% ethanol, dried, then suspended in RNAse free water before 


































Table 2.1 List of PI3K siRNA sequences 
 
 
2.4 Lentiviral generation  
 
The lentivirus expression system allows for the stable expression of a desired 
gene in cells that are otherwise difficult to transfect. Difficulties in transfection may 
arise due to the toxicity associated with chemical transfection reagents or their 
inherent resistance to transfection (Lois et al., 2002). The lentiviral system is 
based on the human immunodeficiency virus and utilises four plasmids; pREV, 
pGAG/Pol, pVSVG, and a final plasmid for the vector to be inserted into the host 
cell. pREV and pGAG/Pol encodes for viral proteins required for efficient viral 
packaging. pVSVG encodes a viral protein required for effective infection of the 
viral particles into the host cells (Dull et al., 1998). These plasmids are combined 
and transfected into HEK293T cells that in turn generate and release viral particles 
into the cell culture medium. This media can then be collected and used to infect 
desired cells.  
 
Bacterial transformation and plasmid preparation 
When required, 1 µg of plasmid DNA was added to chemically competent Stbl3 
E.coli (Invitrogen) on ice. This was incubated for 30 minutes before being heat 
shocked at 42 °C for 30 seconds. SOC media (Invitrogen) was added to the vial 
on ice before being incubated for 1 hour at 37°C with agitation. The contents of the 
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vial were subsequently streaked onto an agar (Fisher Scientific) plate containing 
100 µg/ml ampicillin (Sigma-Aldrich, Poole, UK) and incubated overnight in a 37°C 
oven. Resulting bacterial colonies containing the plasmid DNA were selected the 
following day and cultured in 5 ml of ampicillin containing (100 µg/ml) LB broth 
(Fisher Scientific) for 8 hours. 50 µl of this culture was then placed into a further 50 
ml of ampicillin containing LB broth which was left to grow overnight at 37°C. 
Plasmids were then isolated from the bacterial culture using Qiagen midi prep kits 
(Qiagen, Manchester, UK) following the manufactures instructions. 
 
Lentiviral particle production 
HEK293T cells were grown to 50-70% confluence in a T75 cell culture flask. Four 
hours prior to transfection the cell culture medium was replaced with fresh DMEM: 
F12 culture medium supplemented with 10% FBS and 25 mM HEPES (pH 7.4).  
 
Plasmids composed of 7.71 µg pREV, 7.71 µg pGAG/Pol, 3 µg pVSVG and 12.84 
µg of pCLPS containing a GFP expression vector were combined with H2O to a 
final DNA concentration of 0.5 µg/µl. Plasmids were added to DMEM: F12 cell 
culture medium containing Mirus LT1 transfection reagent (Cambridge Bioscience, 
Cambridge, UK) and incubated for 45 minutes at room temperature. The resulting 
complexes were then added directly to HEK293T cells and incubated at 37°C in a 
5% CO2 incubator. After 48 hours, the resulting viral containing cell culture 
medium was collected, centrifuged to remove cellular debris, divided into aliquant 
volumes and stored at -80°C until use.   
 
Lentiviral infection of cells and embryonic lungs 
A549 cells were grown to 20-30% confluence prior to infection with viral particles. 
Cell culture medium was removed and replaced with fresh cell culture medium 
mixed with virus-containing medium (3:2). 24 hours after infection the infection 
medium was replaced with fresh cell culture medium. 24 hours thereafter the cells 
were analysed for expression of the viral construct.  
 
Following isolation of embryonic murine lungs, explants were cultured at the air 
liquid interface in cell culture medium containing viral medium (1:1). Viral medium 
was removed 24 hours after infection and the explants were analysed for vector 
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expression 24 hours thereafter. For isolated lung epithelium, fresh isolates were 
cultured in lentiviral medium for 1 hour prior to being embedded in Matrigel.  
 
2.5 CPP complex formation 
 
The CPPs HIV-TAT, Antennapedia and Transportan were sourced from 
Cambridge Bioscience (Table 2.2). Electrostatic, non-covalent, CPP: cargo 
complexes were formed by mixing solutions of either HIV-TAT (100 µM), 
Antennapedia (100 µM) or Transportan (50 µM) with either untagged or rhodamine 
tagged bovine serum albumin (BSA-568; 5 µM; Sigma-Aldrich), or VivoTag680-
tagged Sjögren syndrome antigen B (SSB; 50nM) siRNA (Merck, Pennsylvania, 
USA)(Wei et al., 2011) by vigorous pipetting. The resulting solutions were then 
incubated at 37°C for 30 minutes to allow for complex formation. Prior to complex 
formation solutions of HIV-TAT were sonicated for 5 minutes to dissociate 
homogenous complexes.  
 
CPP: cargo complexes were diluted 1:5 in serum free culture medium then applied 
to cells at final concentrations of 20 µM: 1 µM (CPP: BSA-568 Cargo) for HIV-TAT 
and Antennapedia and 10 µM: 1 µM for Transportan. For CPPs in complex with 
SSB siRNA, a final concentration of 10 nM siRNA was applied to cells. Cells were 
incubated with CPP: cargo complexes for 1 hour prior to the addition of serum 
containing culture medium. 
 
Cell Penetrating 
Peptide Amino Acid Sequence 
Molecular Weight 
(Da) 
HIV-TAT GRKKRRQRRRPQ 1720 
Antennapedia RQIKIWFQNRRMKWKK 2247 
Transportan GWTLNSAGYLLGKINKALAALAKKIL 2842 
Table 2.2. Amino acid sequences of cell penetrating peptides  
 
 
2.6 MTT cell viability assay 
 
(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl tetrazolium bromide (MTT) can be used to 
assess the viability of cells. MTT is converted to formazan by mitochondrial 
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succinic dehydrogenase in metabolically active, viable cells. Dissolving the 
formazan with DMSO releases an intense colour, which is proportional to cell 
viability. 
 
Cell culture medium was removed from cells at the required time and replaced 
with fresh cell culture medium containing 0.5 mg/ml MTT (Invitrogen). MTT-
containing cell culture medium is then removed after a further three hours of 
culture and replaced with DMSO to dissolve the produced formazan. Absorbance 
at 550 nm was then recorded.  
 
2.7 IL-6/8 ELISA 
 
ELISA based kits (eBioscience, Hatfield, UK) were used as per the manufacturers 
guidelines to determine the levels of IL-6 and IL-8 present in collected cell 
supernatant. Supernatant from cells cultured with 2 ng/ml TNFα (Peprotech) were 
used as a positive control.  
 
2.8 Preparation of labelled bacterial toxins 
 
Labelled bacterial toxins were provided by Professor Randall Mrsny (University of 
Bath). Briefly, a TEV protease cleavage site (ENLFQS), located between two 
cysteine residues forming a disulphide bond, followed by a histidine tag was 
introduced at the C-terminal end of non-toxic versions of PEx and Chx.  PEx and 
Chx were rendered non-toxic through amino acid substitutions at E553D for PEx 
and E581A for Chx. These protein constructs were then expressed in E.coli 
bacteria before being purified using immobilised metal ion affinity chromatography 
on a HisTrap FF column connected to an AKTA FPLC system (GE healthcare, 
Buckinghamshire, UK). This method isolates proteins labelled with a histidine tag.  
 
Purified protein was then incubated with the TEV protease AcTEV (Invitrogen) and 
the reducing agent DTT. This step separates the histidine tag from the toxin 
protein and reduces the disulphide bond between the two introduced cysteine 
residues, thus providing a free terminal cysteine residue with which to conjugate a 
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cargo. Toxin protein was isolated from the separated histidine tag through a 
superdex 200 HR10/30 gel filtration column (GE healthcare). 
 
Proteins containing a free cysteine residue can be linked to a cargo that contains a 
maleimide group. Maleimide-containing Alexa Fluor 488 or 568 (Invitrogen), or 
VivoTag680-tagged SSB siRNA was added in excess to solutions of isolated toxin 
protein and incubated at room temperature for two hours to initiate the coupling of 
the cargo to the protein. Labelled toxin was finally isolated from remaining free 
cargo by gel filtration before protein concentration was measured using a 
NanoDrop 2000c (Fisher). 
 
Cholera toxin subunit B (CTB) labelled with either Alexa Fluor 488 or Alexa Fluor 
568 was sourced from Invitrogen. 
 
GM1 loading into GM1 deficient MEF cells 
MEFGM1-/- cells were grown to 70% confluence on 12 mm glass coverslips prior to 
lipid loading. The cell culture medium was replaced with HBSS containing 0.034% 
free fatty acid BSA (Sigma-Aldrich) and cooled to 10°C. 5 µM GM1 C16:1, or 7.5 
µM GM1 C18:0 (Provided by Professor Wayne Lencer) was prepared in HBSS 
containing 0.034% free fatty acid BSA and then added to the cells (Chinnapen et 
al., 2012). Cells were then incubated at 10°C for 1 hour before un-adhered lipids 
were washed away with DMEM cell culture medium containing 10% FBS. Cells 
were finally warmed to 37°C before the addition of labelled bacterial toxins as 
outlined below. 
 
Bacterial toxin transport in non-polarised cells 
A431 cells expressing either EGFP tagged Rab5, Rab7, Rab11, Sec61 or 
Golgin97 were grown to 70% confluence on 12 mm glass coverslips. Cell culture 
medium was replaced with HBSS containing 20 µg/ml of either PEx-568, Chx-568, 
or 40 nM CTB-568. Cells were incubated at 37°C in a humidified atmosphere for 2 
hours before the toxin-containing HBSS was removed. Excess toxin was washed 
from cells using DMEM cell culture medium containing 10% FBS. Cells were then 
washed once with HBSS before been processed for immunofluorescence imaging 
as outlined in section 2.11. 
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2.9 Bacterial toxin transcytosis assay 
 
Monolayers of Caco-2 cells were prepared as described in section 2.2. Cell culture 
medium was replaced in both the apical and basolateral compartments with HBSS 
and the cells were allowed to equilibrate for 30 minutes at 37°C prior to the 
addition of bacterial toxins to the apical compartment. HBSS in the basolateral 
compartment was then collected and replaced at 15, 30, 60, 120 and 240 minutes 
of incubation. Where appropriate collected basolateral samples were measured for 
fluorescent content using a FLUOstar omega plate reader (BMG labtech, 
Aylesbury, UK).  
 
Dextran permeability assay 
Dextran is a high molecular weight polymer of glucose that is incapable of 
efficiently crossing polarised cells. Dextran can therefore be used to assess the 
integrity of epithelial monolayers. Following application of dextran to the apical 
compartment of a Transwell insert the amount of dextran present in the basolateral 
compartment is proportional to the integrity of the cell monolayer.  
 
Subsequent to a transcytosis assay, 200 µl of 0.5 mg/ml FITC-labelled 4 kDa 
dextran (Sigma-Aldrich) was added to the apical compartment of a transwell. The 
cells were then incubated at 37°C for 30 minutes before the basolateral 
compartment was collected and assayed for fluorescent content.  
 
Analysis 
Fluorescent values were obtained for dextran from each monolayer-containing well 
(DexTotal), a well devoid of cells (DexBlank), and the background HBSS fluorescence 
(Background). These values were then used to calculate the relative permeability 
of each Transwell (Perm factor) using the equation: 
 
   Perm factor = (DexTotal – Background) ÷ (DexBlank– Background) 
 
Fluorescent values were obtained for labelled toxin from each time point (FluorTotal) 
and the background fluorescence. Using these values and the corresponding 
dextran permeability factor (Perm factor) a final fluorescent value relative to the 
Chapter 2: Materials and Methods 	  
 57 
amount of labelled toxin present in the basolateral compartment that had crossed 
by transcytosis (FluorToxin) was calculated using the equation: 
 
   FluorToxin = (FluorTotal – Background) – ((FluorTotal− Background) × Perm factor))  
 
Incorporation of bacterial toxins into non-polarised cells following 
transcytosis 
Coverslips containing attached J774.2 macrophages were placed in the 
basolateral compartment of Transwell chambers containing monolayers of Caco-2 
cells in the apical compartment. 20 µg of either PEx-488 or PEx-siRNA was then 
added to the apical compartment in DMEM: F12 culture medium supplemented 
with 10% FBS. Cells were incubated up to 48 hours at 37°C before the basolateral 
cells were processed for immunofluorescence (2.11) or Western blotting (section 
2.12). 
 
2.10 FACS analysis 
 
To analyse fluorescent content, adherent cells were removed from cell culture 
plastic by incubation with 0.05% trypsin at 37°C. Cell suspensions were then 
washed by centrifugation, with the cell pellet being suspended in PBS. Cell 
suspensions were finally centrifuged and suspended in 500 µl PBS supplemented 
with 2% FBS and transferred to FACS tubes. Fluorescent content was then 
assessed by flow cytometry using a BD FACS Canto flow cytometer (BD 
Bioscience) 
 
2.11 Immunofluorescence  
 
Sample preparation 
Lung explant cultures were removed from nucleopore track etched membranes 
and placed into the fixative MEMFA (3.8% formaldehyde, 0.15 M MOPS, 2 mM 
EGTA, 1 mM MgSO4, pH7.4) for 1 hour. MEMFA solution was thoroughly washed 
from the lungs using PBS before the fixed lung explants were permeabilised with 
1% Triton-X 100 for 1 hour (Sigma-Aldrich).  
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E12.5 embryonic branch tips stripped of mesenchyme were fixed in 4% 
paraformaldehyde (PFA) for 20 minutes and permeabilised with 0.05% saponin for 
a further 20 minutes. Alternatively, when examining desmin and αSMA expression, 
samples were fixed/permeabilised with ice-cold acetone:methanol (1:1) for 5 
minutes. 
 
Isolated epithelial cultures were first removed from their Matrigel dome through 
incubation with ice-cold Matrigel recovery solution for 40 minutes. Freed epithelial 
isolates were washed in PBS before being fixed with 4% PFA for 20 minutes and 
permeabilised with 0.05% saponin for a further 20 minutes.  
 
Adherent cells cultured on either glass coverslips or Transwell filters were fixed for 
20 minutes in 4% PFA before being permeabilised with 0.05 % saponin for a 
further 20 minutes where appropriate.  
 
Immunofluorescence staining 
Following permeabilisation samples were blocked with 2% BSA in PBS for 1 hour 
and incubated with primary antibody (Table 2.3) diluted in 2% BSA in PBS for 1 
hour at room temperature (overnight at 4°C for whole lung explants). Primary 
antibody was then removed and excess washed away using 2% BSA in PBS. 
Samples were then incubated with an appropriate secondary antibody (Table 2.4) 
(diluted 1/200) as indicated for 2 hours. Secondary antibodies were subsequently 
removed and excess washed away using 2% BSA in PBS. Samples were finally 
incubated in a 1 µg/ml solution of 4', 6-diamidino-2-phenylindole (DAPI, Sigma-
Aldrich) for 20 minutes to label the cell nuclei. Where indicated cellular F-actin was 
labelled by incubating the samples for a further 20 minutes with 1 µM rhodamine-
conjugated phalloidin (Sigma-Aldrich). Excess DAPI and/or rhodamine-conjugated 
phalloidin were removed by washing the samples in PBS before mounting with 
MOWIOL solution onto microscope slides. 
 
Fluorescent images were acquired using a Zeiss LSM 510 confocal microscope. 
Overview images of whole lung explants were acquired using tile-scan settings 
creating a patchwork of 9x9 images each taken with a 40x objective. Isolated 
murine lung epithelium and cell cultures were imaged using a 63x objective unless 
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otherwise stated. Images of MEFGM1-/- cells and A431 cells expressing EGFP 
tagged proteins were acquired using a Zeiss Spinning Disk Confocal microscope 
with Slidebook software (Intelligent Imaging Innovations, CO).  
 
Isolated lung epithelium confocal analysis 
Fluorescent images acquired from isolated lung epithelium labelled for Ki67 and 
with DAPI were collected. Channels were separated and each image adjusted to 
remove background and noise before being converted to a binary image using 
ImageJ software. Merged nuclei were then divided using the ‘watershed’ program 
before the number of nuclei was quantified using the ‘analyse particles’ function, 
discounting any particle less than 5 pixels in size. This was repeated for each 
channel. The resulting values were converted to give a percentage of Ki67 positive 
cells relative to the total number of cells in a single image. 
 
Analysis of CPP mediated BSA-568 cell uptake  
To quantify and compare the delivery of BSA-568 by different CPPs confocal 
images were acquired utilising the same fluorescent settings for each condition. 
Mean fluorescent intensities for rhodamine from each image were then measured 
using the Zeiss LSM image browser software. This value was then adjusted 
relative to the number of cells in the image to give a value representative of the 
amount of BSA-568 incorporated per cell. This could then be used to calculate the 
fold change of BSA-568 delivery between different CPPs. 
 
Co-localisation analysis using iMAB software 
A quantitative value for co-localisation can be calculated from fluorescent images 
composed of two or more signals. Mander’s coefficient represents the fraction of 
co-localising objects in each compartment of a dual-channel fluorescent image 
(Manders et al., 1993).  
 
Fluorescent images were acquired from MEFGM1-/- cells incubated with 
fluorescently labelled bacterial toxin and stained for the Golgi marker GM130. 
iMAB image software (Dr Ramiro Massol, Boston Children’s Hospital, Boston, 
USA)  was used to generate masks encompassing the fluorescent signal for 
labelled bacterial toxin (MaskToxin) and the signal for the GM130 
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immunofluorescence. These two masks were then overlaid and a third mask was 
generated over sites where there was co-localisation (MaskCo-local). Using the 
fluorescent intensities measured from each mask a Mander’s co-localisation 
coefficient with respect to the fraction of signal from the bacterial toxin present in 
the Golgi could then be generated. This was calculated by the equation: 
 
Mander’s Coeff. = Intensity from MaskCo-local ÷ Intensity from MaskToxin 
 
2.12 Western Blotting 
 
Sample preparation  
Whole lung explants were removed from culture and lysed by rotating at 4°C for 2 
hours in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Nonidet P40, 1 mM 
sodium vanadate, 1 mM sodium molybdate, 10 mM sodium fluoride, 40 µg/ml 
PMSF, 0.7 µg/ml pepstatin A, 10 µg/ml aprotinin, 10 µg/ml leupeptin and 10 µg/ml 
soybean trypsin inhibitor). Lysed lung explants were then centrifuged at 10,000 rcf 
at 4°C for 10 minutes to remove debris and the protein containing supernatant 
collected. Samples were diluted in sample buffer (60 mM Tris-HCl pH 6.8, 2% 
SDS, 10% glycerol, 5% 2-mercaptoethanol, 0.01% bromophenol blue) and boiled 
for 5 minutes prior to electrophoresis.  
 
Adherent cell were cultured for the required length of time before the media was 
discarded and excess washed with ice cold PBS. Cells were then removed from 
tissue culture plastic with the aid of a cell scraper following the addition of lysis 




Samples were loaded onto a 10% SDS-PAGE gel positioned in a gel tank 
containing running buffer (25 mM Tris-Base, 192 mM glycine, 0.1% SDS). Proteins 
were stacked at 70V for 20 minutes then resolved at 150V for roughly an hour until 
blue sample buffer could be seen at the base of the gel. Proteins were transferred 
onto nitrocellulose membrane (Fisher Scientific) at 40 mA per membrane for 1 
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hour using semi-dry transfer buffer (48 mM Tris-Base, 39 mM glycine, 0.0375% 
SDS, 20% methanol) and apparatus.   
 
The resulting protein-containing membrane was blocked in 5% milk in TBS tween 
(20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20) for 1 hour. Following the 
blocking step membranes were incubated in primary antibody (Table 2.3), diluted 
in TBS tween containing 1% BSA and 0.01% sodium azide, overnight at 4°C. The 
primary antibody was then removed and the membrane washed several times in 
TBS tween before the membrane was incubated for 1 hour in a species 
appropriate horseradish peroxidase conjugated secondary antibody (Table 2.4; 
diluted 1 in 10,000). The membrane was finally washed in TBS tween and protein 
bands visualised using an EZ-ECL chemiluminescence detection kit (Geneflow, 
Staffordshire, UK) and developed using either a ImageQuant developer (GE 
healthcare) or an X-ray film developer (Photon Imaging Systems, Swindon, UK). 
Where appropriate membranes were stripped of their initial antibodies by 
incubating the membrane in stripping buffer (100 mM 2-mercaptoethanol, 2% 
SDS, 62.5 mM Tris-HCl, pH 6.7) for 30 minutes at 60°C. Excess 2-
mercaptoethanol was removed through repeated washing with TBS tween for 1 
hour before being re-blocked in 5% milk in TBS tween and then re-probed with 
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Antibody Species Manufacturer Catalogue Number Dilution 
E-Cadherin Mouse BD Bioscience 610182 1/100 IF 1/1000 WB 




Rabbit Cell Signalling 2211S 1/1000 WB 
ERK1 Rabbit Santa Cruz SC-93 1/1000 WB 
SOX9 Rabbit Millipore AB5535 1/100 IF 
Pro-SPC Rabbit Seven Hills WRAB-9337 1/100 IF 
TTF-1/ Nkx2.1 Rabbit Seven Hills WRAB-1231 1/100 IF 
Ki67 Mouse BD Bioscience 610968 1/100 IF 
Phospho-Histone H3 (PH3) Mouse Millipore 05-806 1/100 IF 
FGFR1/ flg Mouse Santa Cruz SC-121 1/50 IF 
Desmin Mouse Dako M076029-2 1/100 IF 
Occludin Mouse Invitrogen 33-1500 1/100 IF 
β-Catenin Rabbit Cell Signalling 9582P 1/100 IF 
Fibronectin Mouse Sigma-Aldrich F7387 1/100 IF 
Platelet endothelial cell 





αSMA Mouse Sigma-Aldrich A5228 1/100 IF 
Slug Rabbit Cell Signalling 9585S 1/100 IF 
Phosphorylated NFκB p65 
(Ser563) Rabbit Cell Signalling 3033 1/1000 WB 
SSB Rabbit Sigma-Aldrich HPA012385 1/500 WB 
GM130 Mouse BD Bioscience 610823 1/200 IF 
Table 2.3 List of primary antibodies used for immunofluorescence (IF) and/or   






Antibody Species Manufacturer 
HRP-conjugated anti Rabbit Goat DAKO 
HRP-conjugated anti Mouse Goat DAKO 
FITC-conjugated anti Rabbit Goat Vector Labs 
FITC-conjugated anti Mouse Horse Vector Labs 
Texas Red-conjugated anti Mouse Horse Vector Labs 
Texas Red-Conjugated anti Rat Goat Vector Labs 
Alexa Fluor 647-Conjugated anti Mouse Goat Invitrogen 
Alexa Fluor 568-conjugated anti Rabbit Donkey Invitrogen 
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2.13 Gelatin Zymography 
 
Gelatin zymography is an electrophoretic technique enabling the semi-quantitative 
analysis of the amount and size of proteinases present in a sample based on their 
digestion of a protease substrate, such as gelatin, that is incorporated into an 
SDS-PAGE gel.  
 
Supernatants were collected from stimulated cells and mixed with sample buffer 
(60 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue). 
Samples were then loaded into a 10% SDS-PAGE gel containing 1% w/v porcine 
skin gelatin (Sigma-Aldrich). Proteins were then stacked at 50V for 20 minutes 
then resolved at 150V for a further hour. The gel was then placed into developing 
buffer (50 mM Tris-base pH 7.5, 200 mM NaCl, 5 µM ZnCl, 5 mM CaCl) containing 
2.5% w/v Triton X-100 for 1 hour to remove SDS from the gel and renature 
proteinases present within the sample. Renatured gels were then placed 
developing solution and developed overnight at 37°C. Protein present in the gel 
was then visualised by incubating the gel with SimplyBlue™ SafeStain (Invitrogen) 
for 1 hour. An absence of blue protein stain in the gel was indicative of proteinase 
activity.   
 
2.14 Statistical analysis 
 
Data are represented as mean values ± standard error of the mean (SEM). 
Statistical analysis was performed using GraphPad Prism 6 software. Significant 
differences between experimental and control groups was determined by one-way 
ANOVA followed by Dunnet’s post hoc test for experiments with three or more 
groups and Student’s T-test for experiments with two groups.  
 
Lung explant experiments where branching was measured over 24 and 48 hours 
was analysed for significance by two-way ANOVA with repeated measures 
followed by Dunnet’s post hoc test where appropriate.  
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A statistically significant difference was accepted if P<0.05. Significance is 
indicated on graphical representations of the data by the marks: * P<0.05, ** P< 
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An indication for the severity of a cancer is the ability for the cancerous epithelial 
cells to migrate away from the initial tumour, forming secondary tumours. Migration 
of epithelial cells is commonly found during development particularly in the 
formation of epithelial branches, where epithelial cells invade the surrounding 
mesenchymal tissue in a highly stereotyped fashion. It is therefore unsurprising 
that signalling events in epithelial cancers are also found in the development of the 
lung (De Leij et al., 1987). Similarities between the development of an organ and 
disease are not limited to cancer; a developmental link to fibrosis (Shi et al., 2009), 
COPD (Chen et al., 2005), and asthma (Warner et al., 1998) has also been 
established. Understanding how these signalling events influence the behaviour of 
the cells in their developmental setting may therefore lead to increased 
understanding of the disease state and novel therapeutic approaches.  
 
A common pathway dysregulated during many pathologies is the PI3K signalling 
pathway (Engelman, 2009; Wojtalla et al., 2013). This pathway has also been 
found to be active during the branching program of the lung (Wang et al., 2005). 
However, the precise role for PI3K in this branching program of the lung has yet to 
be fully established with some work reporting a positive role for PI3K (Wang et al., 
2005), and others a negative role (Xing et al., 2008). Moreover, much of the work 
on PI3K in epithelial branching to date has been conducted in other branching 
organs, namely the mammary and salivary glands (Larsen et al., 2003; Utermark 
et al., 2012). Comprehensive understanding of how PI3K functions in the 
branching program of the lung will consequently help influence therapeutics 
directed at PI3K in lung cancers and other developmentally relevant diseases such 
as fibrosis.  
 
EMT is a process relevant to both cancer and fibrosis as it gives rise to motile 
epithelial cells that secrete extracellular matrix. PI3K has been reported to be 
active during hypoxia and TGFβ induced EMT in a number of epithelial cell lines. 
PI3K inhibition has been suggested to prevent the induction of EMT in epithelial 
cell lines although an isoform dependence in this process has yet to be elucidated 
(Bakin et al., 2000; Chen et al., 2012; Yan et al., 2009).  
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The aim of this current chapter was first to examine PI3K in the induction of EMT 
in lung epithelial cells using more selective inhibitors of PI3K and its separate 
isoforms. Secondly, we aimed to establish physiologically relevant models of 
embryonic lung branching, which could be manipulated either genetically or 
pharmacologically to assess the role of PI3K in the branching process. 
 
3.2 PI3K contributes to TGFβ EMT in A549 alveolar epithelial cells 
 
EMT can be easily induced in non-polarised epithelial cells through the application 
of TGFβ. This is characterised in A549 cells by the loss of the epithelial protein E-
Cadherin at the cell surface and the subsequent gain of the mesenchymal protein 
fibronectin following exposure to TGFβ over 48 hours (Figure 3.1A,B). Moreover, 
once these cells had acquired a mesenchymal phenotype they begin to secrete 
MMP-9 (~92 kDa) and MMP-2 (~72 kDa) as identified by gelatin zymography 
(Figure 3.1C). The application of the pan class I PI3K inhibitor ZSTK474 prior to 
the addition of TGFβ appeared to slightly reduce the impact of TGFβ induced E-
Cadherin loss at the cell surface (Figure 3.1A). However, western blot analysis 
revealed that E-Cadherin protein levels were comparable between TGFβ alone 
and TGFβ plus ZSTK474 (Figure 3.1B). This would suggest that PI3K inhibition 
did not prevent the loss of E-Cadherin protein but instead reduced the re-
localisation of the protein from the cell surface. Cells cultured with both TGFβ and 
ZSTK474 also continued to express fibronectin. Interestingly, MMP-2 and MMP-9 
production was markedly reduced with pre-treatment of ZSTK474 (Figure 3.1C).  
 
To identify the isoform of PI3K involved in EMT we applied the PI3Kα selective 
inhibitor PIK-75 and the PI3Kβ selective inhibitor TGX-221 to A549 cells prior to 
the addition of TGFβ. As with ZSTK474, PIK-75 and TGX-221 both appeared to 
reduce TGFβ induced E-cadherin loss from the cell surface, although western blot 
analysis suggested comparable protein levels (Figure 3.2A,B). Moreover PIK-75, 
but not TGX-221, was able to reduce the production of MMP-2 and MMP-9 (Figure 
3.2C). These data would therefore suggest an involvement of PI3Kα in the 
process of EMT.   
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Figure 3.1 Inhibition of PI3K with ZSTK474 prevents complete induction of EMT in 
A549 cells. A. Confocal images of E-Cadherin (Top panels) and fibronectin (bottom 
panels) expression in A549 cells cultured for 48 hours with either 0.1% DMSO (Control), 5 
ng/ml TGFβ or 5 ng/ml TGFβ with 1 µM ZSTK474. Scale bar = 20 µm. Images are 
representative of three independent experiments. B. Western blot analysis of E-Cadherin 
and ERK expression in A549 cells cultured for 48 hours with 5 ng/ml TGFβ alone or with 
either 0.01, 0.1, 1 or 10 µM ZSTK474. C. Gelatin zymography of cell supernatants 
collected from A549 cells after 48 hours of culture with 5 ng/ml TGFβ alone or with 1 µM 
ZSTK474. Protein and zymography bands are representative of three separate 
experiments. 
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 Figure 3.1 Inhibition of PI3Kα, but not PI3Kβ, prevents complete induction of EMT 
in A549 cells. A. Confocal images of E-Cadherin (Top panels) and fibronectin (bottom 
panels) expression in A549 cells cultured for 48 hours with either 0.1% DMSO (Control), 5 
ng/ml TGFβ or 5 ng/ml TGFβ with either 100 nM PIK-75 or 100 nM TGX-221. Scale bar = 
20 µm. Images are representative of two independent experiments. B. Western blot 
analysis of E-Cadherin and ERK expression in A549 cells cultured for 48 hours with 5 
ng/ml TGFβ alone or with 0.1, 1, 10 or 100 nM of either PIK-75 or TGX-221. C. Gelatin 
zymography of cell supernatants collected from A549 cells after 48 hours of culture with 5 
ng/ml TGFβ alone or with 100 nM of either PIK-75 or TGX-221. Protein and zymography 
bands are representative of two separate experiments. 
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3.3 Cultures of murine embryonic lungs recapitulate the branching process 
 
Lung branching morphogenesis is a complex process requiring a number of 
signalling factors and the co-operative growth of a number of cell types. To 
effectively model this process in order to assess the role of PI3K we established a 
model of branching using embryonic lungs to best recapitulate the branching 
process. Lungs were isolated from embryos taken during the early days of the 
pseudoglandular stage of lung development (E12.5) and placed into culture at the 
air-liquid interface as this method has been reported to adequately recapitulate the 
branching process in a manner that can be easily manipulated (Del Moral and 
Warburton, 2010)  (Figure 3.3A).  Over 48 hours the epithelial branches enlarged 
and became more numerous as evidenced by an increase in the number of 
terminal branches (Video 3.1; Figure 3.3B,C). Further, these explant cultures 
exhibited periodic waves of contraction along the proximal branches (Video 3.2), 
consistent with reported observations (Schittny et al., 2000). Confocal analysis of 
the lung explants after 48 hours of culture revealed that these cultures contained 
numerous cell types and a morphology consistent with the embryonic lung during 
the pseudoglandular stage of development. Primitive epithelial tubules are found 
throughout the explants that are positive for the adherens junction E-Cadherin 
(Figure 3.3D,F). The expression of the tight junction marker occludin was also 
observed at the centre of epithelial branches implying the presence of a luminal 
surface (Figure 3.3E). This expression pattern for tight junctions has also been 
reported in the developing salivary glands (Hieda et al., 1996). Further, the distal 
ends of the epithelial tubes express the transcription factor SOX9 (Figure 3.3D), a 
known marker of distal lung epithelium (Rockich et al., 2013; Turcatel et al., 2013). 
These epithelial tubes develop within mesenchymal tissue observed by the 
expression of the mesenchymal marker Slug (Figure 3.3E). Moreover, the 
epithelial branches are surrounded by vasculature indicated by the tissue staining 
for the endothelial cell surface marker CD31 (Figure 3.3F). Again, the mutual 
development of the vasculature with the branching epithelium is consistent with 
the reported interactions between these two cell types (Lazarus et al., 2011).  
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Figure 3.3. Culture of whole embryonic murine lungs recapitulates the 
developmental state. A. Light microscope images of E12.5 murine lung explants cultured 
over 48 hours at the air liquid interface. Images presented are representative of at least 
twelve explants. Scale bar = 0.5 mm. B Quantification of the number of terminal branches 
over 48 hours. Bars show mean ± s.e.m from n=12. C. Percentage increase in the number 
of terminal branches at 24 and 48 hours relative to the number of branches present at 
isolation. Bars show mean ± s.e.m from n=12. D-F. Confocal images of E-Cadherin (D, F, 
left panels), SOX9 (D, middle panel), occludin (E, left panel), Slug (E, middle panel) and 
CD31 (F, middle panel) expression in lung explants following 48 hours of culture. Images 
are representative of three explants. Scale bar = 20 µm.  
Chapter 3: Phosphoinositide 3-kinase in Lung Branching Morphogenesis 	  
 72 
3.4 Inhibition of class I PI3K signalling potentiates lung branching  
 
To examine the role of the PI3K pathway in branching morphogenesis we used a 
range of pharmacological agents targeting various elements of this pathway with 
high selectivity to limit the influence off target effects. We initially applied inhibitors 
targeting the entire class I family of PI3K to cultures of whole lung explants. Over 
48 hours the pan class I inhibitor of PI3K ZSTK474 (Kong and Yamori, 2007) 
significantly increased branching in a concentration dependent manner compared 
to DMSO controls (Figure 3.4A,B). This enhancement of branching correlated with 
a concentration-dependent decrease in levels of phosphorylated Akt (Figure 3.4C), 
an indirect measure of PI3K activity (Franke et al., 1995). Immunofluorescence 
staining of the epithelial marker E-Cadherin also revealed that PI3K inhibition by 
ZSTK474 induced the formation of significantly more, albeit smaller, branches than 
controls (Figure 3.4D).  
 
As well as the ZSTK474 compound we also applied the less specific pan inhibitor 
of class I PI3K LY294002 (Vlahos et al., 1994) to cultures of whole lungs as this 
compound has been used previously to examine PI3K in the branching process of 
the lungs (Wang et al., 2005), urogenital sinus tissue  (Ghosh et al., 2011), and 
salivary glands (Larsen et al., 2003). At 10 µM LY294002 induced a similar 
enhancement of branching as seen with the ZSTK474 compound (Figure 3.5). 
However, at higher concentrations of LY294002 (≥20 µM) we saw a reduction in 
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Figure 3.4. Inhibition of PI3K with ZSTK474 promotes epithelial branching in murine 
lung explants. Light microscope images of E12.5 murine lung explants cultured with 
either 0.1% DMSO (Control) or 0.1, 1 or 10 µM ZSTK474 over 48 hours. Images 
representative of at least twelve explants per condition are shown. Scale bar = 0.5 mm B. 
Percentage increase in epithelial branching over 24 and 48 hours relative to the number 
of branches at initial isolation. Bars show mean ± s.e.m from n=20 C. Western blot 
analysis for levels of phosphorylated Akt (p-Akt) and ERK in explants following 48 hours of 
culture. Protein bands representative of three separate experiments. D. Confocal image of 
E-Cadherin expression in lung explants cultured with or without 10 µM ZSTK474 for 48 
hours. Scale bar = 200 µm. *** P<0.001, * P<0.05, * NS = Not Significant, compared with 
control. 
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Figure 3.5 LY294002 induces contrasting effects on lung branching. A. Light 
microscope images of E12.5 murine lung explants cultured with 0.1% DMSO (Control) or 
10, 20 or 30 µM LY294002 over 24 and 48 hours. Images are representative of at least 
nine explants per condition. Scale bar = 0.5 mm B. Percentage increase in epithelial 
branching over 24 and 48 hours relative to the number of branches at initial isolation. Bars 
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Inhibition of downstream signalling components of PI3K potentiates lung 
branching 
To further confirm the involvement of PI3K in the branching process we examined 
the effect of inhibiting downstream signalling components of PI3K, namely Akt and 
mTOR. As with ZSTK474, Akt inhibitor VIII (Lindsley et al., 2005) produced a 
concentration dependent increase in branching (Figure 3.6A,B). This increase in 
branching was accompanied by a reduction in phosphorylated Akt at the Ser473 
position (Figure 3.6C). Phosphorylated Akt at Ser473 can be used as an indirect 
method of detecting Akt activation due to this residue being phosphorylated by 
mTORC2 following activation by Akt (Facchinetti et al., 2008).  
 
Increased branching was also seen with the mTORC1/2 inhibitor AZD8055 
(Chresta et al., 2010), but not with the mTORC1 inhibitor rapamycin (Guba et al., 
2002) (Figure 3.7A,B). Enhanced branching with 0.1 µM AZD8055 compared to 
controls was also apparent with time-lapse microscopy (Videos 3.1 and 3.3). 
Following activation of mTORC1 by Akt, mTORC1 phosphorylates S6 ribosomal 
protein (Julien et al., 2010). S6 ribosomal protein can therefore be used as an 
indicator of mTORC1 activity. Western blot analysis revealed a reduction in 
phosphorylated levels of S6 ribosomal protein following culture with either 
AZD8055 or rapamycin. However, only AZD8055 induced a loss in levels of 
phosphorylated Akt (Figure 3.7C). 
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Figure 3.6. Inhibition of Akt promotes epithelial branching. A. Light microscope 
images of E12.5 murine lung explants cultured with 0.1% DMSO (Control) or 0.1, 1 or 10 
µM Akt inhibitor VIII over 48 hours. Images are representative of at least twelve explants 
per condition. B. Percentage increase in epithelial branching over 24 and 48 hours 
relative to the number of branches at initial isolation. Bars show mean ± s.e.m from n=12 
C. Western blot analysis for levels of phosphorylated Akt (p-Akt) and ERK in explants 
following 48 hours of culture. Protein bands representative of three separate experiments. 
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Figure 3.7. Inhibition of mTORC2 but not mTORC1 promotes epithelial branching. A. 
Light microscope images of E12.5 murine lung explants cultured in either 0.1% DMSO 
(Control), 1 µM rapamycin or 0.1 µM AZD8055. Images representative of at least twelve 
explants per condition are shown. B. Percentage increase in epithelial branching over 24 
and 48 hours relative to the number of branches at initial isolation. Bars show mean ± 
s.e.m from n=12 C. Western blot analysis for levels of phosphorylated S6 ribosomal 
protein (p-S6), phosphorylated Akt (p-Akt) and ERK in explants cultured for 48 hours. 
Protein bands representative of three separate experiments Scale bar = 0.5 mm. *** 
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The alpha isoform of PI3K regulates branching morphogenesis in the lung 
Given that PI3Kα and PI3Kβ have a divergent role in the branching program of the 
mammary gland (Utermark et al., 2012), we sought to establish the roles of 
individual PI3K isoforms in the branching program of the lung. Whole lung explants 
cultured with a selective inhibitor of PI3Kα, BYL719 (Furet et al., 2013), produced 
a large enhancement of branching compared with DMSO controls (Figure 3.8A). 
Consistent with this, BYL719 induced a reduction in levels of phosphorylated Akt 
(Figure 3.8C). No alteration in branching was seen when whole explants were 
cultured with a selective inhibitor of PI3Kβ, GSK2636771 (Sanchez et al., 2012), 
over 48 hours (Figure 3.8). Further, no reduction in phosphorylated Akt was 
detected from explants cultured with GSK2636771, suggesting a lack of 
involvement for PI3Kβ in this system. 
 
To confirm these findings we first examined the BYL719 and GSK2636771 
compounds over their effective concentration range to determine if the inhibitors 
were exhibiting off target effects. The BYL719 compound produced a 
concentration dependent increase in branching (Figure 3.9A), wheras 
GSK2636771 had no observable effects on branching morphogenesis at 
concentrations up to 10 µM (Figure 3.9C). To further exclude the possibility of an 
off target affect and confirm the involvement of PI3Kα we used a second set of 
PI3Kα and PI3Kβ selective inhibitors. As with BYL719, a concentration dependent 
enhancement of branching was observed with the PI3Kα inhibitor A66 (Jamieson 
et al., 2011) (Figure 3.9B). Similarly, no change in branching was seen at 
concentrations less than 10 µM with the PI3Kβ inhibitor TGX-221 (Figure 3.9D). A 
small enhancement of branching was seen with TGX-221 at 10 µM. However, this 
occurred at concentrations where other isoforms of PI3K would be inhibited 
(Jackson et al., 2005). 
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Figure 3.8. PI3Kα, but not PI3Kβ, regulates lung branching morphogenesis. A. Light 
microscope images of E12.5 murine lung explants cultured with 0.1% DMSO (Control), 10 
µM BYL719 or 10 µM GSK2636771. Images representative of at least twelve explants per 
condition are shown. B. Percentage increase in epithelial branching over 24 and 48 hours 
relative to the number of branches at initial isolation. Bars show mean ± s.e.m from n=12   
C. Western blot analysis for levels of phosphorylated Akt (p-Akt) and ERK in explants 
following 48 hours of culture. Protein bands representative of three separate experiments. 








Figure 3.9. Concentration dependent effects of PI3Kα and PI3Kβ selective inhibitors 
on branching morphogenesis. Percentage increase in branching of E12.5 murine lung 
explants cultured with 0.1% DMSO (Control) or 0.1, 1 or 10 µM of either the PI3Kα 
inhibitors BYL719 (A) and A66 (B) or the PI3Kβ inhibitors GSK2636771 (C) and TGX-221 
(D) over 24 and 48 hours. Bars show mean ± s.e.m from n=12. ***P<0.001 *P<0.05, 
compared with control. 
 
3.5 Isolated lung epithelium: a model to directly examine the branching 
epithelium 
 
The whole lung explant model can be cultured with minimal supplementation to the 
cell culture medium (0.5% FBS in DMEM: F12 medium), easily manipulated 
pharmacologically, and provides a quantifiable output related to epithelial 
branching. Despite these advantages the whole explant model suffers from 
several caveats. Of particular note is that it is difficult to determine if an affect on 
branching is specific to the lung epithelium or secondary to an effect on the 
mesenchyme. This caveat is highlighted by work examining the interplay between 
the branching epithelium and the vasculature of the lung (Lazarus et al., 2011). In 
this study the lungs of mice expressing a soluble VEGFR under the control of the 
SPC promoter exhibited reduced vascularisation, and as a consequence reduced 
Chapter 3: Phosphoinositide 3-kinase in Lung Branching Morphogenesis 	  
 81 
branching, compared to their wild type counterparts. This would imply that 
inhibiting the growth of the vasculature would have a knock on effect of reducing 
epithelial branching. 
  
To overcome this caveat we utilised a method to isolate and culture mesenchyme-
free embryonic lung epithelium (Del Moral and Warburton, 2010). Terminal 
branches were removed from isolated E12.5 lung explants and the mesenchyme 
stripped using fine needles (Figure 3.10A). To confirm that mesenchyme stripping 
was efficient we examined isolated branch tips stripped of mesenchyme for the 
presence of mesenchymal cells. Isolated epithelium contained non-epithelial cells 
as evidenced by the presence of DAPI positive cells that did not express the 
epithelial marker E-Cadherin (Figure 3.10B, bottom panels). Further, some cells 
expressed the mesenchymal marker desmin (Figure 3.10B, top panels). This 
would imply that the stripping process is not entirely efficient and some 
mesenchymal cells do remain. Nevertheless isolated epithelium failed to grow 
when placed in culture in non-supplemented cell culture medium suggesting that 
the remaining mesenchyme is insufficient to maintain the viability of the epithelium 
(Figure 3.10C). 
 
Isolated lung epithelium requires the addition of growth factors in order to maintain 
the growth of the isolate. Different growth factors produce different morphological 
effects on the tissue. FGF7 treatment induces the formation of large cystic 
structures after 96 hours of culture whereas FGF10 induces the formation of 
epithelial branches (Bellusci et al., 1997; Cardoso et al., 1997). FGF1 also 
produces a branched response, but to a lesser extent than FGF10 (Figure 3.10C). 
The effects of pharmacological agents directly on the lung epithelium can therefore 
be assessed with respect to the growth factor used in the culture system. 
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Figure 3.10. Mesenchyme-stripped branch epithelium still shows evidence of intact 
mesenchymal cells yet requires additional growth factors for development. A. Light 
microscope images of an isolated E12.5 murine lung branch before (top panel) and after 
(bottom panel) mesenchyme removal. Scale bar = 200 µm. B. Expression of E-Cadherin 
(top panels) and desmin (bottom panels) in isolated murine lung branches following 
removal of mesenchyme. Scale bar = 20 µm. C. Light microscope images of isolated lung 
epithelium cultured over 96 hours without additional growth factors or with 100 ng/ml 
FGF7, 250 ng/ml FGF10 or 100 ng/ml FGF1. Images are representative of at least six 
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FGF10 and FGF1 induce inconsistent effects on isolated lung epithelium 
Despite initial success with the FGF10 and FGF1 models, FGF10 and FGF1 
produced inconsistent responses from isolated epithelium. In the majority of 
attempts, epithelial isolates cultured with FGF10 or FGF1 would only form into a 
single tubular structure after 96 hours of culture (Figure 3.11A). Remarkably, this 
tubular structure underwent periodic waves of contraction (Video 3.4; Figure 
3.11B). This is in contrast to the reported branching effects of these growth factors 
(Bellusci et al., 1997; Cardoso et al., 1997). Due to the inconsistent nature of this 
culture system, and the strikingly different morphogenic responses compared to 
those reported in the literature, we were unable to examine the affects of PI3K 
inhibition on isolates cultured with either FGF10 or FGF1. 
 
As lung bud isolates cultured with either FGF1 or FGF10 underwent periodic 
waves of contraction we examined the isolates for the presence of smooth muscle. 
After 96 hours isolates cultured with FGF10 demonstrated an enhanced 
expression of αSMA, suggesting the presence smooth muscle cells (Figure 
3.11C). These αSMA positive cells surrounded the epithelial isolate and are 
therefore the likely cause of the contractile responses observed. Furthermore, we 
observed enhanced expression of the mesenchymal marker desmin compared to 
that present at initial isolation. Together, these observations would suggest that 
FGF10 at least, induced the proliferation of the remaining mesenchymal cells 
(Figure 3.11C).  
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Figure 3.11. FGF10 and FGF1 produce inconsistent responses from isolated lung 
epithelium. A. Light microscope images of isolated E12.5 murine lung epithelium in 
culture for 96 hours with 250 ng/ml FGF10 (left panels) or 100 ng/ml FGF1 (right panels). 
Images demonstrating outcomes consistent with reported responses from FGF10 and 
FGF1 are shown as well as images demonstrating outcomes that were inconsistent with 
reported responses. Images are examples from sixty separate isolates. Scale bar = 200 
µm. B. Still images from a movie depicting the contractile waves exhibited by an isolate 
cultured with 250 ng/ml FGF10 for 96 hours. Note the reduction in lumen size between 1 
and 5 seconds (arrow head, dotted line) and an enlargement of one end of the isolate 
(asterisk, dotted line) C. Fluorescent images of the mesenchymal markers αSMA and 
desmin acquired at 40x magnification from either freshly mesenchyme-stripped E12.5 
lung epithelium or isolates cultured for 96 hours in the presence of 250 ng/ml FGF10. 
Images are representative of three experiments. Scale bar = 20 µm. 
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3.6 FGF7-treated lung epithelium develop branches with a defined lumen and 
organised epithelium following inhibition PI3K signalling  
 
To examine the effects of PI3K directly on the lung epithelium we applied inhibitors 
of PI3K to isolated lung epithelium cultured in the presence of FGF7. Epithelial 
isolates cultured with ZSTK474 alone failed to develop (Figure 3.12A), similar to 
isolates cultured with no supplements. Remarkably, culture of epithelial isolates 
with FGF7 and ZSTK474 induced the formation of branch-like structures, which 
were particularly evident at 10 µM (Figure 3.12A). This was strikingly different from 
the large cystic morphology induced by culture with FGF7 alone (Figure 3.12A). To 
understand if these branched structures were fully formed branches or a simple 
scattering of cells we examined the morphology of the isolates by confocal 
microscopy. Z-stack analysis revealed that these structures contained an intact 
lumen, as evidenced by the lack of nuclei in the centre of the branch, surrounded 
by cuboidal epithelial cells. A patchwork of actin was also noted at what appears to 
be a luminal surface (Figure 3.12B).  
 
Next, we examined if the differentiation of the lung epithelium was affected by 
inhibition of PI3K. Following culture with FGF7, the isolated lung epithelium 
ubiquitously expressed SOX9, a marker of distal lung epithelium (Turcatel et al., 
2013); Nkx2.1, a transcription factor required for distal lung morphogenesis (Yuan 
et al., 2000); and pro-SPC, a marker of differentiated lung epithelium (Cardoso et 
al., 1997). Expression of these markers was not appreciably changed in lung 
epithelium cultured with FGF7 and ZSTK474 (Figure 3.13).  
 
Similar to the effects observed with isolated lung epithelium co-cultured with FGF7 
and ZSTK474, co-culture with FGF7 and the mTORC1/2 inhibito3r AZD8055 
elicited the appearance of branch-like structures from the initial isolate. Co-culture 
of FGF7 with the mTORC1 inhibitor rapamycin produced large cystic structures 
similar to culture with FGF7 alone (Figure 3.14). This re-enforces the notion that 
mTORC1 alone is insufficient to promote branching in either the whole explant 
culture or in isolated lung epithelium. Co-culture of FGF7 and Akt inhibitor VIII 
induced death of the isolate at concentrations >10 nM (Data not shown). 
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Figure 3.12. FGF7-treated lung epithelium develop branches with defined lumen and 
organised epithelium following PI3K inhibition. A. Light microscope images of isolated 
E12.5 murine lung epithelium cultured with either 100 ng/ml FGF7 alone (left panels), 10 
µM ZSTK474 alone (right panels) or either 1 or 10 µM ZSTK474 in combination with FGF7 
(middle panels) over 96 hours. Images representative of at least twenty isolates are 
shown. Scale bar = 200 µm. B. Z-stack confocal images of top and mid sections from 
isolated lung epithelium cultured with 100 ng/ml FGF7 alone or in combination with 10 µM 
ZSTK474 showing expression of the epithelial marker E-Cadherin and actin cytoskeleton.  
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Figure 3.13. PI3K inhibition does not affect the differentiation of lung epithelium in 
response to FGF7. Immunofluorescence images of the expression of the lung markers 
SOX9 (top panels), Nkx2.1 (middle panels) and pro-SPC (bottom panels) in isolated lung 
epithelium cultured for 96 hours with 100 ng/ml FGF7 with or without 10 µM ZSTK474. 
Images are representative of three experiments. Scale bar = 20 µm. 
Figure 3.14. FGF7-treated lung epithelium develops branches following mTORC1/2 
but not mTORC1 inhibition. Light microscope images of isolated E12.5 murine lung 
epithelium cultured over 96 hours with 100 ng/ml FGF7 alone (left panels) or in 
combination with either 1 µM rapamycin (middle panels) or 0.1 µM AZD8055 (right 
panels). Images are representative of at least twelve isolates. Scale bar = 200 µm.   
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Inhibition of PI3Kα but not PI3Kβ induces branching in isolated lung 
epithelium cultured with FGF7 
We next wished to confirm if the isoform dependence of PI3K in branching 
morphogenesis observed in the whole lung explant model applied to isolated lung 
epithelium as well. To address this question isolated epithelium was cultured with 
FGF7 in combination with either the PI3Kα inhibitor BYL719 or the PI3Kβ inhibitor 
GSK2636771. As with ZSTK474, culture of isolated lung epithelium with FGF7 and 
BYL719 induced the formation of epithelial branches. Addition of both FGF7 and 
GSK2636771 produced a similar morphological appearance to FGF7 alone 
(Figure 3.15). This goes further to demonstrate that the branching of lung 
epithelium is regulated by the alpha, and not beta, isoform of PI3K.  
 
 
Figure 3.15. Inhibition of PI3Kα but not PI3Kβ induces branching in isolated lung 
epithelium cultured with FGF7. Light microscope images of isolated E12.5 murine lung 
epithelium cultured over 96 hours with 100 ng/ml FGF7 alone (left panels) or in 
combination with either 1 µM BYL719 (middle panels) or 1 µM GSK2636771 (right 
panels). Images are representative of six isolates per condition. Scale bar = 200 µm.    
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ZSTK474-induced branching is not a result of altered proliferation 
As lung bud isolates cultured with ZSTK474 and FGF7 resulted in outgrowths that 
were smaller than those cultured with FGF7 alone we reasoned that proliferation 
may be reduced as PI3K inhibition has been reported to arrest cell growth (Chang 
et al., 2003). To address this, we examined the expression of two markers of 
proliferation (Ki67 and phospho-histone H3 (PH3)) in isolated epithelium after 96 
hours of culture with FGF7 alone or in combination with ZSTK474. Both isolated 
lung buds treated with FGF7 alone or in combination ZSTK474 showed uniform 
appearance of Ki67 after 96 hours of culture. Small, isolated, clusters of cell 
expressing PH3 were also apparent in both culture conditions although these cells 
did not appear to be localised to specific regions (Figure 3.16A). To quantify the 
number of Ki67-positive cells from each treatment group images were processed 
using ImageJ software as outlined in the materials and methods (Section 2.11). As 
an example, representative analysis is provided in figure 3.16B showing the 
conversion of a Ki67 image to a binary image following background and noise 
reduction prior to the quantification of the number of nuclei using the ‘analyse 
particles’ function. Despite the isolates cultured with ZSTK474 and FGF7 being 
smaller in size than the isolates cultured with just FGF7, the proportion of Ki67-
positive cells to the total cell number was not statistically different between the two 
groups (Figure 3.16C). 
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Figure 3.16. FGF7-treated isolated lung epithelium co-cultured with ZSTK474 
continues to express markers of proliferation. A. Immunofluorescence images 
showing the expression of Ki67 (top panels) and phosphorylated-histone H3 (PH3, lower 
panels) in isolated lung epithelium cultured over 96 hours with 100 ng/ml FGF7 alone or in 
combination with 10 µM ZSTK474. Images are representative of twenty isolates per 
condition. B. Example of image analysis for the quantification of positive nuclei. A confocal 
image (right panel) is adjusted to reduce background and noise (middle panel) before 
being converted to a binary image (right panel). This image is then used to calculate the 
number of positive nuclei. C. Percentage of Ki67 positive cells in isolated lung epithelium 
cultured with either FGF7 alone or in combination with ZSTK474. Data pooled from twenty 
images per condition. Scale bar = 20 µm.  
Chapter 3: Phosphoinositide 3-kinase in Lung Branching Morphogenesis 	  
 91 
3.7 Lentiviral and lipid transfection of embryonic lung cultures 
 
To complement our observations with pharmacological inhibitors we attempted to 
manipulate our embryonic branching models with lentiviral particles with the hope 
of introducing shRNA sequences targeting PI3K. To examine the utility of lentiviral 
infection in these models we initially generated lentiviral particles containing a GFP 
expression vector. GFP fluorescence following viral infection in embryonic lungs 
would therefore be an indication of effective delivery and would also demonstrate 
whether a particular cellular compartment favoured lentiviral infection. To confirm 
the effective generation of GFP lentiviral particles we infected cultures of A549 
cells. 48 hours post infection approximately 86% of the A549 cells expressed GFP 
protein as analysed by flow cytometry (Figure 3.17A). Following exposure of lung 
explants to GFP lentiviral particles GFP expression was confined to the 
mesenchymal component of the lung explants (Figure 3.17B). The lack of 
epithelial expression of GFP vector therefore limits the use of lentiviral infection in 
this model. We also applied GFP lentiviral particles to isolated lung epithelium to 
assess the utility of lentiviral infection in this model. Unlike the application of 
lentiviral particles to whole explant cultures, lentiviral particles induced the death of 
isolated lung epithelium (Figure 3.17C). 
 
The utility of siRNA transfection was next examined in the isolated lung epithelium 
model. Due to the fragile nature of the isolated epithelium and a requirement for 
the isolate to be placed within a Matrigel dome we tried multiple methods of siRNA 
transfection (Section 2.3). We incubated isolates with either 10 or 50 nM of siRNA 
targeting p110α (PIK3CA), p110β (PIK3CB), p85α (PIK3R1) or p85β (PIK3R2) in 
complex with either lipofectamine or jetPRIME transfection reagent prior to the 
mounting of the isolate into Matrigel. Following from the transfection step the 
isolates were cultured with FGF7 for 96 hours. None of these transfection 
strategies produced any obvious morphological changes in response to FGF7 
compared with FGF7 alone (Figure 3.18). Equally the use of the transfection 
reagent 3D-Fect, which was combined with Matrigel in order to prolong the 
transfection time of the epithelial isolate, produced no obvious morphological 
change in isolates cultured with FGF7 (Figure 3.18). RNA extracted from 20 
isolates following siRNA transfection and culture amounted to <0.3 µg, which was 
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insufficient for analysis of PI3K transcripts to determine whether PI3K gene 
expression was silenced. 
 
Figure 3.17. Lentiviral gene expression in cultures of embryonic murine lungs. A. 
FACS analysis for GFP expression in A549 cells 48 hours after infection with GFP 
lentiviral particles. B. GFP expression in E12.5 lung explants 48 after infection with 
lentiviral particles. Scale bar = 20 µm. C. Light microscope pictures of E12.5 isolated lung 
epithelium cultured for 96 hours in the presence of 100 ng/ml FGF7 following infection 
with GFP lentiviral particles. Scale bar = 200 µm. FACS plots and images are 
representative of three independent experiments with three separate harvests of GFP 
lentiviral particles.  
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Figure 3.18. siRNA transfection of isolated murine lung epithelium. Light microscope 
images of isolated E12.5 murine lung epithelium after 96 hours of culture with 100 ng/ml 
FGF7. Isolates were transfected with siRNA targeting PIK3CA, PIK3CB, PIK3R1 or 
PIK3R2 in complex with either lipofectamine, jet PRIME or 3D-Fect transfection reagents. 
Images representative of sixty isolates per treatment over three independent experiments. 
Scale bar = 200 µm.  
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3.8 Interactions between FGF7 and heparan sulphate  
 
FGF10 and FGF7 both signal through epithelial FGFR2b yet exhibit different 
morphological effects in isolated lung epithelium. FGF10 promotes directed 
epithelial branching whereas FGF7 directs a uniform growth of the epithelium. 
Studies have identified that a key determinant of directed FGF10 signalling is the 
ability of FGF10, and not FGF7, to bind to locally expressed heparan sulphate. 
This is highlighted by studies demonstrating that addition of exogenous heparan 
sulphate to cultures of isolated epithelium perturbs the natural gradient of heparan 
sulphate. This allows FGF10 to act uniformly across the epithelium, producing a 
morphological effect similar to FGF7 (Izvolsky et al., 2003).  
 
We therefore wished to confirm that the branching response observed from the 
culture of isolated epithelium with FGF7 and ZSTK474 was independent of 
interactions with heparan sulphate. The addition of exogenous heparan sulphate 
to isolated lung epithelium cultured with FGF7 elicited no obvious change in 
morphology after 96 hours. Equally, heparan sulphate had no effect on the 
branching response resulting from co-culture with FGF7 and ZSTK474 (Figure 
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Figure 3.19. Heparan sulphate does not affect FGF7/ZSTK474 induced branching. 
Light microscope images of isolated E12.5 murine lung epithelium cultured over 96 hours 
with 100 ng/ml FGF7 alone or in combination with 10 µM ZSTK474 either in the presence 
of no heparan sulphate (left panels) or with 10 µg/ml heparan sulphate (right panels). 
Images are representative of six isolates per condition. Scale bar = 200 µm.   
 
 
3.9 Does FGFR1b function as branching receptor? 
 
The inability of heparan sulphate to affect the actions of FGF7 are unsurprising 
given that FGF7 natively lacks a binding domain for heparan sulphate 
(Makarenkova et al., 2009). Given the ubiquitous expression of FGFR2b in the 
lung epithelium (Cardoso et al., 1997) we hypothesised that a second receptor 
may be present, localised to sites of branching, that can initiate a branching 
response. FGFR2b would be inactivated following PI3K inhibition thus uncovering 
the actions of FGF7 through this second receptor. A potential candidate is 
FGFR1b as both FGF7 and FGF10 can signal through this receptor (Zhang et al., 
2006). Further, high concentrations are required for the activation of this receptor 
by FGF7 and FGF10, which may account for the high concentrations required for a 
morphogenic response in cultures of isolated epithelium (Bellusci et al., 1997; 
Cardoso et al., 1997). FGFR1b expression has been identified at the tips of the 
branching epithelium of the salivary glands (Steinberg et al., 2005) and kidneys 
(Meyer et al., 2004), which gives more credence to this hypothesis. Moreover, 
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branch-like structures have been shown to form from the activation of FGFR1 in 
mammary organoid cultures (Xian et al., 2005). 
 
To test this hypothesis we first examined the expression of FGFR1 in the 
branching lung epithelium. 3T3 fibroblast cells were used as a positive control for 
the expression of FGFR1 by immunofluorescence (Figure 3.20A). Isolated E12.5 
murine lung epithelial branch tips showed no expression of FGFR1 by 
immunofluorescence (Figure 3.18B). We next examined the morphogenic effects 
of the principle growth factor for FGFR1, FGF2 (Zhang et al., 2006), on isolated 
lung epithelium. FGF2 induced the formation of large cystic structures of similar 
morphology to FGF7 over all concentrations tested (Figure 3.20C).  
 
Finally, we studied the effects of the FGFR inhibitor PD173074 (Kunii et al., 2008; 
Skaper et al., 2000) on the growth of embryonic lungs. PD173074 reduced 
branching in whole embryonic lung explants in a concentration dependent manner 
(Figure 3.21A,B). Although branching was inhibited the explants appeared to be 
healthy given their morphology and the continuation of periodic contractile waves 
(Video 3.5). As FGFR inhibition reduced epithelial branching we wished to see if 
the branching response could be rescued through inhibition of PI3K. Culture with 
both PD173074 and ZSTK474 was found to be toxic to the lung explants (Figure 
3.21C). Lung epithelium co-cultured with PD173074 and FGF7 failed to grow and 
appeared similar to isolated epithelium cultured without growth factors (Figure 
3.21D). A similar inhibition of growth was observed when PD173074 was added to 























Figure 3.20. FGFR1 is not present at the sites of branching and its activation does 
not induce branching. A. Fluorescent images of 3T3 cells labelled with no primary 
antibody or an antibody directed against FGFR1. B. FGFR1 expression in an epithelial 
branch tip isolated from E12.5 murine lung explants. Fluorescent images are 
representative of three independent experiments. C. Light microscope images of isolated 
E12.5 murine lung epithelium cultured over 96 hours with either 100 ng/ml FGF7 or 10 or 
100 ng/ml FGF2. Images are representative of six isolates per condition. Scale bar = 20 
µm for fluorescent images and 200 µm for isolated epithelial cultures. 
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Figure 3.21. Inhibition of FGFR reduces epithelial growth and branching, which is 
not rescued by inhibition of PI3K. A. Light microscope images of E12.5 murine lung 
explants cultured with 0.1% DMSO (Control), 1, 10 or 100 nM PD173074 over 48 hours. 
Images are representative of at least six explants for each of the treatments shown. B. 
Percentage increase in epithelial branching over 24 and 48 hours relative to the number 
of branches at initial isolation. Bars show mean ± s.e.m from n=6 C & D. Light microscope 
images either lung explants (C) or isolated lung epithelium (D) cultured with 0.1% DMSO 
(Control), 10 µM ZSTK474, 10 nM PD173074 or with a combination of ZSTK474 and 
PD173074 over 48 or 96 hours. Images are representative of six explants/isolates per 
condition. Scale bar = 0.5mm for whole lung explants and 200 µm for isolated epithelial 
cultures. *** P<0.001, * P<0.05, NS = Not Significant, compared with control. 
 
3.10 β-Catenin and regulation of cell-cell contacts in branching 
 
Epithelial branching in the lung requires the collective migration of epithelial cells 
towards an FGF10 signal (Park et al., 1998). Work in the migration of the neural 
crest epithelial cells has identified that the collective migration of epithelial cells 
requires the transient loss of cell-cell contacts (Theveneau et al., 2013). Indeed, a 
loss of E-Cadherin mediated cell-cell contacts is pivotal in the acquisition of a 
migratory phenotype in epithelial cancers (Perl et al., 1998). Moreover, forced 
expression of E-Cadherin in isolated murine lung epithelium prevents the induction 
of branching by FGF10 (Liu et al., 2008). 
 
E-Cadherin is anchored to the cell cytoskeleton through β-Catenin. Increasing the 
interactions between E-cadherin and β-Catenin strengthens the cell-cell contacts 
(Lickert et al., 2000). Likewise, decreasing this interaction weakens cell-cell 
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contacts (Behrens et al., 1993). In an epithelial cell there are two pools of β-
Catenin protein; a cytoplasmic pool that is constantly turned over until stabilised 
through Wnt signalling (Aberle et al., 1997; van Noort et al., 2002), and a pool 
present at the adherens junction. The cytoplasmic pool of β-Catenin is regulated 
by the kinase GSK3β, which constantly targets β-Catenin for proteasomal 
degradation until inhibited by Wnt activation (Aberle et al., 1997). The adherens 
pool can be directly regulated by JNK (Lee et al., 2009). Further, these two pools 
of β-Catenin can influence each other. Overexpression of Xenopus C-Cadherin 
sequesters β-Catenin from the cytoplasm of cells thus reducing β-Catenin 
transcriptional activity (Fagotto et al., 1996). Equally, following the disruption of 
cell-cell contacts, β-Catenin can be released from the cadherin pool and signal 
following Wnt activation (Kam and Quaranta, 2009). As both GSK3β and JNK can 
be inhibited by PI3K activity (Aikin et al., 2004; Cross et al., 1995) we 
hypothesised that inhibition of PI3K may indirectly destabilise the cell-cell contacts 
between neighbouring epithelial cells thus priming the cells for a branching event.  
 
To investigate this we examined the distribution of E-Cadherin and β-Catenin at 
the leading edge of a developing branch from isolated lung epithelium cultured 
with both FGF7 and ZSTK474. We imaged an isolate after 48 hours of culture, 
when the epithelial branches begin to form, to give the best chance of seeing cell-
cell contact disruption. β-Catenin co-localised with E-Cadherin consistently across 
the tip of a developing branch suggesting that cell-cell contacts were not being 
disrupted (Figure 3.22). 
 
We next examined the impact of GSK3β on the branching lung utilising the 
selective GSK3β inhibitor 1m (Bone et al., 2009). Inhibition of GSK3β with 1m 
reduced branching in whole lung explants although it was difficult to distinguish an 
epithelial branch from surrounding mesenchyme (Figure 3.23A,B). When applied 
to isolated lung epithelium cultured with FGF7, 1m induced a more uniform growth 
of the epithelium than epithelial isolates cultured with FGF7 alone. Equally, when 
applied to isolated epithelium cultured with FGF7 and ZSTK474, 1m prevented the 
induction of branches and instead induced the uniform growth of the epithelium 
similar to FGF7 and 1m albeit of significantly smaller size (Figure 3.23C).  
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Finally, we investigated the effect of JNK inhibition on the branching response. 
Although there was a trend for the JNK inhibitor SP600125 to promote branching 
in lung explants the difference was not statistically significant. Further at 
concentrations greater than 5 µM SP600125 appeared to be toxic to the explants 
(Figure 3.24A,B). 5 µM SP600125 also had little effect on the morphology induced 
by either FGF7 alone or in combination with ZSTK474 when applied to isolated 
lung epithelium (Figure 3.24C). 
Figure 3.22. Cell-cell contacts between epithelial cells remain intact during 
branching. A. Light microscope image of isolated E12.5 murine lung epithelium after 48 
hours of culture with 100 ng/ml FGF7 and 10 µM ZSTK474. White box represents area of 
imaging in B. Scale bar = 200 µm. B. Z-stack confocal images of top and mid sections of 
A showing localisation of E-Cadherin (red) and β-catenin (green). Images taken at 63x 
magnification with 6x zoom. Images are representative of two independent experiments. 
Scale bar = 2 µm. 
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Figure 3.23. Inhibition of GSK3β reduces branching. A. Light microscope images of 
E12.5 murine lung explants cultured with 0.1% DMSO (Control), 0.2, 1 or 2 µM 1m over 
48 hours. Images representative of at least six explants for each condition are shown. 
Scale bar = 0.5 mm. B. Percentage increase in epithelial branching over 24 and 48 hours 
relative to the number of branches at initial isolation. Bars show mean ± s.e.m from n=6. 
C. Light microscope images of isolated E12.5 murine lung epithelium cultured over 96 
hours with 100 ng/ml FGF7 alone or in combination with 10 µM ZSTK474 either in the 
presence of no 1m (left panels) or with 2 µM 1m (right panels). Images are representative 
of six isolates per condition. Scale bar = 200 µm.   
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Figure 3.24. Inhibition of JNK has no effect on branching. A. Light microscope images 
of E12.5 murine lung explants cultured with 0.1% DMSO (Control) or 1, 5 or 10 µM 
SP600125 over 48 hours. Images representative of at least six explants for each condition 
are shown. Scale bar = 0.5 mm. B. Percentage increase in epithelial branching over 24 
and 48 hours relative to the number of branches at initial isolation. Bars show mean ± 
s.e.m from n=6. C. Light microscope images of isolated E12.5 murine lung epithelium 
cultured over 96 hours with 100 ng/ml FGF7 alone or in combination with 10 µM ZSTK474 
either in the presence of no SP600125 (left panels) or with 5 µM SP600125 (right panels). 
Images are representative of six isolates per condition. Scale bar = 200 µm.    
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3.11 Summary of results 
 
• Inhibition of PI3Kα does not prevent the induction of EMT but does reduce 
the activity of the resulting fibroblasts  
• Culture of embryonic lungs adequately recapitulates the branching process 
• Inhibition of PI3Kα, or its downstream signalling components potentiates 
epithelial branching in cultures of embryonic lungs 
• Contrary to reported results, FGF10 and FGF1 promote growth of residual 
mesenchymal tissue in isolated lung epithelium 
• Inhibition of PI3K results in FGF7 initiating a branched response from 
isolated lung epithelium 
• This induction of branching does not affect the differentiation of the 
epithelial cells nor does it appear to be the result of altered proliferation. 
• Lentiviral and lipid based transfection methods a re largely ineffective in 
cultures of embryonic lungs 
• FGFR1 does not appear to be expressed in the branching lung epithelium  
• Cell-cell contacts remain intact in branches that form from isolated lung 
epithelium as a result of FGF7 treatment and PI3K inhibition 
• Inhibition of GSK3β perturbs branching and causes a more uniform growth 
of isolated lung epithelium 




PI3K in the induction of EMT 
EMT is considered a potential source of myofibroblasts in the progression of lung 
fibrosis. Lung epithelial cells from both mice with experimental fibrosis and patients 
with idiopathic pulmonary fibrosis have been reported to express markers of both 
epithelial cells and fibroblasts, indicative of a cell undergoing EMT (Kim et al., 
2006; Marmai et al., 2011). Evidence for EMT in the fibrotic process is largely 
dependent on the observation of cells expressing markers of both epithelial cells 
and fibroblasts, i.e. cell in a ‘partial EMT’ state, as a cell that has completely 
undergone EMT would be indistinguishable from other, native, fibroblasts. This 
has lead to controversy regarding the involvement of EMT in the fibrotic process 
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with the growing appreciation that, due to the complex 3D nature of the lung, cells 
that have been identified as in a state of partial EMT may simply be two cells 
overlapping. Indeed, confocal analysis of lung sections taken from patients with 
pulmonary fibrosis and lineage tracing studies in mice has failed to identify cells in 
on  
 
Inhibition of PI3K with either ZSTK474 or PIK-75 did not prevent TGFβ induced 
EMT in A549 epithelial cells. However, inhibition of PI3Kα did reduce the 
production of MMP-9 and MMP-2. This would suggest that PI3Kα is not involved in 
the initial loss of epithelial proteins induced by TGFβ but is responsible for the 
induction of a fibroblast phenotype. This observation is different from that reported 
with the LY294002 PI3K inhibitor, which suggested that PI3K inhibition was 
capable of preventing the induction of EMT (Bakin et al., 2000; Chen et al., 2012; 
Yan et al., 2009). Further observations with more selective PI3K inhibitors and 
genetic knockdown approaches will reveal the full extent of PI3K in the EMT 
process. 
 
It has been reported that the activity of both PI3Kα and PI3Kγ are required for the 
conversion of fibroblasts to myofibroblasts, i.e. an increase in cell proliferation, 
αSMA expression and collagen deposition (Conte et al., 2011). This study, and our 
own would therefore suggest that PI3K inhibition would be an attractive target in 
pulmonary fibrosis, as inhibition of fibroblast activity would halt the progression of 
fibrotic lung injury.  
 
Embryonic lung cultures: similarities and differences to lungs in-utero 
Ex-vivo cultures of whole embryonic lungs, taken at the initial stages of the 
branching program, recapitulate many elements of the developmental process. 
They continue to develop epithelial branches in culture and demonstrate the 
expression and arrangement of various cell types consistent with what has been 
observed in-utero. As well as these similarities between the culture of embryonic 
lungs and their growth in-utero there are many differences. For instance the 
branching rate, and growth of the explant is greatly diminished in culture compared 
to the growth in-utero (Metzger et al., 2008). Moreover, the pressure apparent 
during culture is different than that in-utero, which greatly affects the branching 
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response (Unbekandt et al., 2008). The constituents of the cell culture medium 
used to maintain the cultures of embryonic lungs are also different from the 
comparative environment in-utero. A notable difference is the concentration of 
calcium, which is usually 1.05 mM in DMEM cell culture medium (equivalent to the 
levels of calcium found in adult plasma) compared to 1.7 mM found in foetal 
serum. This higher, foetal, level of calcium reduces branching in lung explant 
cultures compared to the lower, adult, level (Finney et al., 2008). Despite these 
differences, cultures of whole embryonic lungs remain an elegant model to study 
the gross effects of a signalling factor on branching. 
 
The culture of isolated lung epithelium overcomes the additional caveat associated 
with the whole explant model in that it is difficult to determine if an affect on 
branching is specific to the lung epithelium or secondary to an effect on the 
mesenchyme. This model allows for the study of the mechanisms involved in 
epithelial morphogenesis with respect to the actions of FGF7, FGF10 or FGF1. 
However, this model lacks any regulation of branching usually provided by the 
surrounding mesenchyme, therefore branching is non-stereotyped compared to in-
utero.   
 
The PI3K pathway negatively regulates lung branching morphogenesis 
We primarily focussed on the role of the PI3K pathway in the branching program of 
the lung due to the current conflicting reports of this pathway in the branching 
process and the strong involvement of this pathway in developmentally related 
diseases such as cancer and fibrosis. We show here, for the first time, that PI3K 
plays a negative role in airway branching morphogenesis. This has been 
demonstrated by a robust increase in murine lung explant branching upon 
pharmacological inhibition of either PI3K or its downstream effectors Akt and 
mTOR.  
 
Notably we observed a potentiation of branching with an inhibitor of both the 
mTORC1 and mTORC2 complexes of mTOR but not with an inhibitor of mTORC1 
alone. Once activated mTORC2 can feedback and potentiate Akt activity 
(Facchinetti et al., 2008), whereas mTORC1 can negatively regulate mTORC2 
(Julien et al., 2010). Thus, inhibition of mTORC1 should increase Akt signalling by 
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removing this inhibitory effect on mTORC2. Moreover, mTORC1 activation of S6K 
can feedback and negatively regulated PI3K signalling at RTKs (Haruta et al., 
2000; O'Reilly et al., 2006). Therefore, inhibition of mTORC1 with rapamycin 
should in fact potentiate PI3K signalling by removing these negative feedback 
loops. However, following treatment of lung explants with rapamycin we observed 
no increase in the levels of phosphorylated Akt compared with controls. This may 
suggest that these feedback loops are not functional in the branching process. 
Alternatively it may reflect the observation that prolonged rapamycin treatment 
inhibits mTORC2 activity, thus reducing Akt activation (Sarbassov et al., 2006). In 
this instance we might expect to see a potentiation of branching and/or a reduction 
in the levels of phosphorylated Akt; although the 48-hour assessment of branching 
may be too early to observe this delayed effect of rapamycin in our system.  
 
In contrast, direct inhibition of both mTORC1 and mTORC2 with AZD8055 would 
remove the negative feedback of mTORC1 but would also remove the positive 
effect of mTORC2 on Akt activity. As a consequence the overall net effect would 
be decreased activation of Akt signalling and thus an increase in branching. The 
dependence of mTORC2 in this system would be best analysed with a selective 
inhibitor of mTORC2. However, there is currently no available pharmacological 
tool with which to assess this.  
 
The observation that inhibition of PI3K potentiates branching in the murine 
embryonic lung is somewhat surprising given that previous work has suggested a 
requirement for PI3K signalling. Wang and colleagues observed a reduction in 
branching in murine lung explants cultured with the pan class I PI3K inhibitor 
LY294002 (Wang et al., 2005). In our study we observed a similar inhibitory effect 
with the LY294002 compound at concentrations used by Wang and colleagues 
(>20 µM). However, this was preceded by an efficient increase in branching at 10 
µM. It therefore seems likely that at higher concentrations the actions of LY294002 
on the lung explants are a consequence of toxicity and/or inhibition of branching 
through one of the many off-target effects of the compound (Davies et al., 2000).  
 
The use of isoform-selective inhibitors of this kinase suggests that the alpha 
isoform of PI3K negatively regulates lung branching. An increase in branching 
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above that seen with the pan PI3K inhibitor ZSTK474 was observed with the 
PI3Kα specific inhibitors A66 and BYL719 but not with the PI3Kβ specific inhibitors 
GSK2636771 and TGX-221. This is in contrast to mammary glands where mice 
deficient in PI3Kα exhibited decreased mammary branching, and mice deficient in 
PI3Kβ exhibited potentiated branching (Utermark et al., 2012). The distinct roles of 
PI3Kα and PI3Kβ in mammary branching may be explained by the fact that PI3Kβ 
is less active and could compete with the more active PI3Kα for lipid substrate. 
Deletion of PI3Kβ would therefore potentiate PI3K signalling through increased 
PI3Kα activity (Utermark et al., 2012).  
 
Using a range of pharmacological agents, targeting PI3K and its downstream 
signalling components, we have been able to better explore the role of PI3K 
signalling in airway branching (summarised in Figure 3.25A). Thus our findings 
more accurately represent the role for the PI3K pathway in lung branching 
morphogenesis. Although the reported IC50 values for these compounds are 
usually in the nanomolar range these values are obtained from cell free assays 
and do not necessarily reflect their potency in cells and tissues. Thus, the higher 
concentrations required in our study to elicit inhibitory effects likely reflects the 
influence of cell membrane permeability and compound stability on inhibitor 
efficiency when using in-vitro cell/tissue based assays. 
 
PI3K inhibition alters morphogenic properties of FGF7 
A particularly striking observation is that branches form from isolated lung 
epithelium cultured with FGF7 when PI3K signalling is inhibited. These structures 
contain a luminal space and organised epithelium confirming that they are not 
merely a scattering of cells but are fully formed branches. Moreover, PI3K 
inhibition did not appreciably alter the differentiation of the epithelial cells, which 
maintained a distal immature type II AEC phenotype, consistent with the state of 
the lung epithelium at this stage of development (Warburton et al., 2010). This was 
demonstrated by the continued expression of SOX9, Nkx2.1 (distal markers) and 
pro-SPC (type II AEC marker) in the lung epithelium following culture with either 
FGF7 alone or in combination with ZSTK474. SOX9 expression has been noted to 
prevent the differentiation of the lung epithelium, maintaining the epithelial cells in 
a branching state (Chang et al., 2013).  
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This is the first reported observation of FGF7 promoting a branched response in 
isolated lung epithelium. As the isolates cultured with FGF7 and the inhibitor of 
PI3K, ZSTK474, were smaller than those cultured with FGF7 alone we examined if 
proliferation was being affected. In the presence of FGF7 and ZSTK474, lung 
epithelial isolates continued to express the proliferation markers Ki67 and PH3. 
The proportion of cells expressing Ki67 was not significantly different between 
isolates cultured in the presence of FGF7 and ZSTK474 and those cultured with 
FGF7 alone suggesting that proliferation was not being altered. Interestingly the 
expression of PH3 was restricted to small populations of cells scattered across the 
epithelial isolate. This could suggest the presence of distal epithelial stem cells 
thought to be instrumental in the differentiation of the epithelial cells following 
branching morphogenesis (Rawlins et al., 2009). 
 
Limitations to the FGF10 and FGF1 models 
An unfortunate caveat of this work is that we were unable to assess the impact of 
PI3K inhibition on the branching response induced natively by FGF10 or FGF1. It 
would have been interesting to examine if inhibition of PI3K switched FGF10, or 
FGF1, signalling from a branching response to uniform growth; or simply induced 
a similar morphology to that seen with FGF7 and an inhibitor of PI3K.  
 
The inability of isolated epithelium to branch in response to FGF10 or FGF1 and 
instead form a single tubule may imply that the epithelium is adopting a phenotype 
consistent with the proximal parts of the airway network. This is supported by the 
observation that smooth muscle cells develop around the tubule and periodically 
contract. However, this may be an unrelated effect attributed to the culture system. 
Epithelial cells that comprise the proximal regions of the branched network 
express the transcription factor SOX2 (Chang et al., 2013). Therefore, if the 
epithelial cells present in the tubules that develop in response to FGF10 also 
express SOX2 it would imply that they have adopted a proximal phenotype. 
 
It has been reported that the contractile phenotype expressed in the developing 
lung requires a pacemaker region that can be influenced by FGF10 (Jesudason et 
al., 2005). If in our culture system we were developing proximal airway epithelium 
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surrounded by contractile smooth muscle then it would suggest that a pacemaker 
region in the lung can develop independently and is not limited to a particular 
region of the lung.  
 
Transfection of embryonic lungs 
We attempted to improve the utility of the whole lung explant model by 
incorporating a lentiviral expression vector into the cultures. This would have 
allowed us to express shRNAs to complement our pharmacological data. Further, 
this would have allowed us to express reporter proteins, such as a GFP labelled 
PH domain of Akt, which would have allowed us to examine where in a branch the 
product of PI3K, PI(3,4,5)P3, accumulates. This would have provided answers as 
to whether PI3K is involved in the elongation of an existing branch, or is required 
for the initiation of an epithelial branch, as is suggested for mammary branching 
(Zhu and Nelson, 2013).  
 
Unfortunately, upon infection with lentiviral particles containing a GFP expression 
vector we only observed fluorescence in the mesenchymal component of the lung 
explants, suggesting a complete lack of infection of the epithelial cells. A 
preference for the mesenchymal cells to take up lentiviral particles has also been 
demonstrated for cultures of salivary gland cultures (Hsu et al., 2012). A solution 
to this caveat is the injection of transfection material (lentiviral particles or siRNA) 
directly into the tracheal lumen of lung explants (Lee et al., 2014). The material is 
then dispersed throughout the airway network and is predominantly incorporated 
into epithelial cells. However, this technique is difficult, requiring the precise 
microinjection of transfection material. Further, a study using fluorescently tagged 
siRNA has suggested that the microinjection technique does not uniformly 
disperse the material across the epithelium, with the majority been taken up by the 
proximal branches closest to the trachea and little ending up in the terminal 
branches (Lee et al., 2014).  
 
A more elegant solution has recently been demonstrated for salivary gland 
cultures and could theoretically be applied to lung cultures as well (Sequeira et al., 
2013). In this system the mesenchyme is removed from the epithelial tissue of the 
salivary gland. The epithelial tissue is then directly infected with a viral construct 
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before the mesenchymal tissue is repositioned around the epithelium. When 
placed in culture at the air liquid interface the mesenchymal tissue appears to 
reform around the epithelium and the salivary gland continues to branch normally. 
By this means, viral constructs are reported to be preferentially expressed in 
salivary gland epithelial cells and their effect on branching can be adequately 
assessed (Sequeira et al., 2013). Although this technique seems relatively 
straightforward it remains to be determined if this could be applied to cultures of 
embryonic lungs. It is currently unknown if the lung mesenchyme can reform 
around the epithelium once removed and subsequently propagate branching. 
Further, it has been demonstrated that different viral particles (e.g. adenoviral and 
lentiviral) have different efficacies in cultures of lung and salivary glands (Hsu et 
al., 2012). Therefore, an appropriate viral infection method specific for the lung 
epithelium would also need to be determined. 
 
We also attempted to transfect isolated epithelium with siRNA targeting different 
elements of PI3K. Following transfection with siRNA we did not see any 
morphological change in response to FGF7 from isolated epithelium. This may 
either be due to ineffective transfection, or that knockdown of PI3K in this instance 
had no effect on FGF7 activity. Given that we were unable to acquire enough RNA 
to assess knockdown by siRNA we could not determine which outcome is correct. 
Nevertheless, given the amount of pharmacological data we acquired it would 
seem likely that we were not achieving efficient knockdown. To expand on this 
work it would first be prudent to ensure that the transfection method of choice was 
adequate for isolated lung epithelium. This could be examined by using a 
fluorescently labelled siRNA to visualise the level of incorporation of the siRNA 
into the epithelium.   
 
Mechanisms of FGF7 induced branching through inhibition of PI3K 
There have been numerous reports to date involving the alteration of FGF10 
signalling to produce a morphological effect similar to FGF7 but we are the first to 
demonstrate the opposite. These studies have primarily altered FGF10 signalling 
by interfering with the interactions between heparan sulphate and FGF10 (Izvolsky 
et al., 2003; Makarenkova et al., 2009; Patel et al., 2008), or overexpressing E-
Cadherin (Liu et al., 2008), in isolated branching epithelium. FGF7 lacks a 
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heparan-binding domain and should therefore act independently of heparan 
sulphate (Makarenkova et al., 2009). Indeed, the addition of heparan sulphate to 
isolated epithelium cultured with FGF7 and ZSTK474 failed to perturb branching. 
Our work is therefore also the first example of a branching response that is 
independent of heparan sulphate.  
 
The canonical branching receptor FGFR2b is expressed ubiquitously across the 
lung epithelium (Cardoso et al., 1997). We therefore hypothesised that a second 
receptor could function in the branching response whose expression is restricted 
to the sites of branching. A prospective candidate was FGFR1b as this receptor is 
found only at the branching tips in the branching salivary glands (Steinberg et al., 
2005), and the forced activation of this receptor is sufficient to induce branching in 
mammary organoid cultures (Xian et al., 2005). Despite this evidence we were 
unable to identify the expression of FGFR1 in the branch ends of isolated 
embryonic lungs. There is the possibility that the antibody was not specific for the 
FGFR1b isoform of FGFR1, and only bound to the relevant FGFR1 isoform 
present in 3T3 cells. Further, the typical FGFR1 agonist, FGF2, was unable to 
induce branching in cultures of isolated lung epithelium, instead inducing a 
morphology similar to FGF7. FGF2 can also signal through FGFR2b, albeit at high 
concentrations (Ornitz et al., 1996). Inhibition of FGFR with PD173074 was able to 
obstruct epithelial branching. However, PD173074 is not specific for a particular 
FGFR (Kunii et al., 2008) so the reduction in branching observed is likely due to its 
inhibitory action on FGFR2b. Alternatively, as PD173074 can also inhibit VEGFR 
signalling (Mohammadi et al., 1998), this inhibition of branching may be a result of 
a knock-on effect from a reduction in angiogenesis (Lazarus et al., 2011).  
Nevertheless, inhibition of PI3K could not rescue the branching response, 
suggesting that PI3K functions downstream of FGFR.  
 
We then investigated if inhibition of PI3K was disrupting the contacts between 
neighbouring epithelial cells, thus promoting branching. Confocal analysis of a 
developing branch from isolated lung epithelium cultured with both FGF7 and 
ZSTK474 demonstrated consistent co-localisation between E-Cadherin and β-
Catenin, indicating that cell-cell contacts were not being disrupted. As this analysis 
was performed on fixed tissue it does not address whether disruptions caused by 
Chapter 3: Phosphoinositide 3-kinase in Lung Branching Morphogenesis 	  
 113 
PI3K inhibition are a transient event. Indeed, a transient loss of cell-cell contacts in 
the migration of epithelial cells has been reported in the migration of cells that from 
the neural crest (Theveneau et al., 2013). A transient loss in cell-cell contacts 
could be examined by expressing fluorescently labelled E-Cadherin and β-Catenin 
within isolated lung epithelium and then live imaging the cell-cell contacts as a 
branch develops.  
 
We then examined if the regulators of β-Catenin, GSK3β and JNK, were influential 
in the branching response. Inhibition of GSK3β appeared to inhibit the branching 
of whole lung explants. Wnt signalling is required for proliferation and growth of the 
lung mesenchyme, mesenchymal deletion of β-catenin results in arrested lung 
growth and reduced branching (Yin et al., 2008). Therefore, overactive β-Catenin 
bought about through inhibition of GSK3β may cause hyper-proliferation of the 
mesenchymal cells that would have a knock-on effect of perturbing epithelial 
branching. Equally, hyperactive β-Catenin signalling in the lung epithelium reduces 
branching and causes an enlargement of the terminal air space. (Okubo and 
Hogan, 2004). We saw a similar morphological effect when we cultured isolated 
lung epithelium with FGF7 and an inhibitor of GSK3β. This effect was reduced with 
inhibition of PI3K. However, in the presence of a GSK3β inhibitor, PI3K inhibition 
was unable to initiate branching. This may suggest that PI3K inhibition induces 
branching via activation of GSK3β. Alternatively the effects of disrupting Wnt 
signalling via GSK3β inhibition may supersede the effect of PI3K inhibition.  
 
We also examined the effect of JNK on lung branching as this kinase appears to 
directly regulated the pool of β-Catenin present at the adherens junctions (Lee et 
al., 2009). JNK inhibition failed to significantly effect either the branching of whole 
embryonic lung explants or the morphological effects induced by FGF7 with or 
without ZSTK474 in isolated lung epithelium. A non-requirement for JNK has also 
been reported for mammary gland branching (Cellurale et al., 2012). Others have 
reported a reduction in branching following JNK inhibition caused through an 
induction of apoptosis (Wu et al., 2009). We observed a similar cell death in 
explants treated with 10 µM of the JNK inhibitor compared with controls. However, 
we believe that this is likely due to the toxicity of the compound at these 
concentrations and not as a result of JNK inhibition.  
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A requirement for PI3K in the signalling output of FGF10 and FGF7 through 
FGFR2b has recently been reported from Hela cells overexpressing this receptor. 
Stimulation of FGFR2b by FGF10 resulted in the p85 subunit of PI3K being 
recruited to the receptor, separate from the classical Grb2/Gab1 interactions. 
Following internalisation, this interaction with PI3K led to the receptor being 
recycled to the cell membrane. In contrast, FGF7/FGFR2b signalling failed to 
recruit PI3K to this site and, upon internalisation, the receptor was degraded. 
Removal of this novel PI3K binding site from FGFR2b resulted in the degradation 
of the receptor following FGF10 simulation, producing a signalling outcome similar 
to FGF7 (Francavilla et al., 2013). PI3K, acting as a switch for FGFR2b trafficking, 
therefore appears to be a critical determinant for the signalling output of a ligand. 
Of particular note is that inhibition of PI3K with LY294002 was shown to promote 
the recycling of FGFR2b following stimulation by FGF7 (Francavilla et al., 2013). 
This work therefore lends a possible explanation as to how inhibition of PI3K is 
sufficient to promote branching from isolated lung epithelium cultured with FGF7. 
When PI3K signalling is inhibited, the FGFR2b receptor would be recycled, not 
degraded, following stimulation by FGF7. The net effect of this would then be an 
FGF10-like signalling event, i.e. a branching response.  
 
This hypothesis could be examined in cultures of embryonic lungs by determining 
whether FGFR2b enters the recycling or late endosomes following stimulation with 
either FGF10 or FGF7. A shift from late to recycling endosomes following inhibition 
of PI3K would support the idea that PI3K acts to direct endosomal sorting of 
FGFR2b, which in turn determines the morphogenic outcome. To achieve this the 
proportion of FGFR2b entering either recycling or late endosomes could be 
visualised by immunofluorescence staining. Alternatively, using transfection 
methods outlined above, fluorescently labelled Rab11 (recycling endosomes, 
(Ullrich et al., 1996)), Rab7 (late endosomes, (Soldati et al., 1995)) and FGFR2b 
could be incorporated into cultures of embryonic lungs. The proportion of FGFR2b 
in the different endosomal compartments could then be imaged in real time. This 
would provide information as to whether PI3K is required for the regulation of 
branch initiation, elongation, or both.  
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FGF10 and FGF7 both act to regulate branching in the lung and salivary glands. In 
the lung, FGF10 promotes branch initiation and elongation (Bellusci et al., 1997) 
whereas FGF7 induces the formation of cysts (Cardoso et al., 1997). In the 
salivary gland FGF10 serves to promote bud elongation and FGF7 promotes 
branch budding (Makarenkova et al., 2009). Differences in FGF actions on the 
branching epithelium may therefore account for the reported differences in the 
function of PI3K in the salivary glands and lungs. In the salivary gland inhibition of 
PI3K would shift the action of FGF7 from a budding response to an elongation 
response (Figure 3.26). This reduction in budding may have the net effect of 
reducing branching, which is what is seen when PI3K is inhibited in salivary gland 
explant cultures (Larsen et al., 2003).  
 
We propose that, in a setting where PI3K signalling is inhibited in the developing 
airways, FGF7 produced in the mesenchyme acting through FGFR2b is modulated 
to produce a signalling outcome similar to FGF10. This would have the net effect 
of inducing the formation of branches that would not otherwise develop (Figure 
3.25B). Local reduction in PI3K activity in the branching epithelium may therefore 
add a novel mode of regulation during branching morphogenesis. 
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Figure 3.25. PI3K inhibition promotes branching morphogenesis through 
manipulation of FGF7 signalling. A. Sites of intervention for PI3K signalling and 
apparent effects of kinase activities on branching morphogenesis. Inhibitory 
pharmacological compounds are presented in red text with apparent biological effect in 
green. Pharmacological inhibition of either PI3Kα, Akt or dual inhibition of mTORC1/2 
potentiates epithelial branching. Inhibition of either PI3Kβ or mTORC1 has no observable 
effects on branching. B. FGF10 and FGF7 signalling during lung branching 
morphogenesis. Lung epithelium is represented as blue with the surrounding 
mesenchyme as orange. Red represents FGF10 producing cells. Classically, FGF10 
promotes branching whereas FGF7 induces the enlargement of the epithelium (left panel). 
In a setting where PI3K is inhibited (right panel) FGF7 signalling through FGFR2b is 
switched to an FGF10 signalling event. This has the outcome of inducing the formation of 
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Figure 3.26. Proposed action of PI3K on the morphogenic responses of FGF10 and 
FGF7 in embryonic lung and salivary gland epithelium. Classically, FGF10 promotes 
branch elongation in both lung and salivary gland epithelium. FGF7 induces the formation 
of cystic structures in lung epithelium and branch budding in salivary gland. Following 
PI3K inhibition the elongation effect to FGF10 is potentially unaffected whereas the 
responses of FGF7 are switched to that of branch elongation.   
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CPPs are small peptides capable to transporting an otherwise cell impermeant 
cargo into the cytoplasm of mammalian cells. Originally derived from natural 
sources, many CPPs have been engineered for therapeutic applications and a 
number are currently in clinical trials for tissue scarring and cancer (Milletti, 2012). 
Despite appearing to be well tolerated in the clinic there is the possibility that these 
CPPs have inherent immunogenic properties that would make them impractical for 
therapeutic use. This seems plausible as many CPPs were originally derived, and 
contain protein sequences, from immunogenic substances. This is the case for the 
CPP HIV-TAT, which originated from a HIV protein (Frankel and Pabo, 1988) and 
several CPPs that have been derived from components present in animal venom 
(Gurrola et al., 2010; Rádis-Baptista and Kerkis, 2011).  
 
Surprisingly, there is currently very little work into the possible immunogenic 
properties possessed by CPPs. Animals that have been administered CPPs show 
little immune response either at the site of administration or in the plasma 
(Khafagy et al., 2013; Suhorutsenko et al., 2011). However, one study has 
reported an innate immune response from mice that had been administered the 
CPP penetratin conjugated to an siRNA (Moschos et al., 2007). Interestingly, 
neither penetratin alone nor HIV-TAT induced a similar immune response. This 
may be due to inherent differences in immunogenicity between CPPs or results 
from differences in intracellular transport between a CPP: Cargo complex and a 
CPP alone.  
 
The application of CPPs therapeutically would ideally be through a non-invasive 
route i.e. through the skin, airway or oral route. Through this course, CPPs would 
first encounter the epithelial cells that form a barrier between the body and the 
outside environment. It is these cells that would likely respond to any immunogenic 
properties possessed by the CPP molecule, potentially through pattern-recognition 
receptors. We therefore sought to examine the immunogenic potential of three of 
the most commonly used CPPs (HIV-TAT, Antennapedia and Transportan) on 
epithelial cell lines representing the skin, airways and intestine.  
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4.2 HIV-TAT, Antennapedia and Transportan effectively deliver a cargo into 
epithelial cells 
 
We first examined the effectiveness of our CPPs by examining the uptake of a 
fluorescently labelled BSA cargo into epithelial cells. After 2 hours of incubation 
with CPP: BSA-568 complexes, using concentrations of CPP reported to deliver a 
protein based cargo, a fluorescent signal indicative of BSA incorporation was 
observed in A431 (epidermal), A549 (alveolar) and Caco-2 (intestinal) epithelial 
cells (Figure 4.1). A fluorescent signal was also observed from cells exposed to 
BSA-568 alone. Although this signal was comparatively weak compared to CPPs it 
would suggest that the epithelial cells were actively taking up some BSA.  
 
To estimate the amount of CPP-mediated delivery of BSA-568 to the epithelial cell 
lines the fluorescence intensity of each image was measured relative to the 
number of cells in the field of view. This was compared to the fluorescent signal 
obtained similarly from cells exposed to the BSA-568 cargo alone, with the fold 
increase being used to estimate the extent of CPP-mediated uptake for a specific 
CPP and cell type (Figure 4.1). Although not statistically different, there was a 
trend for Antennapedia to be the most effective, although inconsistent, CPP for the 
delivery of this protein cargo, with HIV-TAT being the least.   
 
We also examined the CPP-mediated delivery of a fluorescently labelled siRNA 
targeting Sjögren syndrome antigen B (SSB) to A549 cells. Following 2 hours of 
culture a strong fluorescent signal indicative of siRNA entry was observed from 
cells incubated with Antennapedia: siRNA complexes. A comparatively weak 
signal was seen from cells incubated with Transportan: siRNA complexes and very 
little uptake was observed following incubation with HIV-TAT: siRNA complexes 
(Figure 4.2A). After 48 hours of incubation, protein isolated from A549 cell was 
analysed for SSB knockdown by western blotting. Despite confocal microscopy 
demonstrating incorporation of SSB siRNA into A549 cells we could not detect any 
knockdown effect (Figure 4.2B). 
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Figure 4.1. CPPs mediate the entry of a protein cargo into epithelial cells. 
Fluorescent images of A431 (A), A549 (C) and Caco-2 (E) epithelial cells exposed to 
BSA-568 (1 µM) alone or in complex with the CPPs HIV-TAT (20 µM), Antennapedia (20 
µM) and Transportan (10 µM) for 2 hours. Images are representative of three independent 
experiments. Scale bar = 20 µm. The amount of CPP mediated delivery of BSA-568 to 
A431 (B), A549 (D) and Caco-2 (F) was estimated by comparing the increase in mean 
fluorescence intensity per cell from each CPP relative to BSA-568 alone. Data was pooled 
from fifteen separate images taken across three independent experiments.  
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Figure 4.2. CPPs transport siRNA molecules into A549 cells but do not induce a 
knockdown effect. A. Fluorescent images of A549 cells exposed to VivoTag680 tagged 
SSB siRNA (10 nM) either alone or in complex with HIV-TAT (20 µM), Antennapedia (20 
µM) or Transportan (10 µM) for 2 hours. Images are representative of two independent 
experiments. Scale bar = 20 µm. B Western blot analysis for levels of SSB and ERK 
following 48 hours of exposure of A549 cells to CPP: SSB siRNA complexes. Protein 
bands are representative of two independent experiments.  
 
4.3 CPPs do not affect cell viability 
 
It has been reported that CPPs at high concentrations can be cytotoxic to cells 
(Hansen et al., 2012; Kilk et al., 2009; Watkins et al., 2009). It was therefore 
prudent to establish if the concentrations of CPPs selected for these studies were 
exhibiting such an effect on the cells. We examined the effect of both CPPs alone 
and in complex with a cargo on cell viability as the interactions between a CPP 
and its cargo have been suggested to affect the transport of a CPP within a cell 
(Madani et al., 2011; Moschos et al., 2007). Compared to cargo alone we 
observed no change in cell viability for any of the CPPs examined across each of 
the cell types used as measured by MTT assay (Figure 4.3).  
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Figure 4.3. Epithelial cell viability is unaffected flowing exposure to CPP complexes. 
A431 (A), A549 (B) and Caco-2 (C) cells were exposed to HIV-TAT (20 µM), 
Antennapedia (20 µM) or Transportan (10 µM) either alone (left panels) or in complex with 
BSA (1 µM; right panels). After 72 hours of culture cells were assessed for viability by 
MTT assay. Values are expressed as mean ± s.e.m pooled from three independent 
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4.4 CPPs do not activate the NFκB signalling pathway 
 
We reasoned that if CPPs were having an immunogenic response in epithelial 
cells then they would most likely activate pattern recognition receptors. Once 
activated pattern recognition receptors signal via NFκB to induce the production of 
pro-inflammatory cytokines (Medzhitov et al., 1997). We therefore examined NFκB 
activation in epithelial cells after 2 hours of exposure to CPP: cargo complexes. 
Western blot analysis failed to detect any increase in phosphorylated levels of the 
p65 subunit of NFκB for any of the CPPs examined compared to cargo alone for 
the three epithelial cell lines examined (Figure 4.4). 2 ng/ml TNFα failed to induce 
an increase in phosphorylated NFκB but as the protein was extracted 2 hours post 
application of CPP complexes this may have been too late to observe an 
activation of NFκB signalling. 
Figure 4.4. The NFκB pathway is not activated in epithelial cells following exposure 
to CPP complexes. A431 (Top panels), A549 (middle panels) and Caco-2 (bottom 
panels) cells were exposed to HIV-TAT (20 µM), Antennapedia (20 µM) or Transportan 
(10 µM) either alone or in complex with BSA (1 µM) for 2 hours. 2 ng/ml TNFα was used 
as a positive control. Cells were subsequently analysed for expression of phosphorylated 
NFκB. Expression of ERK is shown as a gel loading control. Protein bands are 
representative from three independent experiments.  
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4.5 CPPs do not induce the production of inflammatory mediators from 
epithelial cells 
 
Epithelial cells release ‘danger signals’ in response to an immunogen in order to 
recruit inflammatory cells (Parker and Prince, 2011; Vareille et al., 2011). These 
include IL-6, which induces the activation of neutrophils (Borish et al., 1989), and 
IL-8, which promotes neutrophil recruitment (Atkins et al., 1977). Both of these 
cytokines are also released in response to pattern-recognition receptor activation 
(Adachi et al., 1998; Mukaida et al., 1990). Therefore if CPPs are indeed 
immunogenic then epithelial cells should release at least IL-6 and IL-8 in 
response. We collected supernatant from epithelial cells 72 hours after initial 
exposure to the CPPs alone, or in combination with a BSA protein cargo, in order 
to detect an early or delayed immune response. We also applied TNFα to the 
epithelial cells to induce the production of IL-6 and IL-8 as a positive control 
(Mukaida et al., 1990). We observed no difference in IL-6 (Figure 4.5) or IL-8 
release (Figure 4.6) compared to cargo alone from any of the CPPs examined 
across the cell types tested. A431 and A549 cells demonstrated a robust increase 
in the release of IL-6 and IL-8 in response to TNFα. However, Caco-2 cells 




































































Figure 4.5. IL-6 production from epithelial cells is unchanged following exposure to 
CPP complexes. A431 (A), A549 (B) and Caco-2 (C) cells were exposed for 72 hours to 
the CPPs HIV-TAT (20 µM), Antennapedia (20 µM) or Transportan (10 µM) either alone 
(left panels) or in complex with a BSA protein cargo (1 µM; right panels). An ELISA based 
assay was used to evaluate IL-6 content from collected cell supernatants. 2 ng/ml TNFα 
was used as a positive control. Values are expressed as mean ± s.e.m pooled from three 











Figure 4.6. IL-8 production from epithelial cells is unchanged following exposure to 
CPP complexes. A431 (A), A549 (B) and Caco-2 (C) cells were exposed for 72 hours to 
the CPPs HIV-TAT (20 µM), Antennapedia (20 µM) or Transportan (10 µM) either alone 
(left panels) or in complex with a BSA protein cargo (1 µM; right panels). An ELISA based 
assay was used to evaluate IL-8 content from collected cell supernatants. 2 ng/ml TNFα 
was used as a positive control. Values are expressed as mean ± s.e.m pooled from three 
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4.6 Summary of results 
 
• The CPPs HIV-TAT, Antennapedia and Transportan can effectively deliver 
a fluorescently labelled BSA cargo into epithelial cells. 
• CPPs can also deliver an siRNA cargo into cells. However, this delivery 
does not lead to efficient knockdown. 
• The concentrations of CPPs used to deliver a cargo into cells do not affect 
epithelial cell viability after 72 hours of culture. 
• NFκB signalling in epithelial cells does not appear to be activated following 
exposure to CPPs either alone or in complex with a protein cargo. 
• Neither IL-6 nor IL-8 release is significantly affected 72 hours post exposure 




In this chapter we have demonstrated that CPPs can deliver a protein based cargo 
into epithelial cells lines representing the skin, airways and intestine. We observed 
a small amount of uptake from cells exposed to the labelled BSA cargo alone. It 
has been reported that epithelial cells can take up small amounts of BSA by 
clatherin-mediated endocytosis (Yumoto et al., 2012). This may suggest that the 
fluorescent signal from cells exposed to CPP: BSA complexes was simply the 
result of cellular uptake of the BSA cargo alone. However the large fold increase in 
fluorescence intensity between BSA alone and CPP: BSA complexes would 
suggest that BSA entry was being significantly enhanced by CPPs. We observed 
different levels of uptake for a fluorescently tagged BSA cargo between the CPPs 
HIV-TAT, Antennapedia and Transportan. This is consistent with previous 
observations that different CPPs can utilise separate routes of cargo delivery and 
therefore have different delivery efficacies (Lundin et al., 2008).  
 
We also examined the ability of CPPs to deliver an siRNA cargo into A549 
epithelial cells. Although we also observed siRNA in cells exposed to either 
Antennapedia or Transportan we were not able to detect a knockdown of the SSB 
protein. This lack of knockdown is probably the result of the CPP: siRNA 
complexes being retained in endosomes, thereby preventing the siRNA construct 
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from interacting with the cytoplasmic endoribonuclease Dicer to initiate 
knockdown. The retention of CPPs and their cargos within endosomes is a 
common caveat of CPP-mediated delivery (Rudolph et al., 2003). As a result, 
many of the CPPs in development today contain modifications to promote 
endosomal escape (Lo and Wang, 2008; Lundberg et al., 2007). To demonstrate 
the delivery of siRNA into cells with these CPPs an endosomolytic agent such as 
chloroquine would have to be added to the cells in order to release the CPP: 
siRNA complexes from endosomes (Rudolph et al., 2003). This would have been 
impractical for this study, as endosomolytic compounds may have affected the 
cellular response to a CPP. For instance, chloroquine has been demonstrated to 
have both anti- and pro- inflammatory responses (Fox, 1993; Park et al., 2003).  
 
CPP-mediated cargo entry into epithelial cells did not appear to initiate an immune 
reaction from the epithelial cells examined in this study as evidenced by a lack of 
activation of NFκB signalling, and no increase in IL-6 or IL-8 release. Although this 
is not the complete repertoire of potential pro-inflammatory signalling molecules 
than can be released from epithelial cells in response to an immunogen or material 
that incites an inflammatory response, this outcome provides an indication that an 
overt immune response was not induced. We observed that the intestinal cell line, 
Caco-2, produced far less basal IL-6 and IL-8 compared to A431 and A549 cells 
and failed to respond to TNFα. The intestinal lining is host to a plethora of resident 
microbes. Intestinal cells therefore exhibit a level of tolerance to pro-inflammatory 
signals such as lipopolysaccharide and TNFα (Schuerer-Maly et al., 1994; Vitkus 
et al., 1998). The lack of response exhibited by Caco-2 cells is therefore likely the 
result of this native tolerance to pro-inflammatory signals.  
 
The observation that the CPPs tested in this study do not induce an immune 
response is somewhat surprising given their derivation from harmful substances 
such as viruses and venoms (Frankel and Pabo, 1988; Gurrola et al., 2010; Rádis-
Baptista and Kerkis, 2011); it would seem reasonable to presume that these CPP 
sequences could be recognised by cells as materials that could lead to infection 
and/or cell damage. Our data supporting that these CPPs can be used to deliver a 
protein cargo without acute cytotoxic or inflammatory outcomes is important for the 
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continued use of these molecules as therapeutic tools to enhance the cytoplasmic 
delivery of therapeutic agents.  
 
In pharmaceutical applications involving topical delivery, the concentrations of 
CPPs are likely to be maximal for epithelial cells at the site of administration. 
Therefore epithelial cells would be a likely initiator of an immune response if CPPs 
were indeed immunogenic. Beyond epithelial cells, antigen-presenting cells are 
also a likely source of an immune response, as these cells would encounter CPPs 
in tissues and/or the vasculature following topical application. This has been 
examined elsewhere. CPPs added to the monocytic cell line THP-1 showed no 
release of pro-inflammatory cytokines (Suhorutsenko et al., 2011). Nevertheless, it 
remains to be established if CPPs can be presented to adaptive immune cells via 
major histocompatibility complex molecules. This would determine if CPPs could 
induce an adaptive immune response. A potential way to examine this would be to 
expose isolated antigen presenting cells to CPPs and then culture these with 
naïve CD4+ T lymphocytes. The T lymphocytes could then be examined for 
activation, and skewing toward a particular T helper subset in response to CPP 
presentation by antigen presenting cells. 
 
It has been established that the mechanism by which a CPP can enter a cell is 
dependent on the type of CPP and the cargo used (Lundin et al., 2008). Therefore, 
depending on the type of cargo, a CPP may be directed to an area of the cell 
where it interacts with a pattern recognition receptor that recognises the CPP 
sequence. This is plausible as several pattern recognition receptors, including toll-
like receptors 3, 7, 8 and 9 are found in intracellular compartments (Brinkmann et 
al., 2007). Each type of cargo; oligonucleotides, plasmid DNA, protein etc., should 
therefore be examined when in complex with a CPP to give a more complete 
picture of the immunogenic potential of CPPs. 
  
Future work could examine outcomes elicited by CPPs in-vivo where the full 
repertoire of possible immune responses can be observed. This has been 
examined for a few CPPs utilising protein (Khafagy et al., 2013), DNA 
(Suhorutsenko et al., 2011), and siRNA (Moschos et al., 2007) based cargos. 
Nevertheless, because of the variety of CPPs and cargos currently in 
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development, it would be prudent for researchers to investigate the 
immunogenicity of their own CPP with a particular cargo and a specific method of 
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Bacterial toxins such as PEx, Chx and Dtx have been repurposed for therapeutic 
applications by replacing the receptor-binding domain of the toxin with a cell-
specific antibody; thus creating highly toxic, cell specific immunotoxins (Pastan et 
al., 2006). The continuing success of these immunotoxins, as evidenced by the 
increasing number entering clinical trials, has spurred research into novel 
applications for these bacterial toxins. Bacterial toxins may be modified to 
transport a therapeutic cargo into target cells by exploiting their ability to be 
transported to the cell cytosol following internalisation (Mohammed et al., 2012). 
Although an intriguing idea, a potential obstacle for this approach is that, as toxins 
can exploit multiple pathways within cells (Smith et al., 2006a), it is conceivable 
that substantial amounts of toxin may be lost to degradative pathways that would 
result in an ineffective amount of therapeutic reaching the cytosol.  
 
Identification of factors that influence the sorting of bacterial toxins within cells will 
likely help to overcome this caveat as toxins will be able to be further modified to 
exploit the most efficient route to the cytoplasm. A potential candidate is the lipid 
ganglioside GM1, the native receptor for cholera toxin, as structural changes to 
this lipid have been demonstrate to influence the intracellular target of cholera 
toxin. For example, the C16:1 ceramide chain variant of GM1 targets cholera toxin 
to the Golgi whereas the C18:0 variant directs transport to lysosomes (Chinnapen 
et al., 2012). This may be also true for PEx, which has been identified to bind to 
GM1 (R. Mrsny, unpublished observations) separately from its native receptor 
CD91 (Kounnas et al., 1992).  
 
Naturally, PEx is secreted by Pseudomonas aeruginosa present at mucosal linings 
as a method of host immune evasion. PEx is passively transported across the 
polarised epithelial cells that comprise this lining and subsequently targets antigen 
presenting cells present in the sub-mucosal space (Mrsny et al., 2002). This 
observation suggests that a therapeutic cargo could be attached to a toxin as a 
means to transport the therapeutic across an epithelial barrier. This would allow 
the administration of macromolecule therapeutics through the airway (or possibly 
by the oral route) that would otherwise have to be administered by injection. 
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Questions remain as to whether these toxins would retain their ability to transport 
across epithelial surfaces while carrying a therapeutic cargo or if the cargo would 
still be biologically active following transcytosis.  
 
In this chapter we sought to examine the utility of bacterial toxins as drug delivery 
vehicles. Using fluorescently labelled toxins in order to observe their transport 
within cells, we examined the role GM1 has in the cellular localisation of two 
bacterial toxins, PEx and Chx. Furthermore, we assessed the ability of these 
toxins to deliver an siRNA cargo to cells and whether such a cargo could be 
transported across epithelial monolayers.  
 
5.2 PEx and Chx can enter and be transported within A431 epithelial cells 
 
We initially examined whether the modified, fluorescently labelled, PEx and Chx 
retained their ability to be endocytosed into cells and were capable of being 
transported to distinct intracellular locations. PEx and Chx were tagged with Alexa 
Fluor 568 at a free cysteine residue introduced in place of the REDL sequence at 
the C-terminus (provided by Professor Randall Mrsny). These labelled toxins were 
added to non-polarised A431 epidermal cells expressing GFP-tagged markers that 
defined different intracellular compartments (Chinnapen et al., 2012). After 2 hours 
both PEx-568 and Chx-568 were present in the early endosomes (Rab5, (Bucci et 
al., 1992)), suggesting that they were endocytosed. Equally PEx and Chx were 
found in late endosomes (Rab7, (Soldati et al., 1995)) suggesting a proportion of 
the toxins were transported to lysosomal compartments. PEx and Chx were also 
present in sorting endosomes (Rab11, (Ullrich et al., 1996)), an element of the 
retrograde pathway. Comparatively little PEx-568 and Chx-568 was observed in 
the Golgi network (Golgin97, (Griffith et al., 1997)) and the ER (Sec61, (Deshaies 
et al., 1991)) (Figure 5.1). These observations demonstrate that both PEx-568 and 
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Figure 5.1. PEx and Chx enter non-polarised epithelial cells by endocytosis and are 
transported via the retrograde pathway. Fluorescent images of 20 µg/ml PEx-568 (left 
panels) and Chx-568 (right panels) within non-polarised A431 epidermal cells expressing 
either GFP tagged Rab5, Rab7, Rab11, Sec61 or Golgin97 after 2 hours. Images are 
representative of ten images taken over three independent experiments. Scale bar = 10 
µm.  
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5.3 GM1 influences the intracellular transport of PEx 
 
MEF cells deficient in GD2 synthase lack the capability to produce GM1 
(Chinnapen et al., 2012). These cells are therefore incapable of internalising 
cholera toxin, which uses GM1 as a cell entry receptor (Holmgren et al., 1975). 
These MEFGM1-/- cells can be loaded with different structural variants of the 
ceramide chain of GM1 to assess the dependence of GM1 characteristics on cell 
entry and intracellular transport of a bacterial toxin. To confirm the efficiency of 
GM1 loading we incubated MEFGM1-/- cells with the B subunit of cholera toxin 
conjugated to Alexa Fluor 568 (CTB-568). CTB-568 was capable of being 
internalised into cells loaded with either the C16:1 or C18:0 variants of GM1. We 
observed a greater localisation of CTB-568 to the Golgi network in cells loaded 
with C16:1 GM1 compared to those loaded with C18:0 (Figure 5.2). This is 
consistent with the reported role for GM1 structure in the transport of CTB within 
cells (Chinnapen et al., 2012).  
 
We next examined the influence of GM1 on the transport of PEx and Chx. After 2 
hours of incubation, a very low level of fluorescent signal for Chx-568 was 
observed in un-loaded MEFGM1-/- cells. Incubation of CHx-568 with MEFGM1-/- cells 
loaded with either the C16:1 or C18:0 variants of GM1 demonstrated marginally 
greater levels of intracellular toxin, but no localisation to the Golgi network (Figure 
5.3). Conversely, PEx was found to enter un-loaded MEFGM1-/- cells equally well to 
MEFGM1-/- cells loaded with either C16:1 or C18:0 (Figure 5.4A). To calculate the 
relative amount of PEx-568 that entered the Golgi network images were analysed 
using iMAB software as outlined in the materials and methods (Section 2.11). An 
example of the masks generated for PEx-568, the Golgi network, and the co-
localisation between the two signals is represented in figure 5.4B. There was no 
difference in the relative amount of PEx present in the Golgi network between 
MEFGM1-/- cells and those loaded with C18:0. However, a significant increase in the 
amount of PEx in the Golgi network was observed for MEFGM1-/- cells loaded with 
C16:1 compared with unloaded MEFGM1-/- cells (Figure 5.4C). 
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Figure 5.2. GM1 is required for CTB entry into cells and transport to the Golgi 
network. A. Schematic illustration of C16:1 and C18:0 ceramide chain structures of GM1. 
Adapted from (Chinnapen et al., 2012). B. Fluorescent images of 20 nM CTB-568 after 2 
hours of incubation with MEFGM1-/- cells alone (Control) or MEFGM1-/- cells loaded with 
either 5 µM C16:1 or 7.5 µM C18:0 GM1. Expression of GM130 was used to visualise the 
Golgi network. Images are representative of twelve images acquired from three 










Figure 5.3. Chx transport is not dependent upon GM1 ceramide chain composition. 
Fluorescent images of 20 µg/ml Chx-568 after 2 hours of incubation with MEFGM1-/- cells 
alone (Control) or MEFGM1-/- cells loaded with either 5 µM C16:1 or 7.5 µM C18:0 GM1. 
Expression of GM130 was used to visualise the Golgi network. Images are representative 
of twelve images acquired from three independent experiments. Scale bar = 10 µm. 
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Figure 5.4. The C16:1 ceramide chain variant of GM1 enhances PEx transport to the 
Golgi network. A. Fluorescent images of 20 µg/ml PEx-568 after 2 hours of incubation 
with MEFGM1-/- cells alone (Control) or MEFGM1-/- cells loaded with either 5 µM C16:1 or 7.5 
µM C18:0 GM1. Expression of GM130 was used to visualise the Golgi network. Images 
representative of twenty images acquired from three independent experiments. Scale bar 
= 10 µm. B. Example of mask generation using iMAB software. Masks are generated for 
areas of fluorescence for PEx-568 (Red), GM130 (Blue) and where both signals overlap 
(Green) C. Quantification of PEx-568 co-localisation with the Golgi network in MEF cells 
deficient in GM1 (Control) or loaded with either C16:1 or C18:0. *** P<0.001, NS = Not 
Significant, compared with control.  
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5.4 PEx and Chx do not utilise the same cell surface receptor for cell entry 
 
The differences observed for PEx and Chx entry into MEFs is surprising as they 
were both thought to interact with CD91 given their sequence homology and the 
available cell data to date (Jørgensen et al., 2008). To understand if Chx does in 
fact use CD91 as a receptor we compared the entry of Chx-568 into CHO cells 
deficient in CD91 with PEx-568. After 2 hours of incubation a signal for PEx-568 
was observed in wild type CHO cells (Figure 5.4). Conversely, PEx-568 was not 
detected in CHOCD91-/- cells, thus confirming a need for CD91 in the entry pathway 
for PEx (Kounnas et al., 1992). Unlike PEx, Chx was not detected in either wild 
type CHO or CHOCD91-/- cells (Figure 5.5). 
 
Figure 5.5. Chx does not share the same cell entry receptor as PEx. Fluorescent 
images of wild type and CD91-/- CHO cells incubated for 2 hours with HBSS (Control), or 
20 µg/ml of either PEx-568 or Chx-568. Images are representative of two independent 
experiments. Scale bar = 20 µm 
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5.5 Transcytosis of PEx and Chx across polarised monolayers of Caco-2 
cells 
 
We next examined if PEx and Chx could be transported across polarised 
monolayers of Caco-2 epithelial cells, recapitulating the transport of these toxins 
across mucosal surfaces present at the airways and intestinal tract (Daugherty et 
al., 2000). Although PEx is an airway toxin Caco-2 cells were chosen for these 
experiments as they secrete less mucus than Calu-3 cells (Haghi et al., 2010), 
their respiratory counterpart. Mucus production would have interfered with toxin 
transcytosis preventing an adequate interpretation of their effectiveness. To 
assess the integrity of Caco-2 monolayers fluorescently labelled 4 kDa dextran 
was applied to the apical compartment, any subsequent fluorescent signal present 
in the basolateral compartment would therefore be proportional to the integrity of 
the monolayer. After 30 minutes of incubation with FITC labelled dextran a large 
fluorescent signal was measured in the basolateral compartment of transwells 
devoid of cells. Comparatively little dextran was measured in the basolateral 
compartment of transwells containing confluent monolayers of Caco-2 cells, thus 
confirming the integrity of the epithelial barrier (Figure 5.6A).  
 
Transport of PEx and Chx across monolayers was assessed by initially applying 
20 µg/ml of either PEx-568 or Chx-568 to the apical surface of Caco-2 cells and 
then measuring the amount of fluorescence present in the basolateral 
compartment after 15, 30, 60, 120 and 240 minutes. These values were then 
adjusted for background flourescence and the relative integrity of each respective 
monolayer assessed by the extent of 4 kDa dextran transport as outlined in the 
materials and methods (section 2.9). This type of correction for non-specific 
macromolecular transport not only corrected for monolayer-to-monolayer 
differences but could also be used to ensure that the forms PEx and Chx used in 
these studies had not negatively affected monolayer integrity. Both PEx and Chx 
were able to transport across polarised Caco-2 monolayers over 4 hours (Figure 
5.6B). Although there was a trend for a higher amount of PEx to cross the cells 
compared to Chx this difference was not statistically different.  
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To determine if PEx and Chx could influence the transport of the other we 
assessed the transport of fluorescently labelled PE/Chx when incubated with 
increasing amounts of unlabelled Chx/PEx at the apical surface of Caco-2 
monolayers. Both 20 and 200 µg of unlabelled Chx was able to greatly reduce the 
transport of PEx-568 across Caco-2 monolayers, which was significant at 120 and 
240 minutes in the presence of 200 µg unlabelled Chx (Figure 5.6C). Conversely 
20 µg of unlabelled PEx had no effect on the transport of Chx-568. Surprisingly, 
200 µg of unlabelled PEx significantly enhanced the amount of Chx-568 that 
transported across monolayers at 120 and 240 minutes (Figure 5.6C). 
 
Given that GM1 can influence the transport of PEx within non-polarised cells we 
wished to examine if GM1 could affect the transport of either PEx or Chx, across 
polarised Caco-2 cells. To examine this we applied PEx-568 and Chx-568 to the 
apical surface of Caco-2 monolayers along with equal amounts of CTB. If GM1 
was involved in the transport of PEx or Chx, CTB should compete for GM1 and 
thus influence PEx and Chx transport. In the presence of 20 µg/ml of CTB the 
amount of PEx-568 that crossed polarised Caco-2 cells was significantly reduced 
compared to PEx-568 alone 30 minutes following application (Figure 5.7A). 
Conversely, 20 µg/ml of CTB increased the amount of Chx-568 that transported 
across Caco-2 cells compared to Chx-568 alone, which was significant at 240 
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Figure 5.6. PEx and Chx transport across polarised epithelial cells. A. Amount of 
FITC-labelled 4 kDa dextran present in the basolateral compartment 30 minutes after 
apical addition to blank Transwells compared to Transwells supporting a confluent 
monolayer of Caco-2 cells B. Relative amount of 20 µg/ml of either PEx-568 (squares) or 
Chx-568 (triangles) present in the basolateral compartment over 240 minutes following 
initial application to the apical compartment of Caco-2 monolayers. The amount of PEx-
568 (open squares) or Chx-568 (open triangles) that moved across blank transwells after 
240 minutes of incubation is depicted. C. Relative amount of 20 µg/ml PEx-568 
transported across Caco-2 monolayers over 240 minutes either alone (squares) or in the 
presence of either 20 (triangles) or 200 (circles) µg/ml of unlabelled Chx. D. Relative 
amount of 20 µg/ml Chx-568 transported across Caco-2 monolayers over 240 minutes 
either alone (squares) or in the presence of either 20 (triangles) or 200 (circles) µg/ml of 
unlabelled PEx. Data presented as mean ± s.e.m for each time point pooled from two 
independent experiments, totalling six individual wells. * P<0.05, ** P<0.01, *** P<0.001, 
compared to control at respective time point where appropriate.  
 
 
Figure 5.7. GM1 influences PEx and Chx transport across polarised epithelial cells. 
A. Relative amount of 20 µg/ml PEx-568 transported across Caco-2 monolayers either 
alone (squares) or in the presence of 20 µg/ml CTB (triangles) over 240 minutes. B. 
Relative amount of 20 µg/ml Chx-568 transported across polarised Caco-2 cells either 
alone (squares) or in the presence of 20 µg/ml CTB (triangles) over 240 minutes. Data 
presented as mean ± s.e.m fluorescence for each time point pooled from two independent 
experiments, totalling six individual wells. * P< 0.05, ** P<0.01, compared to control at 
respective time point.   
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5.6 PEx can transport and deliver an siRNA cargo into macrophages 
 
The final facet of this project sought to examine the utility of using bacterial toxins 
as a delivery vehicle for therapeutics. We attached a siRNA targeting Sjögren 
syndrome antigen B (SSB) at the C-terminus of non-toxic PEx using the same 
conjugation strategy and chemistry used to attach the Alexa 568 dye. The siRNA 
duplex itself was labelled with the VivoTag680s that allowed its fate to be 
monitored. We initially examined these constructs in J774.2 macrophages as 
macrophages (or other antigen presenting cells) are the end targets for PEx as 
part of the immune evasion employed by Pseudomonas aeruginosa (Mrsny et al., 
2002). Both siRNA alone and PEx tagged with either Alexa Fluor 488 or 
VivoTag680 SSB siRNA was observed in J774.2 macrophages 1 hour after 
administration (Figure 5.8A). This signal persisted 24 hours post administration 
although the signal was diminished. After 48 hours of incubation with the 
constructs we observed a knockdown of SSB protein from macrophages cultured 
with PEx conjugated to the SSB siRNA but not from macrophages cultured with 
SSB siRNA alone (Figure 5.8B). This would indicate that PEx-siRNA was not 
phagocytosed, but instead entered macrophages through CD91 mediated 
endocytosis and was transported to the cytoplasm where the siRNA could elicit a 
knockdown effect.  
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Figure 5.8. PEx can deliver an siRNA cargo into macrophages to elicit a knockdown 
effect. A. Fluorescent images of J774.2 macrophages incubated for 1 or 24 hours with 
HBSS (Control), VivoTag680 tagged SSB siRNA (SSB siRNA; 10 nM), PEx tagged with 
Alexa Fluor 488 (PEx-488; 20 µg/ml) or an equivalent fluorescent amount of PEx tagged 
with VivoTag680 tagged SSB siRNA (PEx-siRNA). Images are representative of three 
independent experiments. Scale bar = 20 µm B. Western blot analysis for levels of SSB 
and ERK from J774.2 macrophages incubated with either SSB siRNA alone or PEx 
tagged with SSB siRNA for 48 hours. Protein bands representative of three separate 
experiments.    
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PEx and Chx can transport an siRNA cargo across polarised Caco-2 cells 
and subsequently deliver a cargo into macrophages 
 
Next, we examined if an siRNA cargo could be transported across polarised 
monolayers of Caco-2 cells. PEx, or Chx, conjugated to a VivoTag680 tagged SSB 
siRNA was applied to the apical surface of Caco-2 monolayers. After 2 hours both 
PEx-siRNA and Chx-siRNA was observed in Caco-2 monolayers although their 
localisation differed (Figure 5.9A). PEx-siRNA appeared to be transported 
throughout the cytoplasm of polarised Caco-2 cells, whereas Chx-siRNA was 
observed within the periphery of the cells. To explore this further we examined the 
co-localisation of labelled bacterial toxins with the tight junction marker occludin. 
PEx-siRNA weakly co-localised with occludin whereas Chx-siRNA strongly co-
localised (Figure 5.9B). 
 
Once we established that an siRNA cargo could be transported through polarised 
epithelial cells by PEx and Chx we next sought to establish if these toxins could 
still deliver an siRNA cargo to cells present in the basolateral compartment. 2 
hours after the apical addition of labelled toxins to Caco-2 monolayers no siRNA or 
PEx-siRNA was detected in J774.2 macrophages present in the basolateral 
compartment of Transwell chambers. However, after 24 hours PEx-siRNA, but not 
siRNA alone, was observed in macrophages (Figure 5.10A). Moreover, 
knockdown of SSB was observed in J774.2 macrophages cultured in the 
basolateral compartment of Caco-2 monolayers incubated with PEx-siRNA but not 
in those cultured with monolayers exposed to siRNA alone (Figure 5.10B).  
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Figure 5.9. PEx and Chx can transport an siRNA cargo across polarised epithelial 
cells. A. Confocal images of Caco-2 monolayers following incubation with VivoTag680 
tagged siRNA (Control) coupled to either PEx (PEx-siRNA) or Chx (Chx-siRNA). Z-stack 
images of siRNA conjugates crossing Caco-2 monolayers after 2 hours are displayed 
below. Images are representative of two independent experiments. Z-stack = 5 µm. B. 
Expression of occludin in Caco-2 cells incubated with siRNA conjugates over 2 hours. 
Images acquired from a single experiment. Scale bar = 20 µm 
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Figure 5.10. PEx can deliver a functional siRNA cargo to macrophages following 
transport across polarised epithelial cells. Fluorescent images of J774.2 macrophages 
following transport of VivoTag680 tagged SSB siRNA alone (SSB siRNA; 10 nM) or an 
equivalent fluorescent amount conjugated of PEx conjugated to VivoTag680 tagged 
SSB siRNA (PEx-siRNA) across polarised monolayers of Caco-2 cells at 2 and 24 hours. 
Images acquired from a single experiment. Scale bar = 20 µm. Western blot analysis for 
levels of SSB and ERK from J774.2 macrophages present in the basolateral compartment 
of Caco-2 monolayers incubated with either SSB siRNA alone or PEx tagged with SSB 
siRNA for 48 hours. Protein bands are representative from a single experiment.   
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5.7 Summary of results 
 
• Fluorescently labelled PEx and Chx are able to enter non-polarised 
epithelial cells and are capable of being sorted through the retrograde 
pathway. 
• PEx transport to the Golgi network is influenced by the ganglioside GM1. 
The C16:1 ceramide chain variant of GM1 enhances transport to the Golgi, 
whereas the C18:0 variant did not appear to influence transport to the 
Golgi.  
• Minimal amounts of Chx enter MEFGM1-/- compared to PEx, which is only 
marginally increased following GM1 loading. 
• Despite structural similarities PEx and Chx do not share the same cell 
surface receptor.  
• Both PEx and Chx are capable of transcytosis across polarised monolayers 
of Caco-2 epithelial cells. 
• Chx can impair the transport of PEx across monolayers, whereas PEx can 
enhance Chx transport. 
• CTB impairs PEx, yet enhances Chx transport across polarised monolayers 
of Caco-2 cells. 
• PEx can efficiently transport an siRNA cargo into macrophages and elicit a 
knockdown effect.  
• PEx can transport an siRNA cargo across monolayers of epithelial cells and 
then a functional form of this cargo into macrophages present in the 




Cellular receptor for Chx  
Fluorescently labelled PEx and Chx are both capable of entering the epithelial cell 
line A431 wherein they appeared to be transported to endosomal compartments. 
The fact that we observed a fluorescent signal within these intracellular 
compartments would suggest that we are observing the transport of the complete 
toxin and not just the fluorescent cargo that may have separated. Comparatively 
little toxin was observed in the Golgi network and ER, inconsistent with the 
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reported intracellular transport pathway (Smith et al., 2006a). In order to effectively 
couple a cargo onto PEx and Chx the C-terminus had to be modified to include a 
fee cysteine residue required for coupling. This modification removed the REDL 
sequence that is required for effective transport of a toxin to the ER. Therefore, the 
lack of signal in the ER is likely due to the absence of this REDL sequence. 
However, this REDL sequence may not be completely necessary for PEx transport 
to the cytoplasm as studies utilising the translocation domain of PEx, and therefore 
lacking the REDL sequence, fused to GFP has been demonstrated to effectively 
enter the cytoplasm (Mohammed et al., 2012). As transport to the ER occurs after 
entry into the Golgi network (Smith et al., 2006a), a comparatively weak signal for 
toxin in the Golgi in these cells may reflect the small fraction of internalised toxin 
that reaches the retrograde pathway (Kreitman and Pastan, 1998; Yamaizumi et 
al., 1978).   
 
Upon examining these bacterial toxins in MEFGM1-/- cells we were able to observe 
cellular entry with PEx and Chx, although the signal with Chx was significantly 
less. This is surprising as PEx and Chx are both thought to share the same cell 
surface receptor, CD91 (Jørgensen et al., 2008; Kounnas et al., 1992). We 
confirmed that CD91 is the required receptor for PEx by demonstrating the entry of 
PEx into wild type CHO cells but not those deficient in CD91. We also 
demonstrated that Chx is incapable of entering wild type CHO cells, which further 
supports that the receptor for Chx is not CD91.  
 
As we have demonstrated that Chx can effectively enter both A431 and Caco-2 
epithelial cells a way to determine the receptor(s) for Chx would be to pull down 
the epithelial membrane proteins that Chx binds to. Once identified, these proteins 
could then be individually knocked out and Chx entry evaluated. However, a 
caveat to this approach is that it would not identify if the receptor for Chx is a lipid, 
which is the case for CTB that utilises the ganglioside GM1 for cell entry 
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GM1 and the intracellular transport of PEx in non-polarised cells 
We examined the influence of GM1 on the transport of bacterial toxins with a goal 
of identifying mechanisms that could be exploited to enhance the cytoplasmic 
delivery of a toxin. Loading cells with the C16:1 ceramide chain variant of GM1 
greatly enhanced the localisation of PEx to the Golgi network compared to cells 
which lacked GM1. Moreover, cells loaded with the C18:0 ceramide chain variant 
of GM1 did not show a similar enhancement of PEx localisation to the Golgi 
network. Chinnapen and colleagues have demonstrated that different structural 
variants of GM1 can transport to distinct intracellular locations, with C16:1 
predominantly transporting to the Golgi network whereas C18:0 transports to late 
endosomes (Chinnapen et al., 2012). Our work therefore demonstrates that GM1 
can also influence the transport of PEx and does not simply enhance cellular 
entry. Further, the observation that PEx can be still be transported to, albeit less 
so, the Golgi network in the absence of C16:1 GM1 would support the idea that 
PEx can exploit multiple pathways within a cell (Smith et al., 2006a).  
 
We hypothesis that GM1 is required for at least one of the intracellular pathways 
proposed by Smith and colleagues. PEx can be transported either via an Arf1 or a 
Rab6 dependent pathway. As the Rab6 dependent pathway appears to be 
associated with detergent resistant membrane components (Smith et al., 2006a), 
of which GM1 is a component, it would seem likely that in GM1 deficient cells PEx 
transports exclusively through the Arf1 dependent pathway. This could be 
demonstrated by knocking down either Rab6 or Arf1 in GM1 deficient MEFs. If our 
hypothesis is correct, then the transport of PEx to the Golgi network should be 
prevented following knockdown of Arf1 and unaffected in Rab6 deficient cells. 
Further, PEx localisation to the Golgi network should not be enhanced by C16:1 
GM1 in Rab6 deficient cells. 
 
Moreover it would be important to determine at which stage in the transport 
process GM1 can influence PEx. This could be inferred by examining the binding 
of PEx to GM1 at different pH levels. An appropriate pH to examine would be pH 
6.8 as this is the pH of the airway surface and is therefore relevant to the natural 
activity of PEx (Jayaraman et al., 2001), which is derived from the respiratory 
pathogen Pseudomonas aeruginosa. This would be compared with binding at pH 
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5.5, which is representative of endosomal pH (Geisow and Evans, 1984). This 
method could also be used to examine if GM1 can bind, and therefore influence, 
Chx. In this instance Chx binding to GM1 could be compared between endosomal 
pH (pH 5.5) and a pH relative to the intestinal tract (pH 6 – 7) as Chx is derived 
from the intestinal pathogen Vibrio cholerae (Fallingborg, 1999). 
 
Although we have identified that GM1 can influence the transport of PEx to the 
Golgi network it still remains to be established if GM1 can influence the toxicity of 
PEx. This could be examined by measuring inhibition of protein synthesis following 
the application of the toxic form of PEx to MEF cells either deficient in GM1 or 
loaded with the C16:1 ceramide chain variant.  
 
Transcytosis of PEx and Chx 
In this study we have developed an in-vitro system with which to assess the 
transcytosis of PEx and Chx across polarised epithelium. As well as PEx and Chx, 
CTB is capable of undergoing transcytosis across polarised epithelial cells (Lencer 
et al., 1995). Once internalised CTB is either transported to the basolateral surface 
or enters the retrograde pathway leading to the Golgi network (Saslowsky et al., 
2013). These two pathways are independent and it has been demonstrated that 
the amount of CTB that undergoes transcytosis can be enhanced though inhibition 
of the retrograde pathway. 
 
PEx and Chx appear to affect the transport of the other. Excess Chx reduces the 
transcytosis of PEx, whereas excess PEx actually enhances Chx transcytosis. 
This may suggest that there are two transport routes for these toxins within 
polarised epithelial cells; one that leads to transcytosis, and one that leads to an 
intracellular compartment. If Chx has a preference for the transcytotic pathway 
over PEx then an excess of Chx would push PEx down the intracellular pathway 
thus reducing PEx transcytosis. Equally, if PEx has a preference for the 
intracellular pathway then an excess of PEx would make more Chx available for 
transcytosis. However, this explanation assumes that the two toxins share the 
same intracellular pathway. 
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We observed different distributions of Chx and PEx within polarised epithelial cells, 
Chx appeared to be transported within the periphery of the cells whereas PE 
transported across the cytoplasm. This may suggest that the two toxins are 
transported differently across polarised epithelium. Alternatively it may reflect a 
preference of Chx for the transcytosis pathway and PEx for an intracellular 
pathway. Brefeldin A is a protein transport inhibitor that blocks entry into the 
retrograde pathway (Chinnapen et al., 2012; Saslowsky et al., 2013). If the 
observed distribution of the toxins is due to their preference for one pathway over 
another then a similar distribution of PEx to Chx would be observed in cells treated 
with Brefeldin A as this would push more PEx into the transcytosis pathway. If not, 
then it would suggest that the two toxins travel via different intracellular pathways.  
 
The sorting of CTB to either the transcytotic or retrograde pathway in polarised 
cells appears to be influenced by the structure of GM1; with the C16:1 ceramide 
chain variant promoting transcytosis (Saslowsky et al., 2013). This also appears to 
be true for PEx transcytosis as CTB was able to reduce the transcytosis of PEx. 
This is also consistent with a requirement for GM1 in the transport of PEx within 
non-polarised cells. Surprisingly CTB was able to enhance the transcytosis of Chx 
suggesting a difference in GM1 interactions between Chx and PEx. These 
observations could be explored further by utilising Caco-2 cells deficient in GM1. 
This model would allow for the characterisation of different GM1 structures on the 
transport of toxins across polarised cells.   
 
We examined transcytosis of these toxins in Caco-2 cells, an intestinal cell line, 
which more accurately reflects the natural environment for the intestinal toxin Chx 
over the respiratory toxin PEx. Therefore a preference for Chx over PEx for the 
transcytotic pathway may simply be a reflection of the system used. A way to 
examine this further would be to study the transcytosis of these toxins in an airway 
epithelial cell line such as Calu-3 cells, although the mucus produced from Calu-3 
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Transcytosis Pathway for PEx and Chx 
The intracellular pathway for PEx and Chx transcytosis remains to be established 
and would have implications for the use of these toxins as therapeutic agents. As 
mentioned, a possible caveat for this therapeutic approach in non-polarised cells 
at least is the possibility of losing an effective amount of toxin to lysosomal 
degradation. The same may be true for transcytosis so it would be important to 
determine how much of an applied toxin is effectively transported to the 
basolateral side.  
 
Aside from bacterial toxins, immunoglobulins are capable of undergoing 
transcytosis from the apical to basolateral surface of epithelia (Dickinson et al., 
1999; Sakagami et al., 2006). This mechanism serves to transfer maternal IgG to 
the foetus and neonate and extend the half life of circulating IgG in the adult 
(Roopenian and Akilesh, 2007). It seems possible that bacterial toxins such as 
PEx and Chx could exploit this type of natural transcytosis mechanism to mediate 
their transfer across mucosal surfaces.  
 
During Pseudomonas aeruginosa infection the bacterium crosses mucosal 
surfaces to invade the blood stream and avoid the host immune system. It has 
been reported that in order for Pseudomonas aeruginosa to undergo transcytosis 
the bacterium requires the recruitment of basolateral proteins to the apical surface 
of polarised epithelial cells (Kierbel et al., 2007). This process is dependent on the 
activity of PI3K, which has previously been reported to be sufficient to transform 
the apical surface of polarised epithelium to basolateral (Gassama-Diagne et al., 
2006). As part of the host immune response dimeric IgA is secreted into the 
luminal space by epithelial cells. To achieve this dimeric IgA enters polarised 
epithelial cells through interactions with the polymeric immunoglobulin receptor 
present on the basolateral surface of epithelial cells. Dimeric IgA is then 
transported across the epithelium and is secreted on the apical side (Apodaca et 
al., 1994; Mostov et al., 1984). This mechanism is exploited by the pathogen 
Streptococcus pneumonia in host invasion (Zhang et al., 2000). Given the 
requirement of basolateral proteins for Pseudomonas aeruginosa invasion, and a 
dependency of PI3K for effective dimeric IgA transcytosis (Cardone and Mostov, 
1995), we hypothesis that Pseudomonas aeruginosa (and possibly PEx) also 
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exploits this transcytosis mechanism. However, this hypothesis would require that 
PEx alone is sufficient to induce a switch of an apical surface to basolateral.  
 
Bacterial toxin mediated cargo delivery 
The primary aim of this project was to examine the potential use of bacterial toxins 
as drug carriers. We have been able to demonstrate that PEx is capable of both 
transporting an siRNA cargo across polarised epithelial cells by transcytosis and 
delivering said cargo into cells present in the basolateral compartment. The 
observation that knockdown can be achieved is particularly promising and 
suggests that PEx was able to transport the siRNA to the cytosol of a cell, which 
would be required for a therapeutic effect. However, it remains to be determined if 
the PEx-siRNA construct could induce knockdown in the polarised monolayer of 
cells. This would seem unlikely as the natural, toxic; PEx can be transported 
across polarised epithelial cells without inducing the death of the cells. Together 
these data suggests that toxins can be used in place of other cell delivery reagents 
that are limited by their retention in endosomal compartments (Plank et al., 1994; 
Rudolph et al., 2003). Cytoplasmic delivery of a cargo has been previously 
reported with PEx (Mohammed et al., 2012), but we are the first to demonstrate a 
therapeutic effect.  
 
The repertoire of cargos that can be delivered by bacterial toxins remains to be 
elucidated. Given that these toxins require sorting within vesicles it is likely that 
there is a size limit to the overall toxin that may preclude certain macromolecule 
cargos from being used with this system. Another consideration for the therapeutic 
use of these toxins is whether their immunogenic properties will hinder their use. 
This is a common problem for the related immunotoxins, as a patient develops 
neutralising antibodies following prolonged use (Posey et al., 2002). The removal 
of B cell epitopes reduces the immunogenicity of immunotoxins (Onda et al., 2008; 
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6.1 PI3K in lung branching morphogenesis 
 
Overview 
This thesis began by examining how the PI3K pathway, a critical mediator of a 
number of disease processes, operates during the development of the lung. This 
builds on the appreciation that developmental pathways can become reactivated 
in, and contribute to, the pathogenesis of a number of lung diseases (Shi et al., 
2009). We utilised a range of pharmacological agents targeting different elements 
of the PI3K signalling cascade to ensure that the observations made were due to 
inhibition of PI3K signalling and not a result of off-target effects. Using these 
compounds and ex-vivo culture models of whole embryonic lungs we were able to 
identify a novel role for PI3K in the epithelial branching program of the lung. We 
discovered that inhibition of either PI3Kα, or its downstream signalling components 
Akt and mTORC2, greatly enhanced the branching potential of isolated embryonic 
lung cultures. This was a surprising observation as similar experiments have 
reported the opposite effects of PI3K inhibition in other epithelial branching organs 
such as the salivary glands (Larsen et al., 2003), mammary glands (Utermark et 
al., 2012), urogenital sinus tissue (Ghosh et al., 2011), and ureteric bud (Tang et 
al., 2002). Moreover, PI3K activation in the salivary gland, mimicked through 
exogenous application of PI(3,4,5)P (Larsen et al., 2003), has been shown to 
promote branching, further supporting a positive role for PI3K in branching. 
 
To understand why our observations conflicted with the literature we examined the 
PI3K pathway in preparations of isolated branching epithelium stimulated with the 
morphogen FGF7. In this context we observed that inhibition of PI3K was sufficient 
to dramatically alter the morphogenic properties of FGF7 from the formation of 
epithelial cysts to the formation of numerous epithelial branches resembling the 
morphogenic response to the related factor FGF10. The unique effect of PI3K on 
the branching program of the lung could therefore be explained by the different 
responses to FGF7 and FGF10 between the lung and salivary gland epithelium. In 
the salivary glands FGF7 initiates the formation of numerous small branches 
whereas FGF10 promotes branch elongation (Makarenkova et al., 2009). If PI3K 
inhibition switches FGF7 signalling to that of FGF10 then the budding response 
would be lost in salivary glands, and as a result there would be fewer branches. 
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This has implications for the use of PI3K directed therapies for regenerative 
medicine in that a therapeutic effect in one organ may have a deleterious effect in 
another.  
 
To attempt to explain how inhibition of PI3K alters the morphogenic properties of 
FGF7 we examined the influence of heparan sulphate, the FGFR1b receptor and 
the regulation of cell-cell contacts. Heparan sulphate has been reported to be 
critical for the branching response elicited by FGF10 (Izvolsky et al., 2003). 
However, removal of the heparan sulphate gradient failed to perturb the branching 
response achieved through FGF7 in the presence of an inhibitor of PI3K singalling. 
FGFR1b was considered to be a branching receptor due to the ubiquitous 
expression across the lung epithelium of the canonical branching receptor 
FGFR2b (Cardoso et al., 1997), and because FGFR1 has been reported to be 
expressed in the branch tips of the developing salivary glands and ureteric bud 
(Meyer et al., 2004; Steinberg et al., 2005). We were unable to identify the 
expression of FGFR1b in isolated lung epithelium. Moreover, we also failed to 
observe a branching response with the FGFR1 agonist FGF2. Together these 
results would suggest that FGFR1b was redundant in this system. Finally, we 
examined the impact of PI3K on cell-cell contacts and branching as regulation of 
the cell-cell contacts has been reported to be required for the collective migration 
of epithelial cells (Theveneau et al., 2013). Additionally, E-Cadherin cell-cell 
contacts can be regulated by JNK and GSK3β, which can themselves be 
controlled by PI3K activity (Aberle et al., 1997; Aikin et al., 2004; Cross et al., 
1995; Lee et al., 2009). We observed no disruption of cell-cell contacts in the 
branching tip of isolated lung epithelium. However, inhibition of GSK3β, and 
potentially enhanced cell-cell contacts, resulted in a more uniform cyst structure in 
response to FGF7 and prevented the induction of branches in response to FGF7 
and PI3K inhibition. Inhibition of JNK, on the other hand, failed to affect the 
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Future directions 
The difficulties associated with manipulating this model genetically, either through 
direct transfection of genetic material or viral infection, limit the use of this model. 
However, new approaches are emerging that will overcome this caveat that will 
give more power to this physiologically relevant model of lung development. These 
include novel infection techniques with which to directly infect the epithelium of a 
branching organ (Sequeira et al., 2013). Alternatively as we have demonstrated a 
robust method of genetic delivery to cells using modified bacterial toxins this may 
present an alternative means to introduce genetic tools into embryonic lung tissue. 
This model does not require the removal and subsequent reinstatement of the 
mesenchymal tissue as required by Sequeira and colleagues, which may damage 
the growth of the whole explant. Moreover, as these bacterial toxins can be 
modified to replace the receptor-binding domain with an antibody, this approach 
has the added benefit of allowing a specific subset of cells within the explant to be 
targeted.   
 
A mechanistic explanation for how PI3K inhibition can alter the signalling event of 
FGF7 to that of FGF10 has been reported that warrants further investigation in 
models of branching morphogenesis. Francavilla and colleagues reported that 
PI3K can control the sorting of internalised FGFR2b to either the recycling or late 
endosomes (Francavilla et al., 2013). FGF10 was shown to promote the recycling 
of FGFR2b whereas FGF7 promoted the degradation. The recycling of FGFR2b 
required the scaffolding properties of the p85 subunit of PI3K, which was recruited 
to the receptor solely in response to FGF10 interactions. However, inhibition of 
PI3K was demonstrated to be able to promote the recycling of FGFR2b following 
FGF7 stimulation (Francavilla et al., 2013), thus providing a mechanism for the 
observations from our experiments.  
 
It would be valuable to establish if a similar mechanism exists in the branching 
epithelium. This would be best achieved by expressing fluorescently tagged 
constructs of FGFR2b and elements of the recycling and late endosomes in 
isolated lung epithelium. The transport of internalised FGFR2b could then be 
visualised in real time in response to FGF7 with or without an inhibitor of PI3K 
signalling. Moreover the same experiment could be preformed in isolated salivary 
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gland epithelium to establish if the conflicting reports of PI3K inhibition on the 
branching response between organs are indeed as a result of differences in FGF 
signalling.  
 
The finding that FGFR2b sorting is critical in the morphogenic output of a factor 
would give more importance to the signals that drive endosomal sorting in 
development and disease. Identification of whether distinct signalling pathways are 
activated in separate endosomal compartments would provide answers as to how 
sorting can effect the morphogenic output of a growth factor. Given the 
involvement of the class II and III PI3K family members in endosomal transport 
(Ikonomov et al., 2006; Schu et al., 1993; Xu et al., 2001), these kinases may also 
be able to direct branching morphogenesis through the manipulation of FGF 
signalling.   
 
Aside from the branching response, an intriguing question in the development of 
the branched airway network is how the airway lumen forms during successive 
branch generations and expands to such a size as to minimise the work required 
to overcome flow resistance and reduce the amount dead space volume (Murray, 
1926; Weibel and Gomez, 1962). As observed in the whole explant model the 
proximal branches of a developing lung are surrounded by smooth muscle 
generated from the FGF10 producing cells of the mesenchyme (Agha et al., 2014). 
These cells periodically contract, forcing fluid back and forth along the luminal 
space (Schittny et al., 2000). An exciting prospect that warrants further 
investigation is that the fluid that surges through the lumen during each contractile 
wave serves to test the luminal space for efficiency. The epithelium may be 
capable of responding to these mechanical cues and altering their growth 
accordingly to optimise the luminal space. If correct then lung disorders may arise 
from inefficient airway peristalsis that induces the formation of inadequate lumen. 
During an asthma attack the smooth muscle that lines the airways contracts, 
restricting airflow. Given that the same smooth muscle is active in this model of 
embryonic lung branching this model could potentially be used to assess drugs 
designed to reduce the muscular contraction during an asthmatic attack. 
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In this study we have explored the role of disease-associated pathways in 
developmental processes using physiologically relevant models. Beyond 
examining signalling pathways these models could potentially be used to recreate 
the diseased environment.  During the fibrotic process myofibroblasts secrete a 
range of factors to promote matrix reorganisation and the proliferation and 
differentiation of surrounding fibroblasts (Scotton and Chambers, 2007). It would 
be interesting to see what effect the application of conditioned media from fibrotic 
myofibroblasts, or the myofibroblasts themselves, has on cultures of lung explants. 
An induction of a fibrotic process in the explants would be exciting and would allow 
for a physiologically relevant model with which to test potential anti-fibrotic drugs. 
However, given that a prominent pro-fibrotic cytokine released from myofibroblasts 
is TGFβ (Popova et al., 2010), the effects of these cells on embryonic lung 
explants may likely be akin to the reported effects of TGFβ on lung branching 
(Xing et al., 2008).  
 
6.2 Immunogenicity of CPPs 
 
Overview 
The second facet of this thesis sought to determine if CPPs, a widely used 
transfection carrier that is emerging in the clinic, have underlying immunogenic 
properties. Given their initial derivation from proteins isolated from viruses and 
venoms (Frankel and Pabo, 1988; Gurrola et al., 2010; Rádis-Baptista and Kerkis, 
2011), it seem reasonable to presume that these CPP protein sequences could be 
recognised by cells to initiate an immune response, making it surprising that their 
potential immunogenic nature has not been explored in great detail in the 
literature. We have demonstrated that three commonly used CPPs were capable 
of delivering a fluorescent cargo to epithelial cells in-vitro albeit with different 
efficacies. These CPPs did not affect the viability of the epithelial cells, which has 
been reported for CPPs at high concentrations (Hansen et al., 2012; Kilk et al., 
2009; Watkins et al., 2009). After initial application, these CPPs did not appear to 
activate NFκB signalling, a commonly activated inflammatory pathway. 
Furthermore, prolonged exposure (72 hours) of cells to these CPPs failed to incite 
the release of the pro-inflammatory cytokines IL-6 and IL-8. Together this would 
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suggest that CPPs are not immunogenic, at least towards epithelial cells in an in-
vitro system.  
 
Future directions 
A limitation of this study is that it was performed in an in-vitro system; this 
therefore removed the ability to examine the full immune response including 
whether a CPP could be ‘presented’ to adaptive immune cells. As mentioned, this 
could be examined in-vitro by exposing antigen presenting cells with CPPs and 
observing if these cells are then capable of activating cells of the adaptive immune 
system.   
 
Multiple studies have reported that CPPs can be transported to different 
intracellular locations dependent on the CPP and the type of cargo (Lundin et al., 
2008; Moschos et al., 2007). It is therefore possible that the CPPs in this study 
failed to induce an immune response, as they did not transport to an area of the 
cell where they would be recognised as immunogenic. It would therefore seem 
prudent to test each individual type of CPP: Cargo complex for immunogenic 
potential before the therapeutic reaches the clinic. 
 
6.3 Bacterial toxins as drug delivery tools 
 
Overview 
The final part of this thesis examined the intracellular transport of two bacterial 
toxins and explored their potential as therapeutic delivery agents. We have 
demonstrated that PEx and Chx are internalised by epithelial cells and are 
subsequently transported to intracellular locations consistent with their intoxication 
pathway. Interestingly we determined that the ganglioside GM1 is influential in the 
intracellular transport of PEx, with the C16:1 ceramide chain variant enhancing the 
localisation of PEx to the Golgi network.  
 
We have also studied the transcytosis of these bacterial toxins across polarised 
monolayers of Caco-2 cells. Both PEx and Chx were able to transport across 
Caco-2 cells from the apical side and be released into the basolateral 
compartment. We briefly explored the transcytosis pathway for these toxins by 
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studying the impact of one on the transport of the other. We identified that these 
toxins can compete with each other and that Chx can disrupt PEx transcytosis 
whereas PEx can enhance Chx transcytosis. This was also apparent with CTB, 
implying that GM1 may also affect the transcytosis pathway. Indeed, a role for 
GM1 structure has been identified in the transcytosis pathway of CTB (Saslowsky 
et al., 2013).  
 
Finally, we were able to combine these two approaches to demonstrate that PEx, 
when coupled with an siRNA cargo, can effectively transport across a polarised 
monolayer of cells and deliver the cargo into cells present in the basolateral 
compartment. A particularly striking finding is that this siRNA construct could then 
initiate knockdown of a target protein within cells. 
 
Future directions 
During this study we discovered that the receptor for Chx is not the same as PEx, 
which was assumed based on the similarities between the structure of the two 
toxins (Jørgensen et al., 2008). Future work should endeavour to identify the 
cellular receptor for Chx entry, as this will be critical for identifying which cells a 
Chx based therapeutic could target.  
 
It would be also be beneficial to identify the transcytosis pathway for PEx and Chx. 
In nature Streptococcus pneumonia has evolved to exploit natural transcytosis 
pathways in the body to aid in host invasion (Zhang et al., 2000). It would therefore 
seem reasonable that PEx and Chx evolved to exploit similar pathways. A likely 
candidate is the neonatal Fc receptor, which transports IgG from the apical to the 
basolateral surface of mucosal linings (Dickinson et al., 1999; Sakagami et al., 
2006). An alternative is the polymeric immunoglobulin receptor, which naturally 
transports dimeric IgA from the basolateral surface of mucosal linings and 
secretes dimeric IgA into the mucosa (Apodaca et al., 1994; Mostov et al., 1984). 
This second prospect is more appealing given that Pseudomonas aeruginosa 
requires the translocation of basolateral proteins to the apical surface in order to 
transport across polarised epithelium (Kierbel et al., 2007). 
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We have established that bacterial toxins can effectively transport a cargo across 
polarised epithelial surfaces and deliver said cargo into cells present on the 
basolateral side. The next step would be to demonstrate the same effect in-vivo. It 
would be important to see if a bacterial toxin applied to the mucosal surface of the 
airways or intestine is capable of overcoming the added barrier of mucosa and 
fluid flux to be transported either into the bloodstream or the surrounding tissue. 
Moreover, the repertoire of potential cargos needs to be determined, answering 
whether there is a size limit for a therapeutic cargo. 
 
Finally, there is the potential to further tailor bacterial toxins for therapeutic use by 
removing both the receptor binding domain and the toxic domain and replacing 
with a cell-specific immunoglobulin and drug cargo respectively. This would allow 
for the intracellular delivery of a drug cargo to a specific cell type of interest.  
 
6.4 Concluding remarks 
 
Developmental pathways that orchestrate the growth of an organ can show a 
resurgence in the diseased state. These developmental pathways control the 
remodelling of an organ to a degree where function becomes impaired. An 
example of this is TGFβ, which is critical for lung growth. Too much or too little of 
this factor greatly perturbs the branching program of the developing lung. 
Signalling of this factor is also overactive in fibrosis where it is seen as one of the 
predominant pathogenic signals (Shi et al., 2009). Insight into how signalling 
pathways (that act to remodel an organ during disease) function in the 
development of an organ will aid in the understanding of how the remodelling 
occurs and will lead to novel therapeutic strategies for regenerative medicine.  
 
We have identified a novel role for PI3K in the development of the lung that will 
have implications for the use of PI3K based therapies particularly because we 
have observed a contrasting effect of PI3K than what is seen in other epithelial 
branching organs. As we have examined a process that involves the migration of 
epithelial cells this work will have particular impact on epithelial cancers, where 
PI3K signalling is consistently found to be overactive (Engelman, 2009).   
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We have provided evidence to suggest that CPPs are passive entities that do no 
incite an immune response. However, more work is needed before we can know 
for sure if they do not exhibit immunogenic properties. As these CPPs progress 
through clinical trials covering a range of CPPs and cargos across many diseases 
more data will emerge regarding their safety.  
 
The repurposing of bacterial toxins as drug carriers is an exciting prospect. We 
have demonstrated the proof of concept, showing that toxins can deliver an active 
cargo into cells wherein they can exhibit a therapeutic effect. Historically these 
toxins have been detrimental to society, but with the generation of these toxins as 
drug carriers and the continued success of related immunotoxins we will see them 
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Figure A1. No primary antibody controls for embryonic lung explant 
immunofluorescence. Confocal images of indicated fluorescent secondary antibodies 
from isolated E12.5 murine lung explants cultured for 48 hours. Explants were processed 
for immunofluorescence as outlined in section 2.11 with the exception that there was no 
primary antibody step. Images are representative of three independent experiments. 

















Figure A2. No primary antibody controls for isolated embryonic lung epithelium 
immunofluorescence. Confocal images of indicated fluorescent secondary antibodies 
from isolated E12.5 murine lung epithelium cultured for 96 hours with 100 ng/ml FGF7. 
Isolates were processed for immunofluorescence as outlined in section 2.11 with the 
exception that there was no primary antibody step. Images are representative of three 





Video 3.1. E12.5 murine lung explants continue to branch in culture. Time-
lapse video of an E12.5 murine lung explant cultured over 48 hours. The video is 
representative of at least 12 explants. Scale bar = 50 µm. 
 
Video 3.2. Embryonic murine lungs exhibit periodic waves of contraction 
along epithelial branches. Video clip of a peristaltic wave in cultured embryonic 
lung explants. Contractile waves appear roughly once every 30 seconds. The 
video is representative of at least 24 explants.  
 
Video 3.3. AZD8055 potentiates epithelial branching in cultures of E12.5 
murine embryonic lungs. Time-lapse video of an E12.5 murine lung explant 
cultured over 48 hours with 0.1µM of the mTORC2 inhibitor AZD8055. The video 
is representative of at least 12 explants. Scale bar = 50 µm. 
 
Video 3.4. Isolated murine lung epithelium cultured with FGF10 develops 
smooth muscle that periodically contracts. Video clip of contractile wave 
present in isolated E12.5 murine lung epithelium cultured with 250 ng/ml FGF10 at 
96 hours of culture. The video is representative of at least 20 epithelial isolates.  
 
Video 3.5. Contractile waves persist in murine lung explants cultured with an 
inhibitor of FGFR. Video clip of contractile waves present in an E12.5 lung 
explant at 48 hours of culture with 100 nM of the FGFR inhibitor PD173074. The 
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